<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002779.pub3" GROUP_ID="ORAL" ID="079900071114110280" MERGED_FROM="" MODIFIED="2016-11-14 12:04:45 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch" REVIEW_NO="0044" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-11-14 11:59:17 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<TITLE MODIFIED="2016-06-27 11:40:47 +0100" MODIFIED_BY="Luisa Fernandez Mauleffinch">Interventions for treating burning mouth syndrome</TITLE>
<CONTACT>
<PERSON ID="22187610132714408961101021171802" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roddy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McMillan</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant and Honorary Clinical Teaching Fellow in Oral Medicine and Facial Pain</POSITION>
<EMAIL_1>Roddy.McMillan@uclh.nhs.uk</EMAIL_1>
<EMAIL_2>roddymcmillan@nhs.net</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine and Facial Pain</DEPARTMENT>
<ORGANISATION>Eastman Dental Hospital</ORGANISATION>
<ADDRESS_1>256 Gray's Inn Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1X 8LD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-11-14 11:59:17 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<PERSON ID="22187610132714408961101021171802" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Roddy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McMillan</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant and Honorary Clinical Teaching Fellow in Oral Medicine and Facial Pain</POSITION>
<EMAIL_1>Roddy.McMillan@uclh.nhs.uk</EMAIL_1>
<EMAIL_2>roddymcmillan@nhs.net</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine and Facial Pain</DEPARTMENT>
<ORGANISATION>Eastman Dental Hospital</ORGANISATION>
<ADDRESS_1>256 Gray's Inn Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1X 8LD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15500" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Heli</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Forssell</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>heli.forssell@utu.fi</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Oral &amp; Maxillofacial Surgery, Institute of Dentistry</DEPARTMENT>
<ORGANISATION>University of Turku</ORGANISATION>
<ADDRESS_1>Lemminkäisenkatu 2</ADDRESS_1>
<ADDRESS_2>20520</ADDRESS_2>
<CITY>Turku</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="FI">Finland</COUNTRY>
<PHONE_1>+ 358 40 5392030</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17670" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>John AG</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Buchanan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>J.A.G.Buchanan@qmul.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine</DEPARTMENT>
<ORGANISATION>Barts and The London School of Medicine and Dentistry</ORGANISATION>
<ADDRESS_1>Turner Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>E1 2AD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7514" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Glenny</LAST_NAME>
<SUFFIX/>
<POSITION>Professor in Health Sciences Research</POSITION>
<EMAIL_1>a.glenny@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health</DEPARTMENT>
<ORGANISATION>The University of Manchester</ORGANISATION>
<ADDRESS_1>JR Moore Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7811</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18251424409769280032110615123512" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Jo</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Weldon</LAST_NAME>
<SUFFIX/>
<POSITION>Research Coordinator</POSITION>
<EMAIL_1>jo.weldon@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health</DEPARTMENT>
<ORGANISATION>Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester</ORGANISATION>
<ADDRESS_1>JR Moore Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9118" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joanna</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Zakrzewska</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Oral Medicine and Facial Pain Lead</POSITION>
<EMAIL_1>jzakrzewska@nhs.net</EMAIL_1>
<EMAIL_2>j.zakrzewska@ucl.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine and Facial Pain</DEPARTMENT>
<ORGANISATION>Eastman Dental Hospital</ORGANISATION>
<ADDRESS_1>256 Gray's Inn Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1X 8LD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7915 1195</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7915 1105</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-10-12 13:49:28 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="12" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="12" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="11" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-09 22:48:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-11-09 22:46:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<DATE DAY="9" MONTH="11" YEAR="2016"/>
<DESCRIPTION>
<P>15 new studies added. New authors. Methods updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-09 22:48:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<DATE DAY="31" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>Searches updated to 31 December 2015</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-11-09 22:42:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-11-09 22:42:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<DATE DAY="19" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-09 22:42:01 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<DATE DAY="15" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Searches updated to October 2004</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-11-09 22:42:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<DATE DAY="15" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment. 2 studies previously awaiting assessment have been excluded; a further 4 randomised controlled trials have been included and 1 previously included trial excluded<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-11-07 10:04:25 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-11-03 23:36:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<SOURCE>
<NAME>St Bartholomew's and the Royal London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University Dental Hospital of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-05-19 21:26:25 +0100" MODIFIED_BY="[Empty name]">
<NAME>Turku University</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2016-11-03 23:36:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<NAME>National Institute for Health Research (NIHR) University College London (UCL) Hospitals Biomedical Research Centre</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Research time </P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2015-11-18 13:36:35 +0000" MODIFIED_BY="[Empty name]">
<NAME>School of Dentistry, The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2016-05-10 17:32:12 +0100" MODIFIED_BY="Jo C Weldon">
<NAME>Manchester Academic Health Sciences Centre (MAHSC)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Cochrane Oral Health is supported by MAHSC and the NIHR Manchester Biomedical Research Centre</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-11-07 10:04:25 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-11-07 10:04:25 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This project was supported by the NIHR, via Cochrane Infrastructure funding to Cochrane Oral Health. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-11-03 23:33:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<NAME>Cochrane Oral Health Global Alliance</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>The production of Cochrane Oral Health reviews has been supported financially by our Global Alliance since 2011 (<A HREF="http://ohg.cochrane.org/partnerships-alliances">ohg.cochrane.org/partnerships-alliances</A>). Contributors over the past year have been the British Association for the Study of Community Dentistry, UK; the British Society of Paediatric Dentistry, UK; the Canadian Dental Hygienists Association, Canada; the Centre for Dental Education and Research at All India Institute of Medical Sciences, India; the National Center for Dental Hygiene Research &amp; Practice, USA; New York University College of Dentistry, USA; and NHS Education for Scotland, UK</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-11-14 12:03:01 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-11-14 12:03:01 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-11-10 14:53:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">Interventions for treating burning mouth syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2016-11-14 12:03:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Which treatments help to relieve symptoms for people with burning mouth syndrome (BMS)?</P>
<P>
<B>Background</B>
</P>
<P>BMS is a common painful condition. Symptoms include burning, dryness or uncomfortable sensations in the mouth and changes to taste, with no obvious underlying medical or dental cause. BMS is usually persistent and suffered long term, and can lead to a reduced quality of life (QoL). Currently, scientific research suggests that BMS is caused by underlying damage to the nerves. There are many treatments available including drugs for anxiety, other psychological conditions and increasing saliva production, protective barriers and treatments applied to the mouth surface amongst others.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review of studies was carried out through Cochrane Oral Health, and the evidence is current up to 31 December 2015.</P>
<P>We found 23 studies (assessing 1121 people; 83% were women), published between 1995 and 2015 to include in this review. Twenty-one studies assessed short-term (up to three months) symptom relief, and four studies assessed long-term (from three to six months) symptom relief. Seventeen studies provided information about side effect occurrence, seven studies assessed a measure of QoL, and two studies assessed changes in taste and feeling of dryness.</P>
<P>All of the 23 treatments included in this review were compared to a placebo (fake treatment): antidepressants and antipsychotics (two studies), antiseizure drugs (one study), types of tranquillisers (four studies), saliva stimulants (one study), dietary supplements (12 studies), directed energy waves (one study), physical barriers (one study), psychological therapies (one study), and treatments applied to the mouth surface (five studies).</P>
<P>
<B>Key results</B>
</P>
<P>
<I>
<B>Short-term symptom relief</B>
</I>
</P>
<P>We found evidence of short-term symptom relief for directed energy waves (one study, 58 participants), a type of tranquilliser used topically (that is held in the mouth before being removed, and which also acts as an antiseizure drug) called clonazepam (two studies, 111 participants), thin plastic tongue covers (one study, 50 participants), and an antiseizure drug called gabapentin (one study, 100 participants).</P>
<P>There was no difference in short-term symptom relief found for antidepressants, saliva stimulants, and another type of tranquilliser used systemically (one that is swallowed) also called clonazepam. We were unable to show whether dietary supplements or treatments applied to the mouth surface provide symptom relief in the short term or not.</P>
<P>Short-term relief was not reported for the single study that assessed a psychological therapy.</P>
<P>
<I>
<B>Long-term symptom relief</B>
</I>
</P>
<P>We found evidence of long-term symptom relief for psychological therapy (one study, 30 participants), chili pepper mouthrinse (one study, 18 participants) and the topical tranquilliser called clonazepam (one study, 66 participants).</P>
<P>We found there was no difference in long-term symptom relief for dietary supplements or treatments applied to the mouth surface.</P>
<P>Studies which assessed antidepressants, directed energy waves, saliva stimulants, antiseizure drugs, or physical barriers did not evaluate long-term symptom relief.</P>
<P>
<I>
<B>Change in QoL</B>
</I>
</P>
<P>There was evidence of short-term improvement in QoL for directed energy waves (one study, 58 patients), although no difference was found for antidepressants, tranquillisers, dietary supplements and physical barriers. No study assessed long-term QoL changes.</P>
<P>
<I>
<B>Change in taste or feeling of dryness</B>
</I>
</P>
<P>A few studies assessed short-term change in taste or feeling of dryness (none evaluated these outcomes long-term), but there was not enough evidence to judge the effects of treatment on these outcomes.</P>
<P>
<I>
<B>Side effects</B>
</I>
</P>
<P>Side effects were more likely to be experienced with antidepressants (dizziness and drowsiness more likely: one study, 37 people), and with a dietary supplement called alpha lipoic acid (also known as ALA) with or without other ingredients (headaches more likely: two studies, 118 people; and upset stomachs more likely: three studies, 138 people).</P>
<P>
<B>Quality of the evidence</B>
<BR/>Overall, we found very low-quality evidence for each short- and long-term outcome we investigated (symptom relief; changes in QoL, taste and feeling of dryness; and side effects) in all types of assessed treatment: antidepressants and antipsychotics, antiseizure drugs, types of tranquillisers, saliva stimulants, dietary supplements, directed energy waves, physical barriers (except side effects, which was assessed as low quality), psychological therapies, and treatments applied to the mouth surface. As we found so few studies at low risk of bias, we are currently unable to prove or disprove the effectiveness of any treatments for managing BMS.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-09 22:37:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<ABS_BACKGROUND MODIFIED="2016-10-31 10:56:23 +0000" MODIFIED_BY="Jo C Weldon">
<P>Burning mouth syndrome (BMS) is a term used for oral mucosal pain (burning pain or discomfort in the tongue, lips or entire oral cavity) without identifiable cause. General population prevalence varies from 0.1% to 3.9%. Many BMS patients indicate anxiety, depression, personality disorders and impaired quality of life (QoL). This review updates the previous versions published in 2000 and 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-11-09 22:19:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>To determine the effectiveness and safety of any intervention versus placebo for symptom relief and changes in QoL, taste, and feeling of dryness in people with BMS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-11-09 22:23:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 31 December 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 11) in the Cochrane Library (searched 31 December 2015), MEDLINE Ovid (1946 to 31 December 2015), and Embase Ovid (1980 to 31 December 2015). We searched <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> and the <A HREF="http://apps.who.int/trialsearch/">World Health Organization International Clinical Trials Registry Platform</A> for ongoing trials. We placed no restrictions on the language or date of publication when searching the electronic databases</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-08-08 11:51:57 +0100" MODIFIED_BY="Jo C Weldon">
<P>Randomised controlled trials (RCTs) comparing any treatment against placebo in people with BMS. The primary outcomes were symptom relief (pain/burning) and change in QoL. Secondary outcomes included change in taste, feeling of dryness, and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-05-18 08:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>We used standard methodological procedures expected by Cochrane. Outcome data were analysed as short-term (up to three months) or long-term (three to six months).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-11-09 22:36:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>We included 23 RCTs (1121 analysed participants; 83% female). Interventions were categorised as: antidepressants and antipsychotics, anticonvulsants, benzodiazepines, cholinergics, dietary supplements, electromagnetic radiation, physical barriers, psychological therapies, and topical treatments.</P>
<P>Only one RCT was assessed at low risk of bias overall, four RCTs' risk of bias was unclear, and 18 studies were at high risk of bias. Overall quality of the evidence for effectiveness was very low for all interventions and all outcomes.</P>
<P>Twenty-one RCTs assessed short-term symptom relief. There is very low-quality evidence of benefit from electromagnetic radiation (one RCT, 58 participants), topical benzodiazepines (two RCTs, 111 participants), physical barriers (one RCT, 50 participants), and anticonvulsants (one RCT, 100 participants). We found insufficient/contradictory evidence regarding the effectiveness of antidepressants, cholinergics, systemic benzodiazepines, dietary supplements or topical treatments. No RCT assessing psychological therapies evaluated short-term symptom relief.</P>
<P>Four studies assessed long-term symptom relief. There is very low-quality evidence of a benefit from psychological therapies (one RCT, 30 participants), capsaicin oral rinse (topical treatment) (one RCT, 18 participants), and topical benzodiazepines (one RCT, 66 participants). We found no evidence of a difference for dietary supplements or lactoperoxidase oral rinse. No studies assessing antidepressants, anticonvulsants, cholinergics, electromagnetic radiation or physical barriers evaluated long-term symptom relief.</P>
<P>Short-term change in QoL was assessed by seven studies (none long-term).The quality of evidence was very low. A benefit was found for electromagnetic radiation (one RCT, 58 participants), however findings were inconclusive for antidepressants, benzodiazepines, dietary supplements and physical barriers.</P>
<P>Secondary outcomes (change in taste and feeling of dryness) were only assessed short-term, and the findings for both were also inconclusive.</P>
<P>With regard to adverse effects, there is very low-quality evidence that antidepressants increase dizziness and drowsiness (one RCT, 37 participants), and that alpha lipoic acid increased headache (two RCTs, 118 participants) and gastrointestinal complaints (3 RCTs, 138 participants). We found insufficient/contradictory evidence regarding adverse events for anticonvulsants or benzodiazepines. Adverse events were poorly reported or unreported for cholinergics, electromagnetic radiation, and psychological therapies. No adverse events occurred from physical barriers or topical therapy use.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-11-09 22:37:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Given BMS' potentially disabling nature, the need to identify effective modes of treatment for sufferers is vital. Due to the limited number of clinical trials at low risk of bias, there is insufficient evidence to support or refute the use of any interventions in managing BMS. Further clinical trials, with improved methodology and standardised outcome sets are required in order to establish which treatments are effective. Future studies are encouraged to assess the role of treatments used in other neuropathic pain conditions and psychological therapies in the treatment of BMS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<BACKGROUND MODIFIED="2016-11-04 10:03:27 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-11-03 23:08:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Burning mouth syndrome (BMS) is defined as burning or painful sensations from an oral mucosa with no clinical signs of pathology or identifiable medical or dental causes (<LINK REF="REF-IHS-2013" TYPE="REFERENCE">IHS 2013</LINK>). In addition to pain, many BMS patients also report subjective xerostomia (dryness), oral paraesthesia and/or altered taste (<LINK REF="REF-Bergdahl-1999" TYPE="REFERENCE">Bergdahl 1999</LINK>; <LINK REF="REF-Woda-1999" TYPE="REFERENCE">Woda 1999</LINK>).</P>
<P>There is confusion in the literature as a wide variety of different terms have been used to describe the sensation of a burning mouth (<LINK REF="REF-Buchanan-2010" TYPE="REFERENCE">Buchanan 2010</LINK>; <LINK REF="REF-Fortuna-2013" TYPE="REFERENCE">Fortuna 2013</LINK>). These include glossodynia, glossopyrosis, stomatodynia, stomatopyrosis, sore tongue, burning mouth and oral dysaesthesia. A sensation of oral burning can be associated with systemic or local causes such as hyposalivation, oral candidiasis, oral parafunction, some deficiency states or side effects of drug treatments (<LINK REF="REF-Buchanan-2010" TYPE="REFERENCE">Buchanan 2010</LINK>; <LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>). In these instances the treatment of the underlying cause results in resolution of the burning mouth symptom, and a diagnosis of BMS cannot be made. The diagnosis of primary BMS is thus a diagnosis of exclusion.</P>
<P>The International Association for the Study of Pain (IASP) classification of chronic pain defines BMS as a "distinctive nosological entity characterized by unremitting oral burning or similar pain in the absence of detectable oral mucosal changes" (<LINK REF="REF-Merksey-1994" TYPE="REFERENCE">Merksey 1994</LINK>); however, it does not draw the distinction between burning as a symptom and primary BMS. The International Headache Society (IHS) describes BMS as "an intraoral burning or dysaesthetic sensation, recurring daily for more than 2 hours per day over more than 3 months, without clinically evident causative lesions" (<LINK REF="REF-IHS-2013" TYPE="REFERENCE">IHS 2013</LINK>).</P>
<P>The epidemiological data on BMS are generally poor, due in part to lack of strict adherence to diagnostic criteria (<LINK REF="REF-Zakrzewska-1999" TYPE="REFERENCE">Zakrzewska 1999</LINK>). Reported prevalence rates of burning mouth symptoms in general populations vary from 0.1% to 3.9% (<LINK REF="REF-Bergdahl-1999" TYPE="REFERENCE">Bergdahl 1999</LINK>; <LINK REF="REF-Kohorst-2015" TYPE="REFERENCE">Kohorst 2015</LINK>). A recent epidemiological study using strict diagnostic criteria (albeit reporting from a predominantly Caucasian population) estimated a BMS incidence rate of 11.4 cases per 100,000 person-years (18.8 cases per 100,000 person-years for women, and 3.7 cases per 100,000 person-years for men) (<LINK REF="REF-Kohorst-2014" TYPE="REFERENCE">Kohorst 2014</LINK>). The incidence of BMS sharply increases after the age of 50 in both women and men, with the highest incidence in women (70.3 cases per 100,000 person-years) aged 70 to 79 years (<LINK REF="REF-Kohorst-2014" TYPE="REFERENCE">Kohorst 2014</LINK>). The natural history of BMS has not been clearly defined and there are no reports of longitudinal cohort studies (<LINK REF="REF-Zakrzewska-1999" TYPE="REFERENCE">Zakrzewska 1999</LINK>). There is anecdotal evidence of at least partial spontaneous remission in approximately half of these patients within six to seven years (<LINK REF="REF-Grushka-1987a" TYPE="REFERENCE">Grushka 1987a</LINK>). In another study, only two out of 53 patients reported complete spontaneous remission of their symptoms within five years after onset (<LINK REF="REF-Sardella-2006" TYPE="REFERENCE">Sardella 2006</LINK>).</P>
<P>The prominent feature of BMS is the symptom of burning pain or discomfort, which can be localised just to the tongue or lips or both but can be more widespread and involve the whole of the oral cavity (<LINK REF="REF-Grushka-1987b" TYPE="REFERENCE">Grushka 1987b</LINK>; <LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>). In most patients the symptoms are bilateral. Often words such as 'pricking', 'tingling', 'numbness' or 'itching' instead of 'burning' are used to describe the pain (<LINK REF="REF-Braud-2013" TYPE="REFERENCE">Braud 2013</LINK>). In most cases the symptoms have continued for many months and the intensity of pain tends to increase towards the end of the day (<LINK REF="REF-Forssell-2012" TYPE="REFERENCE">Forssell 2012</LINK>). Altered taste sensation and a symptom of oral dryness (in patients with no alteration of the salivary flux) are frequently reported (<LINK REF="REF-Bergdahl-1999" TYPE="REFERENCE">Bergdahl 1999</LINK>; <LINK REF="REF-Grushka-1987b" TYPE="REFERENCE">Grushka 1987b</LINK>; <LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>), and recent studies indicate that 67% to 80% of BMS patients suffer from sleep disturbance (<LINK REF="REF-Almoznino-2016" TYPE="REFERENCE">Almoznino 2016</LINK>; <LINK REF="REF-L_x00f3_pez_x002d_Jornet-2015" TYPE="REFERENCE">López-Jornet 2015</LINK>).</P>
<P>Recent neurophysiologic, psychophysical, neuropathological functional imaging studies have elucidated that several neuropathic, mainly subclinical mechanisms, act at different levels of the nervous system and contribute to the pathophysiology of primary BMS (<LINK REF="REF-J_x00e4__x00e4_skel_x00e4_inen-2012" TYPE="REFERENCE">Jääskeläinen 2012</LINK>). Thermal quantitative sensory threshold (QST) studies have demonstrated signs of small-fibre mediated neuropathy (<LINK REF="REF-Forssell-2002" TYPE="REFERENCE">Forssell 2002</LINK>; <LINK REF="REF-Granot-2005" TYPE="REFERENCE">Granot 2005</LINK>; <LINK REF="REF-Svensson-1993" TYPE="REFERENCE">Svensson 1993</LINK>), sometimes together with extrasegmental sensory alterations; suggesting possibly more generalised somatosensory dysfunction in BMS (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2010" TYPE="STUDY">Grémeau-Richard 2010</LINK>; <LINK REF="REF-Puhakka-2016" TYPE="REFERENCE">Puhakka 2016</LINK>; <LINK REF="REF-Svensson-1993" TYPE="REFERENCE">Svensson 1993</LINK>). Furthermore, blink reflex studies have demonstrated subclinical trigeminal nerve lesions in approximately 20% of BMS patients (<LINK REF="REF-Forssell-2002" TYPE="REFERENCE">Forssell 2002</LINK>; <LINK REF="REF-J_x00e4__x00e4_skel_x00e4_inen-1997" TYPE="REFERENCE">Jääskeläinen 1997</LINK>). The frequent report of taste dysfunction in patients with BMS has prompted the hypothesis that there could be hyperactivity of the somatosensory fibres of the trigeminal nerve, following loss of central inhibition due to taste fibre damage (<LINK REF="REF-Kolkka_x002d_Palomaa-2016" TYPE="REFERENCE">Kolkka-Palomaa 2016</LINK>). Supporting this, three electrogustatometric studies have reported evidence for chorda tympani hypofunction in BMS (<LINK REF="REF-Eliav-2007" TYPE="REFERENCE">Eliav 2007</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2010" TYPE="STUDY">Grémeau-Richard 2010</LINK>; <LINK REF="REF-Just-2010" TYPE="REFERENCE">Just 2010</LINK>). In line with the thermal QST and electrogustatometric evidence for focal small fibre hypofunction in BMS, several studies have demonstrated loss of epithelial nerve fibres in tongue mucosal biopsies from BMS patients (<LINK REF="REF-Lauria-2005" TYPE="REFERENCE">Lauria 2005</LINK>; <LINK REF="REF-Penza-2010" TYPE="REFERENCE">Penza 2010</LINK>; <LINK REF="REF-Puhakka-2016" TYPE="REFERENCE">Puhakka 2016</LINK>; <LINK REF="REF-Yilmaz-2007" TYPE="REFERENCE">Yilmaz 2007</LINK>).</P>
<P>Central nervous system pathology seems also to be involved in the generation of BMS pain symptoms. Giving further evidence for the neuropathic nature of BMS, the characteristics in functional magnetic resonance imaging (fMRI) activation patterns to painful stimuli have been shown to be similar in BMS patients and patients with other neuropathic pain conditions (<LINK REF="REF-Albuquerque-2006" TYPE="REFERENCE">Albuquerque 2006</LINK>). A recent study on cerebral reorganisation demonstrated altered grey and white matter volumes in the hippocampus and medial prefrontal cortex in BMS patients, as well as altered functional connectivity patterns of these regions (<LINK REF="REF-Khan-2014" TYPE="REFERENCE">Khan 2014</LINK>). Two positron emission tomography (PET) studies have demonstrated a decline in endogenous dopamine levels in BMS, suggesting deficiencies in central pain modulation (<LINK REF="REF-Hagelberg-2003" TYPE="REFERENCE">Hagelberg 2003</LINK>; <LINK REF="REF-J_x00e4__x00e4_skel_x00e4_inen-2001" TYPE="REFERENCE">Jääskeläinen 2001</LINK>).</P>
<P>The question concerning the relative involvement of peripheral versus central mechanisms in BMS pain has important implications, especially concerning different treatment approaches. A study investigating the effects of peripheral lingual nerve block on spontaneous burning pain in BMS showed that in half of the patients the lingual nerve block relieved the pain, suggesting predominantly peripheral mechanisms acting in this subgroup. In some cases, lingual nerve anaesthesia had no effect or even increased the pain intensity, indicating that central mechanisms may be more important in the pathophysiology of pain in some BMS patients (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2010" TYPE="STUDY">Grémeau-Richard 2010</LINK>).</P>
<P>Most studies on the pathophysiology of BMS have explored the neuropathic background of these pains, but many other factors may be involved. A hypothesis linking BMS with dysregulation of adrenal, gonadal and neuroactive steroids has been presented (<LINK REF="REF-Woda-2009" TYPE="REFERENCE">Woda 2009</LINK>). Autonomic nervous system impairment (<LINK REF="REF-Heckmann-2001" TYPE="REFERENCE">Heckmann 2001</LINK>; <LINK REF="REF-Koszewicz-2012" TYPE="REFERENCE">Koszewicz 2012</LINK>) or immune function suppression (<LINK REF="REF-Koike-2014" TYPE="REFERENCE">Koike 2014</LINK>) have also been suggested to have a role in BMS pathophysiology. It has also been speculated that salivary dysfunction plays a role in BMS because more than half of BMS patients complain of dry mouth (i.e. xerostomia) (<LINK REF="REF-Bergdahl-1999" TYPE="REFERENCE">Bergdahl 1999</LINK>). However, while some investigators have demonstrated decreased salivary gland output in BMS (<LINK REF="REF-Lee-2015" TYPE="REFERENCE">Lee 2015</LINK>), some studies have indicated that the salivary flow rate in BMS patients is the same as in controls (<LINK REF="REF-De-Moura-2009" TYPE="REFERENCE">De Moura 2009</LINK>). Methodological and patient population differences may explain the contradictory results; according to the current definition, patients with hyposalivation should not receive the primary BMS diagnosis. Moreover, studies concerning the composition of saliva in BMS have yielded conflicting results (<LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>).</P>
<P>BMS is well studied from the psychological perspective, showing convincing evidence for close relationship between psychological factors and the pain experience (<LINK REF="REF-Galli-2016" TYPE="REFERENCE">Galli 2016</LINK>). Many BMS patients show evidence of anxiety, depression or personality disorders. One study demonstrated that when compared with a control group, BMS patients had a significantly lower scores in socialisation, significantly higher scores in somatic anxiety and more negative thoughts (<LINK REF="REF-Bergdahl-1995b" TYPE="REFERENCE">Bergdahl 1995b</LINK>). It has been demonstrated that patients with BMS show an increased tendency for somatisation, as well as several other psychiatric features when measured on the SCL-90 (Symptom Checklist-90) questionnaire (<LINK REF="REF-Eli-1994" TYPE="REFERENCE">Eli 1994</LINK>). Psychological disorders could theoretically be associated with BMS by several mechanisms. While one such mechanism, dopaminergic hypofunction has been shown to be related to BMS pain, it has been suggested that the high psychological or psychiatric comorbidity in BMS can be understood in terms of shared vulnerability to both chronic pain and psychiatric disorders, mediated by dysfunctional brain dopamine activity (<LINK REF="REF-Taiminen-2011" TYPE="REFERENCE">Taiminen 2011</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-11-01 15:20:29 +0000" MODIFIED_BY="[Empty name]">
<P>These recent findings from BMS research suggest both central and peripheral neuropathological changes are present in the condition. Consequently, it could be proposed that BMS may respond to those treatments offered for other neuropathic conditions, such as antidepressants, anticonvulsants, dietary/nutritional supplements and topical anaesthetic or analgesic agents (<LINK REF="REF-Finnerup-2015" TYPE="REFERENCE">Finnerup 2015</LINK>; <LINK REF="REF-Foster-2007" TYPE="REFERENCE">Foster 2007</LINK>; <LINK REF="REF-NICE-2013" TYPE="REFERENCE">NICE 2013</LINK>). Moreover, the increasing evidence associating BMS with psychological comorbidities such as anxiety and depression, would suggest anxiolytics, antidepressants, and psychological therapies may be helpful in the management of BMS. The application of a physical barrier may also work to reduce the impact of parafunctional habits which may induce or sustain BMS (<LINK REF="REF-L_x00f3_pez_x002d_Jornet-2009a" TYPE="REFERENCE">López-Jornet 2009a</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-11-04 10:03:27 +0000" MODIFIED_BY="[Empty name]">
<P>Topical anaesthetic treatments would reduce BMS pain by blocking peripheral pain pathways, while topical capsaicin therapy aims to desensitise peripheral nerves. Antidepressant drugs produce blockade of various central nervous system (CNS) receptors, such as serotonin and norepinephrine, thereby increasing the activity of the descending inhibitory pain pathways. Some older antidepressants used commonly in pain management, such as the tricyclic antidepressants (TCAs), have complex pharmacodynamics and act by inhibiting multiple CNS receptors. This lack of specificity may in part be why the TCAs are clinically effective in managing pain, but also why they tend to produce adverse effects. More modern antidepressants such as the selective serotonin reuptake inhibitors (SSRIs), are more selective in their effects on CNS receptors, hence tend to produce less side effects than the TCAs. The roles of SSRIs in pain management have yet to be fully explored.</P>
<P>Anticonvulsant medications achieve their analgesic effects through a variety of mechanisms which include blockade of voltage-dependent sodium and calcium channels in peripheral neurones and actions on neuropeptides such as glutamate and substance P. The benzodiazepine class of drugs possesses anxiolytic and anticonvulsant properties, achieved through enhancing the effect of the neurotransmitter <I>gamma</I>-Aminobutyric acid (GABA) (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>).</P>
<P>Clinical psychology is known to help patients with chronic pain conditions improve their quality of life, despite having a background of persistent pain (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>). Recently, electromagnetic radiation (by low-level laser and transcranial magnetic stimulation) has been used as a non-invasive analgesic intervention for chronic pain, and its application in treating drug-resistant BMS is now being explored (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Umezaki-2016" TYPE="STUDY">Umezaki 2016</LINK>).</P>
<P>Several topical agents are used in the management of BMS, with varying degrees of biological plausibility in how they exert their effects: benzydamine hydrochloride is known to have topical analgesic properties (<LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>); lactoperoxidase oral rinse is considered because of its previous role in the management of xerostomia symptoms (<LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>); topical urea is thought to exert a hydrating effect on the oral mucosa in a similar way to its potential effects on the skin (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>); and, capsaicin has been found to act as a topical desensitising agent in other neuropathic pain conditions (<LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>).</P>
<P>The mechanisms of many treatments used in BMS are unclear and not well described: bethanecol is a parasympathomimetic which is reported to alleviate dry mouth symptoms; alpha lipoic acid is reported to exert "a neuro-regenerative action" (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>); hypericum perforatum extract is used due to its previous role in the management of depression (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>); 'Catuama' is reported to have analgesic and antidepressant properties (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>); lycopene and olive oil compound are used due to their antioxidant properties (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>); and lastly, 'tongue protectors' have been studied alone and also in conjunction with topical aloe vera - they are reported to control 'parafunctional habits' that may cause mucosal trauma, coupled with the potential mucosal healing benefits of aloe vera (<LINK REF="REF-L_x00f3_pez_x002d_Jornet-2013" TYPE="REFERENCE">López-Jornet 2013</LINK>).</P>
<P>It is likely that there is substantial diversity amongst neuropathic pain patients with respect to clinical presentation, sensory examination features and possibly the underlying pain mechanisms (<LINK REF="REF-Chaparro-2012" TYPE="REFERENCE">Chaparro 2012</LINK>). This diversity in pain mechanisms may be one reason for the limited analgesic efficacy of monotherapy pharmacological agents. Moreover, dose-related drug side effects (e.g. drowsiness, dizziness) may limit the tolerability of higher and more effective dosages. Therefore, combining medications with different pharmacological mechanisms may result in greater effectiveness and relatively less side effects (<LINK REF="REF-Chaparro-2012" TYPE="REFERENCE">Chaparro 2012</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-11-01 15:28:28 +0000" MODIFIED_BY="[Empty name]">
<P>Burning mouth syndrome is a common, often chronic, condition that appears to have a negative impact on quality of life. Several investigators have found reduced quality of life in BMS patients compared to controls when using SF-36 (36-Item Short Form Health Survey) and OHIP-49 (Oral Health Impact Profile-49) outcome measures (<LINK REF="REF-L_x00f3_pez_x002d_Jornet-2008" TYPE="REFERENCE">López-Jornet 2008</LINK>; <LINK REF="REF-Souza-2011" TYPE="REFERENCE">Souza 2011</LINK>), although we highlight that neither measure's use is specific to BMS. </P>
<P>This is an update of the Cochrane review first published in 2000 and previously updated in 2005 (<LINK REF="REF-Zakrzewska-2000" TYPE="REFERENCE">Zakrzewska 2000</LINK>; <LINK REF="REF-Zakrzewska-2005" TYPE="REFERENCE">Zakrzewska 2005</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-11-01 15:30:18 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and safety of any intervention versus placebo for symptom relief and changes in quality of life, taste, and feeling of dryness in people with burning mouth syndrome.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-11-03 23:23:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<SELECTION_CRITERIA MODIFIED="2016-11-01 15:33:00 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-11-01 15:31:36 +0000" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) comparing any treatment against placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-08-10 11:58:57 +0100" MODIFIED_BY="Jo C Weldon">
<P>People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms. Trials recruiting participants with other types of pain were only to be included if data on BMS participants could be separated out. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-05-10 17:03:45 +0100" MODIFIED_BY="Jo C Weldon">
<P>All treatments that were evaluated in placebo-controlled RCTs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-11-01 15:33:00 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-11-01 15:32:21 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Relief of burning or discomfort (symptom relief).</LI>
<LI>Change in quality of life (e.g. depression, anxiety).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-11-01 15:33:00 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Change in taste.</LI>
<LI>Change in feeling of dryness.</LI>
<LI>Adverse effects. We assessed treatment safety from reported adverse events.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-11-01 15:34:10 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-11-01 15:34:10 +0000" MODIFIED_BY="[Empty name]">
<P>Cochrane Oral Health's Information Specialist conducted systematic searches in the following databases for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions:</P>
<UL>
<LI>Cochrane Oral Health's Trials Register (searched 31 December 2015) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 11) in the Cochrane Library (searched 31 December 2015) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI>
<LI>MEDLINE Ovid (1946 to 31 December 2015) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI>
<LI>Embase Ovid (1980 to 31 December 2015) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
<P>Subject strategies were modelled on the search strategy designed for MEDLINE Ovid. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions,</I> Chapter 6 (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-10-13 10:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following trial registries for ongoing studies:</P>
<UL>
<LI>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">clinicaltrials.gov</A>; searched 31 December 2015) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>);</LI>
<LI>World Health Organization International Clinical Trials Registry Platform (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch</A>; searched 31 December 2015) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</LI>
</UL>
<P>The review authors handsearched the following conference proceedings from January 2005 to December 2015:</P>
<UL>
<LI>British Society for Oral Medicine (BSOM);</LI>
<LI>British Society for Dental Research (BSDR);</LI>
<LI>International Association for Dental Research (IADR).</LI>
</UL>
<P>We also scrutinised bibliographies of identified publications and reviews for potentially relevant references, and attempted to contact authors of relevant studies to identify missing data from unreported trials.</P>
<P>We did not perform a separate search for adverse effects of interventions used, we considered adverse effects described in included studies only.<BR/>
</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-11-03 23:23:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2016-08-10 16:12:24 +0100" MODIFIED_BY="Jo C Weldon">
<P>Teams of two review authors independently screened the titles and abstracts retrieved from the initial electronic searches. Reports from the studies that fulfilled the inclusion criteria were obtained. When there was insufficient information available to determine whether a study fulfilled the inclusion criteria, the full report was obtained and assessed independently by the same review authors. Disagreements were resolved by discussion. The review authors were not blinded to the studies' authorship.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-11-01 15:35:27 +0000" MODIFIED_BY="[Empty name]">
<P>At least two review authors independently extracted data from each study included using a tool developed for the review. All studies meeting the inclusion criteria underwent data extraction and an assessment of risk of bias using a standardised data extraction form. Studies rejected at this and subsequent stages were recorded in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Differences were resolved by discussion. For each study with more than one control or comparison group for the intervention, the results were extracted for each intervention arm. The review authors were not blinded to the studies' authorship.</P>
<P>We extracted the following data.</P>
<UL>
<LI>Year of publication, country of origin, number of centres, source of study funding and any conflicts of interest.</LI>
<LI>Details of the participants including demographic characteristics and criteria for inclusion/exclusion.</LI>
<LI>Details on the type of intervention and comparisons.</LI>
<LI>Details on the study design.</LI>
<LI>Details on the outcomes reported which included method and timings of assessments and adverse outcomes.</LI>
</UL>
<P>We contacted authors of the relevant studies, to supply missing information or data where necessary. We contacted trial authors for missing data if the study was published from the year 2000 onwards. We considered it unfeasible to obtain data for trials published prior to this cut-off date.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-11-01 15:48:12 +0000" MODIFIED_BY="[Empty name]">
<P>Teams of two review authors independently assessed the risk of bias for each included study. The 'Risk of bias' assessment was conducted using Cochrane's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>) and in accordance with guidance included in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). For each included study we assessed the following seven key domains.</P>
<UL>
<LI>Sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding of participants and personnel (performance bias).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Completeness of outcome data (attrition bias).</LI>
<LI>Selective outcome reporting (reporting bias).</LI>
<LI>Risk of other potential sources of bias (other bias).</LI>
</UL>
<P>For each study, we determined the overall risk of bias according to the following criteria:</P>
<UL>
<LI>low risk of bias - when there was a low risk of bias across all seven key domains;</LI>
<LI>unclear risk of bias - when there was an unclear risk of bias in one or more of the seven key domains (no domains judged to be at high risk of bias);</LI>
<LI>high risk of bias - when there was a high risk of bias in one or more of the seven key domains.</LI>
</UL>
<P>For consistent rating application, one author (Anne-Marie Glenny) arbitrated all assessments. We completed a 'Risk of bias' table for each included study, a 'Risk of bias' summary and 'Risk of bias' graph.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-11-01 15:50:40 +0000" MODIFIED_BY="[Empty name]">
<P>We analysed outcome data as short-term (&#8804; 3 months from baseline) or long-term (&gt; 3 to &#8804; 6 months from baseline) as a manageable cut-off threshold. For continuous outcomes (e.g. pain/burning on a visual analogue scale (VAS)), we used mean differences (MDs) and 95% confidence intervals (CIs) to summarise the data; in the event that different studies measured outcomes using different scales, we would have expressed the estimate of effect of an intervention as standardised mean differences (SMDs) and 95% CIs. Dichotomous outcomes (e.g. greater or less than 50% reduction in pain intensity as measured by a VAS, or improvement from baseline versus no change/worsened score), we expressed the estimate of effect of an intervention as risk ratios (RRs) together with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-11-03 23:23:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>If cluster-randomised trials had been included, we would have undertaken data analysis, whenever feasible, at the same level as the randomisation, or at the individual level accounting for the clustering. Analysis of cross-over studies took into account the two-period nature of the data using for example, a paired t-test (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). We entered MDs and standard errors into Review Manager (RevMan) software (<LINK REF="REF-Review-Manager-2014" TYPE="REFERENCE">Review Manager 2014</LINK>), using the generic inverse variance method (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-11-01 15:51:43 +0000" MODIFIED_BY="[Empty name]">
<P>When required we contacted trial authors for missing data if the study had been published in the year 2000 or after. The review authors considered it unfeasible to request data for trials published prior to this date. We used methods outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) to estimate missing standard deviations (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-11-01 15:52:08 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed clinical and methodological heterogeneity. We further assessed the significance of any discrepancies in the estimates of the treatment effects from the different trials, by means of Cochran's test for heterogeneity - heterogeneity would have been considered significant if P value &lt; 0.1 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We also utilised the I<SUP>2</SUP> statistic, which describes the percentage total variation across studies due to heterogeneity rather than chance, to quantify heterogeneity with I<SUP>2 </SUP>over 50% being considered substantial heterogeneity (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-05-10 17:15:39 +0100" MODIFIED_BY="Jo C Weldon">
<P>If there had been a sufficient number of trials (more than 10) included in any meta-analysis, we would have assessed publication bias in accordance with the recommendations on testing for funnel plot asymmetry, described by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-11-01 15:52:34 +0000" MODIFIED_BY="[Empty name]">
<P>Where data allowed, we performed meta-analysis of studies which assessed the same comparisons and outcomes. We combined RRs for dichotomous outcomes, and MDs (we would have produced SMDs if different scales had been used) for continuous outcomes, using a random-effects model where there were four or more studies, or a fixed-effect model for less than four studies.</P>
<P>We included data from cross-over studies (provided they incorporated a washout period) in meta-analyses using the generic inverse variance method described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), combining them with parallel studies using the methods described in <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>. For cross-over studies not incorporating a washout period, we utilised the first period data only, in accordance with Section 16.4.5 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
<P>Where single studies compared more than one active intervention with a placebo within the same analysis, the number of participants in the study's control group was halved before combining study data to avoid double-counting control participants within a single meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-11-01 15:56:17 +0000" MODIFIED_BY="[Empty name]">
<P>If there were sufficient studies, we would have used sensitivity analyses and meta-analysis regression (using Stata software (<LINK REF="REF-Stata-2015" TYPE="REFERENCE">Stata 2015</LINK>)) to explore, quantify, and control for sources of heterogeneity between studies for type of therapy.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-11-01 16:01:53 +0000" MODIFIED_BY="[Empty name]">
<P>If the number (and quality) of studies had allowed, we would have undertaken a sensitivity analysis for each intervention and outcome limiting the analysis to studies at low overall risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">Presentation of main results</HEADING>
<P>We produced a 'Summary of findings' table for the main outcomes. We assessed the quality of the body of evidence, taking into account the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, the risk of publication bias and the magnitude of the effect. We categorised the quality of the body of evidence of each of the main outcomes as high, moderate, low or very low.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<STUDY_DESCRIPTION MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Details of the trial participants, interventions and outcomes measured can be seen in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SEARCH_RESULTS MODIFIED="2016-11-01 16:04:38 +0000" MODIFIED_BY="[Empty name]">
<P>The literature search for this review identified 377 records after the duplicates were removed. These 377 records were screened independently and in duplicate. After screening, we retained 64 records for further assessment and categorised 313 records as not relevant.</P>
<P>We obtained published papers for 60 records. Following our assessment of the 60 full-text articles, we excluded a total of 37 studies (37 articles) with reasons provided (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</P>
<P>We included 23 studies (a total of 25 articles, including eight already included studies from the previous version of the review), of which 21 studies (all except <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> and <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>) provided useable data. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the study selection process.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Previously, this review included nine trials (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Pisanty-1975" TYPE="STUDY">Pisanty 1975</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>). This update excludes a previously included trial (<LINK REF="STD-Pisanty-1975" TYPE="STUDY">Pisanty 1975</LINK>), due to insufficiently indicating whether its patients had burning mouth syndrome and also not being a randomised controlled trial (RCT), and includes an additional 15 RCTs (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</P>
<P>A total of 23 RCTs (1285 patients included; 1121 patients assessed) were included in this latest update of the review (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of studies</HEADING>
<P>Included studies were undertaken in several countries.</P>
<UL>
<LI>Eight trials (35%) were conducted in Italy (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>).</LI>
<LI>Six trials (26%) in Spain (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>).</LI>
<LI>Four trials (17%) in Brazil (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</LI>
<LI>The remaining five single studies (4% each, totalling 22% of included studies) were conducted in Argentina (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>), Finland (<LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>), France (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>), Germany (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>), and Sweden (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>).</LI>
</UL>
<P>All trials were published in English, except one Italian study (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>).</P>
<P>All studies were placebo-controlled parallel RCTs, except three (13%) cross-over studies (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). Of these three studies, only two incorporated a washout period into the cross-over study design (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>: 20 days; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>: 1 week).</P>
<P>
<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK> was a multicentre trial, and all other studies operated from a single centre. Sixteen trials (70%) contained two arms (intervention versus placebo), one three-armed trial (4%) contained a 'no treatment' arm in addition to comparing intervention with placebo (<LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>), and the remaining six trials (26%) were multi-armed to investigate several interventions (five arms: <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; four arms: <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; three arms: <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>).</P>
<P>Follow-up varied greatly between included studies, and ranged between one week (<LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>) to six months (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>). Four trials (17%) followed up their patients for longer than three months (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>).</P>
<P>Nine studies (39%) provided information on source of funding:</P>
<UL>
<LI>São Paulo State Research Foundation (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>);</LI>
<LI>funded by universities (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>);</LI>
<LI>national dental professional body (<LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>);</LI>
<LI>mixed funding from a university and national government bodies (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>);</LI>
<LI>mixed funding from a university and a national dental professional body (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>);</LI>
<LI>unfunded (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>).</LI>
</UL>
<P>The remaining 14 studies (61%) did not report on source of funding.</P>
<P>Five trials (22%) reported no conflict of interests (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>), while 18 trials (78%) omitted reporting their authors' conflicts of interests.
<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants</HEADING>
<P>All 23 included RCTs appropriately defined their participants as having burning mouth syndrome (BMS) - that is, persistent oral mucosal pain with no dental or medical cause for such symptoms (<LINK REF="REF-IHS-2013" TYPE="REFERENCE">IHS 2013</LINK>). Excerpted details of diagnosis and duration are presented in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>In total, 1061 women (83%) and 221 men (17%) are reported to have participated in the included studies.</P>
<P>The mean age of participants ranged from 45 years (<LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>) to 73 years old (<LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>); however, the average age of participants was older than 60 years in 19 trials (83%: <LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</P>
<P>Twenty-one studies (91%) did not report any data relating to socioeconomic status. Of the two studies which did, <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> reported participants' number of schooling years, and <LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK> reported data on race, occupation, and marital status.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of interventions</HEADING>
<P>A broad range of interventions were investigated by the included studies, categorised into nine groups.</P>
<UL>
<LI>Antidepressants and antipsychotics</LI>
<UL>
<LI>Paroxetine (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>)</LI>
<LI>Amitriptyline (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>)</LI>
<LI>Amisulpride (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>)</LI>
<LI>Trazodone (<LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Anticonvulsants</LI>
<UL>
<LI>Gabapentin (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>)</LI>
<LI>Gabapentin + alpha lipoic acid (ALA) (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>).</LI>
</UL>
<LI>Benzodiazepines</LI>
<UL>
<LI>Systemic clordemetildiazepam (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>)</LI>
<LI>Topical clonazepam (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>)</LI>
<LI>Systemic clonazepam (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Cholinergics (parasympathomimetics)</LI>
<UL>
<LI>Bethanechol (<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Dietary supplements</LI>
<UL>
<LI>ALA without adjunctive active ingredients (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>)</LI>
<LI>ALA + vitamins (Tiobec) (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>)</LI>
<LI>ALA + adjunctive lycopene + green tea extract (Thioderm) (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>)</LI>
<LI>Hypericum perforatum (St John's Wort) (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>)</LI>
<LI>'Catuama' herbal compound (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>)</LI>
<LI>Lycopene (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Electromagnetic radiation</LI>
<UL>
<LI>Low-level laser therapy (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</LI>
</UL>
</UL>
<UL>
<LI>Physical barriers</LI>
<UL>
<LI>Tongue protector + adjunctive reinforced self-control instruction (RS-CI)) (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>).</LI>
</UL>
<LI>Psychological therapies</LI>
<UL>
<LI>Cognitive therapy (CT) (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>).</LI>
</UL>
<LI>Topical treatments</LI>
</UL>
<UL>
<UL>
<LI>Benzydamine hydrochloride oral rinse (<LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>)</LI>
<LI>Lactoperoxidase oral rinse (Biotene) (<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>)</LI>
<LI>Topical urea (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>)</LI>
<LI>Capsaicin oral rinse (<LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>).</LI>
</UL>
</UL>
<P>There was heterogeneity in the administration of some treatments. For example, alpha lipoic acid was issued in total daily dosages ranging from 600 to 800 mg, either as single or as split doses; and topical clonazepam was given as 1 mg three times daily or 0.5 mg up to four times daily as required (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of outcome assessment</HEADING>
<P>The outcomes used by the included studies are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. A wide variety of outcome measures were employed by the various studies (Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>Due to heterogeneity in follow-up duration between included studies (ranging from one week (<LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>) to six months (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>)), it was agreed it would be more clinically useful to separate outcome assessment by short term (&#8804; 3 months) and long term (&gt; 3 to &#8804; 6 months).</P>
<P>Twenty-one studies (91%) reported short-term outcome assessment (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>). Three studies (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>) which reported short-term outcome assessment also reported long-term outcomes. The remaining study (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>) only reported long-term outcome assessment.</P>
<P>We were unable to include data from two studies, due to excessive attrition in the placebo arm (79%) in one study (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>), and in the other study there was not only substantial attrition (23%) during the cross-over trial's first phase, but all patients that developed side effects were also withdrawn (<LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). All other trials were included in the quantitative analysis.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Symptom relief</HEADING>
<P>A broad range of scales were used to assess symptom relief (characterised by included studies as change in burning/symptom intensity/pain).</P>
<UL>
<LI>Visual analogue scale (VAS), or an alternatively named variation, of varying widths (n = 17) (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK> (reported separately for pain and burning); <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</LI>
<LI>Bespoke BMS symptomology change scale (n = 3) (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>).</LI>
<LI>Clinical Global Impression I (CGI I) scale (n = 1) (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>).</LI>
<LI>Bespoke geographical burning distribution numerical scale (0 to 4) (n = 1) (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>).</LI>
<LI>EDOF-HC (Orofacial Pain Clinic - Hospital das Clinicas) protocol (n = 1) (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>).</LI>
</UL>
<P>Furthermore, four studies supplemented their VAS assessment of symptom relief with:</P>
<UL>
<LI>McGill Pain Questionnaire (MPQ) (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>);</LI>
<LI>Faces scale (FS) (0 to 5) (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>);</LI>
<LI>visual numeric scale (VNS) (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>);</LI>
<LI>Global Perceived Effect (GPE) scale (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Change in quality of life (QoL)</HEADING>
<P>Seven studies either directly assessed change in QoL or used surrogate markers for its assessment.</P>
<P>Four studies directly assessed change in QoL.</P>
<UL>
<LI>Two studies used a combination of assessing both general QoL (by using the 36-Item Short Form Health Survey (SF-36)) and the impact of oral health on patients' QoL (by using one of two versions of the Oral Health Impact Profile (OHIP-14 or OHIP-49)) (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK> (SF-36 and OHIP-14); <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK> (SF-36 and OHIP-49)).</LI>
<LI>One study singularly used OHIP-14 to assess change in QoL (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</LI>
<LI>The fourth study assessed QoL by posing simple questions to patients, rather than using a standardised or validated QoL questionnaire (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>).</LI>
</UL>
<P>The remaining three studies used surrogate markers to assess change in QoL.</P>
<UL>
<LI>Two studies assessed change in depression using the Beck Depression Inventory (BDI) (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</LI>
<LI>The third study assessed change in anxiety using the HARS scale, and change in depression using the Montgomery Asberg Depression Rating Scale (MADRS) (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>).</LI>
</UL>
<P>Furthermore, two studies supplemented their direct assessment of change in QoL with adjunctive use of the HAD (Hospital Anxiety and Depression) scale to also assess anxiety and depression as surrogate markers of QoL (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Change in taste</HEADING>
<P>Only two studies assessed change in taste. One study used a taste test score (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>), and the other assessed change in taste by use of the gustative threshold from the Quantitative Sensory Testing (QST) protocol's combination battery of 12 tests (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>). One study contributed data to quantitative synthesis (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Change in feeling of dryness</HEADING>
<P>A single study (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>) assessed change in feeling of dryness, using a xerostomia questionnaire; however no data contributed to quantitative synthesis due to it being narratively reported only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Adverse effects</HEADING>
<P>Side effects were included as an outcome measure in this review update, despite not formally being included as an outcome in the original protocol.</P>
<UL>
<LI>Seven studies clearly reported the occurrence of adverse effects experienced in their trials (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</LI>
<LI>Six studies did not report adverse effects (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</LI>
<LI>Five studies reported that no adverse effects occurred (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>).</LI>
</UL>
<P>The remaining five studies provided a partial narrative report of the occurrence of adverse effects.</P>
<UL>
<LI>Three studies indicated potential missing adverse effects data ("without notable adverse effects" (<LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>); "very mild" (although data were provided by author upon request) (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>); "minimal" (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>)).</LI>
<LI>One multi-armed trial omitted reporting adverse effects data for one of the arms (lactoperoxidase data missing (<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>)).</LI>
<LI>One trial reported the occurrence of an adverse event as rationale for a patient withdrawal but made no further mention of adverse effects experienced (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>).</LI>
</UL>
<P>Nine included studies contributed adverse events data towards quantitative synthesis (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-11-02 10:34:04 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 37 studies (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). The main reasons for exclusion were that the trial did not have a placebo arm (13 studies: <LINK REF="STD-Bai-2010" TYPE="STUDY">Bai 2010</LINK>; <LINK REF="STD-Bessho-1998" TYPE="STUDY">Bessho 1998</LINK>; <LINK REF="STD-Campisi-1997" TYPE="STUDY">Campisi 1997</LINK>; <LINK REF="STD-Grechko-1996" TYPE="STUDY">Grechko 1996</LINK>; <LINK REF="STD-Huang-2006" TYPE="STUDY">Huang 2006</LINK>; <LINK REF="STD-Huang-2009" TYPE="STUDY">Huang 2009</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2013" TYPE="STUDY">López-Jornet 2013</LINK>; <LINK REF="STD-Lu-2002" TYPE="STUDY">Lu 2002</LINK>; <LINK REF="STD-Maina-2002" TYPE="STUDY">Maina 2002</LINK>; <LINK REF="STD-Peng-2001" TYPE="STUDY">Peng 2001</LINK>; <LINK REF="STD-Pisanty-1975" TYPE="STUDY">Pisanty 1975</LINK>; <LINK REF="STD-Qui-2010" TYPE="STUDY">Qui 2010</LINK>; <LINK REF="STD-Yong-2003" TYPE="STUDY">Yong 2003</LINK>); was not an RCT (10 studies: <LINK REF="STD-Ferguson-1981" TYPE="STUDY">Ferguson 1981</LINK>; <LINK REF="STD-Forabosco-1992" TYPE="STUDY">Forabosco 1992</LINK>; <LINK REF="STD-Grushka-1998" TYPE="STUDY">Grushka 1998</LINK>; <LINK REF="STD-Hirsch-2011" TYPE="STUDY">Hirsch 2011</LINK>; <LINK REF="STD-Hugoson-1991" TYPE="STUDY">Hugoson 1991</LINK>; <LINK REF="STD-Ito-2010" TYPE="STUDY">Ito 2010</LINK>; <LINK REF="STD-Kho-2010" TYPE="STUDY">Kho 2010</LINK>; <LINK REF="STD-Petruzzi-2004" TYPE="STUDY">Petruzzi 2004</LINK>; <LINK REF="STD-Romeo-2010" TYPE="STUDY">Romeo 2010</LINK>; <LINK REF="STD-Woda-1998" TYPE="STUDY">Woda 1998</LINK>); there were insufficient details to permit inclusion as the articles were conference abstracts or letters to the editor (three studies: <LINK REF="STD-Palacios_x002d_Sanchez-2010" TYPE="STUDY">Palacios-Sanchez 2010</LINK>; <LINK REF="STD-Pellegrini-2010" TYPE="STUDY">Pellegrini 2010</LINK>; <LINK REF="STD-Vukoja-2011" TYPE="STUDY">Vukoja 2011</LINK>); we were unable to locate the articles (three studies: <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Ma-2006" TYPE="STUDY">Ma 2006</LINK>; <LINK REF="STD-Mo-2003" TYPE="STUDY">Mo 2003</LINK>); inappropriate design (two studies: placebo group outcome assessed after one month and intervention group assessed after three months (<LINK REF="STD-Miziara-2009" TYPE="STUDY">Miziara 2009</LINK>) and intervention/placebo immediately assessed, no clinical application (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2010" TYPE="STUDY">Grémeau-Richard 2010</LINK>)); the diagnosis of BMS was uncertain (two studies: <LINK REF="STD-Bogetto-1997" TYPE="STUDY">Bogetto 1997</LINK>; <LINK REF="STD-Toida-2009" TYPE="STUDY">Toida 2009</LINK>); or data for BMS participants were combined with other non-BMS diagnoses (four studies: <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>; <LINK REF="STD-Lamey-1986" TYPE="STUDY">Lamey 1986</LINK>; <LINK REF="STD-Lindholm-2015" TYPE="STUDY">Lindholm 2015</LINK>; <LINK REF="STD-Loldrup-1989" TYPE="STUDY">Loldrup 1989</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>A summary of the risk of bias for each individual study is presented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, and overall across studies for each risk of bias domain in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. One study was deemed to have a low overall risk of bias (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>), four studies were deemed to have an unclear overall risk of bias (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>), and the remainder were deemed to have a high overall risk of bias.</P>
<ALLOCATION MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Nine studies were deemed to have a low risk of selection bias, after taking into account both random sequence generation and allocation concealment (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>). Ten studies were found to have an unclear risk of selection bias, after taking into account both random sequence generation and allocation concealment (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>). The remaining four studies were deemed to be at high risk of selection bias (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Twelve studies were assessed as being at low risk of performance bias (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>); seven were assessed as being at high risk of performance bias (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). All other studies were assessed as at unclear risk of performance bias.</P>
<P>With regard to detection bias, 15 studies were assessed as being at low risk of bias (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>); six studies were assessed as being at high risk of bias (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). All other studies were assessed as unclear risk of detection bias.</P>
<P>Twelve studies were assessed as being at low risk of bias for both performance and detection bias (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</P>
<P>Reasons for assessing studies at unclear or high risk of bias for performance and detection bias included vast differences in treatment arm modalities, authors of studies describing them as 'open label', and adverse events likely to have precluded blinding of participants.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Twelve studies were deemed to have a low risk of attrition bias, after accounting for incomplete outcome data (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</P>
<P>Seven studies were deemed to have a high risk of attrition bias, after accounting for incomplete outcome data (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>). In five studies, there was inadequate explanation as to why dropouts occurred (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>); one study presented data in a flow diagram (which stated two participants in each arm were excluded from the analysis), which did not match details provided in the text (which stated seven patients had their data excluded from analysis) - hence the study was assessed as at high risk of bias (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>); one study removed participants who had experienced adverse events from the analysis (<LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>).</P>
<P>Four studies were deemed to have an unclear risk of attrition bias, after accounting for incomplete outcome data (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Twelve studies were deemed to have a low risk of reporting bias, after accounting for selective outcome reporting (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>). </P>
<P>Eight studies were deemed to have a high risk of reporting bias, after accounting for selective outcome reporting (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). </P>
<UL>
<LI>Five studies failed to report on prespecified or expected outcomes (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>). </LI>
<LI>Three studies did not report their prespecified outcomes appropriately or fully (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>). </LI>
</UL>
<P>Three studies were deemed to have an unclear risk of reporting bias, after accounting for selective outcome reporting (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Seven studies were determined to have a low risk of other potential sources of bias (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>)</P>
<P>Ten studies were considered to have a high risk of other potential sources of bias (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</P>
<UL>
<LI>Eight studies indicated cause for concern over baseline comparability in addition to their study's unclearly described randomisation process (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>).</LI>
<LI>We had lesser concerns over baseline comparability in one study (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>) due to reporting appropriate randomisation; however the distribution of anxiolytic use amongst patients was unclear.</LI>
<LI>One study (<LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>) indicated wide use of psychoactive medication within sample and adjunctive non-standardised psychotherapy delivered at the discretion of three uncalibrated clinicians; however, the distribution of patients in receipt of psychotherapy was not reported.</LI>
</UL>
<P>Six were judged to have an unclear risk of other potential sources of bias (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>).</P>
<UL>
<LI>Three studies (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>) indicated concerns over baseline comparability, although an appropriate randomisation process was undertaken.</LI>
<LI>One study's intervention was a systemic anxiolytic drug (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>), correspondingly baseline anxiety should have been assessed to account for confounding.</LI>
<LI>One study (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>) allowed patient use of anxiolytics within sample although the distribution between groups was unclear.</LI>
<LI>The remaining study (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>) presented contradictory text within paper, raising concerns of reporting accuracy.</LI>
</UL>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-11-09 11:15:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Interventions were allocated between nine groups to assess their efficacy: antidepressants and antipsychotics, anticonvulsants, benzodiazepines, cholinergics, dietary supplements, electromagnetic radiation, physical barriers, psychological therapies, and topical treatments. The quality of the evidence was assessed as very low for all outcomes (both short (up to three months from baseline) and long term (three to six months from baseline)) in all intervention categories (with the exception of adverse effects for physical barriers, which were assessed as low-quality evidence). See Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> for full details of reported adverse effects, Additional <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> for adverse effect outcome data, and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>; <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>; <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>; <LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>; <LINK REF="SOF-09" TYPE="SOF">Summary of findings table 9</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Antidepressants and antipsychotics</HEADING>
<P>Two studies (104 participants), at either high or unclear risk of bias, provided very low-quality evidence comparing antidepressants and/or antipsychotics against placebo (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> (paroxetine 20 mg daily; amitriptyline 25 mg daily; amisulpride 50 mg daily); <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK> (trazodone 200 mg daily)).</P>
<P>Data from <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> are not presented due to excessive attrition (19/24; 79%) in the study's placebo arm.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>One study (37 participants: <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>) compared an antidepressant (trazodone 200 mg daily) against placebo. There was no evidence to demonstrate a difference in short-term symptom relief (mean visual analogue scale (VAS) pain score, scale 0 to 10: lower better; mean difference (MD) 1.26, 95% confidence interval (CI) -0.24 to 2.76; effect P = 0.10) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Long term (&gt; 3 to &#8804; 6 months)</HEADING>
<P>No included studies, comparing antidepressants and antipsychotics versus placebo, provided data on long-term symptom relief.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in quality of life (QoL)</HEADING>
<P>A single study (37 participants: <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>) narratively reported assessment of short-term change in depression as a surrogate measure for QoL, and indicated that both intervention and placebo participants were less depressed at trial completion, but there was no evidence of a difference between groups. No included study assessed long-term change in QoL.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>No included studies, comparing antidepressants or antipsychotics against placebo, provided data on short- or long-term change in taste or feeling of dryness.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>One study (37 participants: <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK>) reported adverse effect data, comparing an antidepressant (trazodone) against placebo. There was evidence to suggest trazodone resulted in an increase in dizziness (risk ratio (RR) 11.61, 95% CI 1.66 to 81.04; effect P = 0.01) and drowsiness (RR 4.75, 95% CI 1.18 to 19.07; effect P = 0.03); however, there was no evidence of a difference between trazodone and placebo in terms of abdominal pains (RR 1.32, 95% CI 0.42 to 4.15; effect P = 0.64), headache (RR 1.58, 95% CI 0.30 to 8.40; effect P = 0.59), palpitations (RR 1.06, 95% CI 0.17 to 6.72; effect P = 0.95), tremor (RR 2.11, 95% CI 0.21 to 21.32; effect P = 0.53), dry mouth (RR 3.17, 95% CI 0.36 to 27.72; effect P = 0.30) or urinary incontinence (RR 3.16, 95% CI 0.14 to 72.84; effect P = 0.47).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Anticonvulsants</HEADING>
<P>One multi-armed study (100 participants: <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK> ), at high risk of bias, provided very low-quality evidence comparing an anticonvulsant (gabapentin 300 mg daily ± alpha lipoic acid (ALA) 600 mg daily) against placebo. This study did not assess long-term outcome data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>Overall, there was evidence of short-term symptom relief in favour of the anticonvulsant (bespoke geographical burning distribution numerical scale 0 to 4, dichotomised; RR 4.00, 95% CI 2.09 to 7.67; effect P &lt; 0.0001). Two subgroups were formed: gabapentin only versus placebo and gabapentin with adjunctive ALA versus placebo. No between-subgroup difference was shown (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>Neither short- nor long-term change in QoL data were available for the comparison of anticonvulsants (with or without ALA) against placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>No short- or long-term data on change in taste or feeling of dryness were available for the comparison of anticonvulsants (with or without ALA) against placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>The single study (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>) comparing an anticonvulsant (gabapentin, without and with adjunctive ALA) against placebo, narratively reported adverse effects as being "very mild". Data obtained from the study author indicated that drowsiness was more likely to be experienced when using gabapentin (without adjunctive ALA) (80 participants; RR 31.95, 95% CI 1.84 to 553.64; effect P = 0.02). There was no evidence of a difference in drowsiness (80 participants; RR 14.52, 95% CI 0.73 to 290.44; effect P = 0.08) or mild headache (80 participants; RR 8.71, 95% CI 0.37 to 205.80; effect P = 0.18) when using gabapentin with ALA.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Benzodiazepines</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>Four studies (166 participants), at either high or unclear risk of bias, provided very low-quality evidence comparing benzodiazepines against placebo (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> (systemic clordemetildiazepam 1 mg daily); <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK> (topical clonazepam 3 mg daily); <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK> (systemic clonazepam 0.5 mg daily); <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK> (topical clonazepam 0.5 to 2 mg daily)).</P>
<P>Data from <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> are not presented due to excessive attrition (19/24; 79%) in the study's placebo arm.</P>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>Three studies (131 participants: <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>) provided short-term data on symptom relief for the comparison of benzodiazepines versus placebo. Two studies (111 participants) evaluated topical benzodiazepine use and showed an improvement in symptom relief between clonazepam and placebo, in favour of clonazepam (mean VAS pain score, scale 0 to 10: lower better; MD -1.89, 95% CI -2.19 to -1.59; effect P &lt; 0.00001) (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>). No difference in symptom relief was shown between systemic clonazepam and placebo (mean VAS pain score, scale 0 to 10: lower better; 20 participants; MD 0.00, 95% CI -1.86 to 1.86; effect P = 1.00) (<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>).</P>
<P>The pooled results for the topical and systemic administration of clonazepam showed evidence of short-term symptom relief however, there was substantial statistical heterogeneity between subgroups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Long term (&gt; 3 to &#8804; 6 months)</HEADING>
<P>Only one study (66 participants: <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>) assessed benzodiazepines (topical clonazepam) against placebo for long-term symptom relief. There was evidence of symptom improvement in favour of clonazepam (mean VAS pain score, scale 0 to 10: lower better; MD -1.39, 95% CI -1.96 to -0.83; effect P &lt; 0.00001) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>
<LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK> (20 participants) assessed depression, as a surrogate marker of QoL. No difference was shown of short-term change in depression (mean depression score, scale 0 to 4: lower better; MD -0.20, 95% CI -0.95 to 0.55; effect P = 0.60) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). No included studies assessed long-term change in QoL, or its surrogate markers.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Change in taste</HEADING>
<P>One study (20 participants: <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>) compared benzodiazepines (systemic clonazepam) against placebo. No difference was shown of short-term change in taste (mean taste test score, scale 0 to 16: higher better; MD -1.00, 95% CI -3.11 to 1.11; effect P = 0.35) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). No included studies assessed long-term change in taste.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in feeling of dryness</HEADING>
<P>No included studies assessed short- or long-term change in feeling of dryness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Two studies (114 participants: <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>), comparing benzodiazepines (both topical clonazepam) against placebo, demonstrated no difference in drowsiness (RR 2.71, 95% CI 0.84 to 8.74; effect P = 0.09).</P>
<P>One of the two studies (48 participants: <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>) also showed no difference in dry mouth, spasmophilia, or euphoric behaviour (all three side effects independently: RR 3.00, 95% CI 0.13 to 70.16; effect P = 0.49).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cholinergics</HEADING>
<P>One study (40 participants: <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>), at high risk of bias, provided very low-quality evidence comparing a cholinergic (bethanechol 15 mg daily) against placebo. This study did not assess long-term outcome data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>The single study evaluating a cholinergic showed no difference in short-term symptom relief between bethanechol and placebo (bespoke burning mouth syndrome (BMS) symptomology change scale, dichotomised; RR 5.00, 95% CI 0.26 to 98.00; effect P = 0.29) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>Neither short- nor long-term change in QoL data were available to compare cholinergics against placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>No short- or long-term data on change in taste or feeling of dryness were available for the comparison of cholinergics versus placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>
<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK> narratively reported adverse effect data, comparing a cholinergic (bethanechol) against placebo. Four participants (20%) in the bethanechol arm reported adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain). Reported data did not present the distribution of these outcomes by participant.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dietary supplements</HEADING>
<P>Twelve studies (628 participants) provided very low-quality evidence comparing dietary supplements against placebo (ALA without adjunctive active ingredients (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>); ALA + vitamins (Tiobec) (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>); ALA + adjunctive lycopene + green tea extract (Thioderm) (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>); hypericum perforatum (St John's Wort) (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>); 'Catuama' herbal compound (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>); lycopene (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>)). All studies were at either high or unclear risk of bias, apart from one assessed at low risk of bias (<LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>Twelve studies (628 participants) compared dietary supplements against placebo (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>). There was insufficient or contradictory evidence regarding the benefit of any of the evaluated dietary supplements over placebo (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
<P>No difference in symptom relief was found between ALA + adjunctive vitamins and placebo when assessed using continuous outcome data (two studies, 66 participants: <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; mean VAS pain score, scale 0 to 10: lower better; MD -0.49, 95% CI -1.79 to 0.81; effect P = 0.46) (not shown in <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Three studies (142 participants: <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>) reported data for relief/no relief. There was a short-term benefit for ALA with adjunctive vitamins (bespoke BMS symptomology change scale, dichotomised; RR 4.10, 95% CI 2.63 to 6.38; effect P &lt; 0.00001). There was a substantial amount of heterogeneity (P = 0.02; I<SUP>2</SUP> = 75%) between the results of these three studies (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Long term (&gt; 3 to &#8804; 6 months)</HEADING>
<P>Two studies (94 participants: <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>) provided long-term data comparing dietary supplements against placebo. Both studies compared ALA (either with or without adjunctive vitamins). Overall, there was no difference in long-term symptom relief (mean VAS pain score, scale 0 to 10: lower better; MD -0.89, 95% CI -2.37 to 0.59; P = 0.24). There was no evidence of statistical heterogeneity (P = 0.83; I<SUP>2</SUP> = 0%) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>One included study (50 participants: <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>), comparing lycopene against placebo, provided data assessing short-term change in QoL. Overall QoL was assessed by OHIP-14 (Oral Health Impact Profile 14), and anxiety and depression were also assessed adjunctively, as surrogate markers of QoL (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
<P>There was no difference in short-term change in QoL (mean OHIP-14 score, scale 0 to 70: lower better; MD 0.93, 95% CI -3.14 to 5.00; effect P = 0.65), or in depression (as a surrogate marker of QoL: mean HAD (Hospital Anxiety and Depression) depression score, scale 0 to 21: lower better; MD -1.87, 95% CI -4.23 to 0.49; effect P = 0.12); however, there was short-term benefit for lycopene with a mean score reduction in anxiety of -2.85 (mean HAD anxiety score, scale 0 to 21: lower better; 95% CI -5.28 to -0.42; effect P = 0.02).</P>
<P>One study (43 participants: <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>), comparing hypericum perforatum extract with placebo, evaluated QoL from patient self-reports and narratively indicated that both intervention and placebo participants were better able to cope at trial completion.</P>
<P>No included studies assessed long-term change in QoL, or its surrogate markers.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>No included studies assessed short- or long-term change in taste or feeling of dryness, when comparing dietary supplements against placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Three studies (138 participants: <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>), comparing dietary supplements (all three studies used ALA, with or without adjunctive active ingredients) against placebo, provided evidence that gastrointestinal complaints were four times more likely to be experienced (RR 4.00, 95% CI 1.21 to 13.27; effect P = 0.02). There was no evidence of heterogeneity (P = 0.78; I<SUP>2</SUP> = 0%). The gastrointestinal effect was sufficiently severe to cause an intervention-allocated participant to abandon treatment in one trial (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>).</P>
<P>Two studies (118 participants: <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>), comparing dietary supplements (ALA, with or without adjunctive active ingredients) against placebo, indicated evidence of an 11-fold increase in headache occurrence (RR 10.87, 95% CI 1.36 to 87.03; effect P = 0.02). There was no evidence of heterogeneity (P = 0.82; I<SUP>2</SUP> = 0%). One study (43 participants: <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>), comparing hypericum perforatum with placebo, failed to report adverse effect occurrence; however, the study authors indicated a severe headache was sufficient cause for an intervention-allocated participant to abandon treatment.</P>
<P>Two studies (110 participants: <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>), comparing dietary supplements (ALA (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>); 'Catuama' herbal compound (<LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>)) against placebo, showed no difference in drowsiness (RR 1.58, 95% CI 0.21 to 11.71; effect P = 0.65). There was no evidence of heterogeneity (P = 0.64; I<SUP>2</SUP> = 0%).</P>
<P>One study (38 participants: <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>), comparing dietary supplements (ALA without adjunctive active ingredients) against placebo, demonstrated there was no difference in blood pressure (RR 1.00, 95% CI 0.07 to 14.85; effect P = 1.00); however the study authors reported increase in blood pressure was sufficient to cause an intervention- and a placebo-allocated participant to abandon treatment.</P>
<P>One study (80 participants: <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>), comparing dietary supplements (ALA) against placebo, indicated there was no difference in intermittent facial skin rash (RR 8.71, 95% CI 0.37 to 205.80; effect P = 0.18).</P>
<P>One study (72 participants: <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>), comparing dietary supplements ('Catuama' herbal compound) against placebo, showed no difference in exacerbation of symptoms (RR 1.12, 95% CI 0.33 to 3.83; effect P = 0.86), insomnia or weight gain (both side effects independently: RR 2.69, 95% CI 0.11 to 63.96; effect P = 0.54).</P>
<P>Four studies (224 participants) comparing dietary supplements (ALA alone and ALA with adjunctive vitamins (Tiobec) (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>) and lycopene (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>)) against placebo, narratively reported that no adverse effects occurred.</P>
<P>
<LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK> (60 participants, ALA with adjunctive vitamins) reported no "notable adverse effects", and <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK> (40 participants, ALA with adjunctive vitamins) narratively reported four intervention participants (20%) had experienced heartburn, before being corrected by administration of ranitidine (150 mg). <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK> (43 participants, hypericum perforatum extract) reported that one intervention participant (5%) developed severe headache and discontinued treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Electromagnetic radiation</HEADING>
<P>One study (58 participants: <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>) at high risk of bias, provided very low-quality evidence comparing electromagnetic radiation (infrared laser; red laser) against placebo. This study did not assess long-term outcome data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>
<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK> compared two types of low-level laser therapy (infrared laser; red laser) against placebo. It demonstrated a short-term benefit in symptom relief (mean VAS pain score, scale 0 to 100: lower better; MD -30.36, 95% CI -44.22 to -16.50; effect P &lt; 0.0001) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>There was evidence of a short-term improvement in QoL from low-level laser therapy (58 participants: <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>) compared with placebo (mean OHIP-14 score, scale 0 to 56: lower better; MD -5.24, 95% CI -7.38 to -3.09; effect P &lt; 0.00001) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>
<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK> did not assess change in taste, feeling of dryness, or report the occurrence of adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Physical barriers</HEADING>
<P>One study (50 participants: <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>) at high risk of bias, provided very low-quality evidence comparing a physical barrier (tongue protector + adjunctive reinforced self-control instruction (RS-CI)) against placebo. This study did not assess long-term outcome data.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>In this single study (50 participants: <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>), there was a short-term benefit for physical barriers with a mean score reduction in symptoms of -1.10 (mean VAS pain score, scale 0 to 10: lower better; 95% CI -2.14 to -0.06; effect P = 0.04) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>
<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK> assessed short-term change in overall QoL by OHIP-49, and adjunctively assessed anxiety and depression as surrogate QoL markers. There was no difference in short-term change in overall QoL (mean OHIP-49 score, scale 0 to 196: lower better; MD -9.20, 95% CI -26.90 to 8.50; effect P = 0.31), or in anxiety (mean HAD anxiety score, scale 0 to 21: lower better; MD 0.16, 95% CI -3.19 to 3.51; effect P = 0.93) or depression (mean HAD depression score, scale 0 to 21: lower better; MD -0.64, 95% CI -3.98 to 2.70; effect P = 0.71) either (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>This study did not assess change in taste or feeling of dryness.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>
<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK> narratively reported that no adverse effects occurred.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Psychological therapies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>One study (30 participants: <LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>) at high risk of bias, provided very low-quality evidence comparing a psychological therapy (cognitive therapy (CT)) against placebo. The study presented long-term outcome data only.</P>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Long term (&gt; 3 to &#8804; 6 months)</HEADING>
<P>
<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK> demonstrated a long-term benefit for psychological therapy with a mean score reduction in symptoms of -3.20 (mean VAS pain score, scale 1 to 7: lower better; 95% CI -4.22 to -2.18; effect P &lt; 0.00001) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>Neither short- nor long-term change in QoL data were available to compare psychological therapy against placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>
<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK> did not assess change in taste, feeling of dryness, or report the occurrence of adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical treatments</HEADING>
<P>Five studies (180 participants), at either high or unclear risk of bias, provided very low-quality evidence comparing topical treatments (benzydamine hydrochloride oral rinse (<LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>); lactoperoxidase oral rinse (Biotene) (<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>); topical urea (10%) (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>); and capsaicin oral rinse (<LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>)) against placebo.</P>
<P>Data from <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK> (30 participants) are not presented due to attrition (7/30; 23%) in this cross-over study's first phase and their protocol requirement for participants who develop adverse effects to be withdrawn from the trial.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptom relief</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Short term (&#8804; 3 months)</HEADING>
<P>Four studies (150 participants: <LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>) compared topical treatments with placebo to estimate their short-term effect on symptom relief. Pooling of data was not undertaken due to symptom data being presented in both dichotomous and continuous form. There is insufficient or contradictory evidence regarding the benefit of any of the evaluated topical interventions over placebo (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Long term (&gt; 3 to &#8804; 6 months)</HEADING>
<P>One multi-armed study (27 participants: <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>) provided data on long-term symptom relief of topical treatments (capsaicin oral rinse and lactoperoxidase oral rinse (Biotene)) compared with placebo. This study, assessed at high risk of bias, demonstrated a long-term benefit for capsaicin oral rinse (mean VAS pain score, scale 0 to 10: lower better; MD -2.60, 95% CI -5.11 to -0.09; effect P = 0.04)). No effect was shown for the lactoperoxidase oral rinse (Biotene) data (MD -1.50, 95% CI -3.91 to 0.91; effect P = 0.22) (<LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in QoL</HEADING>
<P>No included studies comparing topical treatments against placebo provided data assessing short- or long-term change in QoL.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Change in taste</HEADING>
<P>One study (38 participants: <LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>) comparing a topical treatment (topical urea (10%)) against placebo reported narratively that there were no differences in short-term gustation thresholds after treatment (Mann-Whitney: sweet P = 0.376; salty P = 0.689; sour P = 0.689; bitter P = 0.689).<BR/>No included studies comparing topical treatments assessed long-term change in taste.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Change in feeling of dryness</HEADING>
<P>The same single study (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>) reported narratively that there were no differences in short-term xerostomia questionnaire assessment after treatment.<BR/>No included studies comparing topical treatments assessed long-term change in feeling of dryness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>One study (20 participants: <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>) comparing benzydamine hydrochloride oral rinse against placebo, reported narratively that no adverse effects occurred.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-11-03 18:32:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<SUMMARY_OF_RESULTS MODIFIED="2016-11-03 10:55:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>A total of 23 placebo-controlled randomised controlled trials (RCTs) were included in this review, evaluating the effectiveness of 23 different interventions for the treatment of burning mouth syndrome (BMS) symptoms (distributed between nine intervention categories: antidepressants and antipsychotics; anticonvulsants; benzodiazepines; cholinergics; dietary supplements; electromagnetic radiation; physical barriers; psychological therapies; and topical treatments). There was a considerable amount of heterogeneity in the types of interventions studied, and how the interventions were delivered.</P>
<P>There was some evidence of a benefit in short-term symptom relief for electromagnetic radiation, topical benzodiazepines, physical barriers and anticonvulsants. We found insufficient/contradictory evidence regarding the short-term effectiveness of antidepressants, systemic benzodiazepines, cholinergics, dietary supplements or topical treatments. No RCT assessing psychological therapies evaluated short-term symptom relief.</P>
<P>We also found some evidence of long-term symptom relief for psychological therapies, capsaicin oral rinse (topical treatment) and topical benzodiazepines. We found no evidence of a difference for dietary supplements or lactoperoxidase oral rinse. No studies assessing antidepressants, anticonvulsants, cholinergics, electromagnetic radiation, or physical barriers evaluated long-term symptom relief.</P>
<P>We found some evidence of a short-term quality of life (QoL) improvement for electromagnetic radiation, however findings were inconclusive for antidepressants, benzodiazepines, dietary supplements and physical barriers. No studies assessing anticonvulsants, cholinergics, psychological therapies, or topical treatments evaluated short-term change in QoL, and no RCTs from any category assessed long-term change in QoL.</P>
<P>Changes in taste and feeling of dryness were assessed by included studies in the short term only, and the findings for each were inconclusive.</P>
<P>With regard to adverse events, there is very low-quality evidence that antidepressants increase dizziness and drowsiness, and that alpha lipoic acid increased headache and gastrointestinal complaints. We found insufficient/contradictory evidence regarding adverse events for anticonvulsants or benzodiazepines. Adverse events were poorly reported or unreported for cholinergics, electromagnetic radiation, and psychological therapies. No adverse events occurred from physical barriers or topical therapy use.</P>
<P>See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>; <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>; <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>; <LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>; <LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>; <LINK REF="SOF-09" TYPE="SOF">Summary of findings table 9</LINK>.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>All of the study participants included in the current review were deemed to adhere to an appropriate diagnostic classification of BMS (Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>We had serious concerns regarding the applicability of the evidence for seven of the nine intervention categories contained in this review (excepting dietary supplements and physical barriers), as studies from these seven categories assessed only one type of each intervention and the effects of other types of these interventions (antidepressants and antipsychotics; anticonvulsants; benzodiazepines; cholinergics; electromagnetic radiation; psychological therapies; and topical treatments) may differ.</P>
<P>While we were able to assess short-term symptom relief for all intervention categories except psychological therapies, fewer data were available for long-term assessment. Consequently, we are currently unable to estimate long-term symptom relief resulting from use of antidepressants, anticonvulsants, cholinergics, electromagnetic radiation, or physical barriers.</P>
<P>Furthermore, we were only able to assess:</P>
<UL>
<LI>short-term change in QoL for dietary supplements, electromagnetic radiation, and physical barriers (no interventions long term),</LI>
<LI>short-term change in depression (as a surrogate measure of QoL) for antidepressants and benzodiazepines,</LI>
<LI>short-term change in taste for benzodiazepines and topical treatments (no interventions long term),</LI>
<LI>short-term change in feeling of dryness for topical treatments alone (no interventions long term).</LI>
</UL>
<P>Nor do we have any data to assess adverse event occurrence from electromagnetic radiation or psychological therapies.</P>
<P>Most studies provided baseline demographics of their included participants. A single study (<LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>) reported participants' race. In terms of the gender and age distribution presented, the majority of studies were consistent; both in comparison to each other and when compared to previously published epidemiological data (<LINK REF="REF-Bergdahl-1999" TYPE="REFERENCE">Bergdahl 1999</LINK>). Several studies, however, were inconsistent with expected male-to-female (M/F) ratios: <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK> (M/F: 18/42), <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK> (M/F: 32/48), <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK> (M/F: 7/13), <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK> (M/F: 0/37). There were no obvious reasons as to why these studies had unusual gender spreads.</P>
<P>There is a paucity of RCTs evaluating neuropathic pain medications (<LINK REF="REF-Finnerup-2015" TYPE="REFERENCE">Finnerup 2015</LINK>; <LINK REF="REF-NICE-2013" TYPE="REFERENCE">NICE 2013</LINK>) in the management of BMS - with only amitriptyline (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>) and very low-dosage gabapentin (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>) being included in this review. This is in spite of the growing body of evidence to support the role of neuropathic mechanisms in BMS (<LINK REF="REF-J_x00e4__x00e4_skel_x00e4_inen-2012" TYPE="REFERENCE">Jääskeläinen 2012</LINK>). Moreover, only a single included RCT looked at clinical psychology as a way of managing BMS (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>); despite a wealth of evidence supporting the use of psychological therapies in chronic pain management (<LINK REF="REF-Sturgeon-2014" TYPE="REFERENCE">Sturgeon 2014</LINK>).</P>
<P>Some of the treatments assessed within this review, or other interventions not covered by the included studies, may be effective in the management of BMS symptoms. However, until further high-quality evidence is forthcoming we will not be able to make any recommendations for the treatment for BMS.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-11-03 18:32:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The quality of the evidence was assessed as very low for all outcomes (both short- and long-term) in all intervention categories (with the exception of adverse events for physical barriers, which were assessed as low-quality evidence).</P>
<P>Of the 23 studies included in this review, only one was deemed to have a low overall risk of bias; four were found to have an unclear risk of bias; and the remaining 18 studies were judged to be at high overall risk of bias. 'Other bias' was the most frequent cause of a high risk of bias assessment of a study (n = 10; 43%), followed by selective outcome reporting (n = 8; 35%) and blinding of participants (n = 7; 30%). Trials with open assessment of the outcome, as described by Femiano and colleagues (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>) and Bogetto and colleagues (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>), have been shown to overestimate the treatment effects by 35% (<LINK REF="REF-J_x00fc_ni-1999" TYPE="REFERENCE">Jüni 1999</LINK>). Indeed, this may explain why the two open-label trials of alpha-lipoic acid (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>) provided greater estimates of effect than the double-blinded trial of the same intervention (<LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>).The most commonly occurring cause for an 'other bias' assessment was due to failing to present baseline demographics for each study arm (n = 8; 35%).</P>
<P>We were unable to perform sensitivity analyses with regard to risk of bias due to the fact that only one included study was assessed to have a low overall risk of bias.</P>
<P>Inappropriate and misleading use of graphs and tables which did not contain usable data was commonplace, although we sought data directly from study authors where possible to do so. More recently, authors have been able to publish online supplements containing all of the relevant study data; they no longer have to select which restricted set of data to report. In many of the studies a high risk of reporting bias could have been avoided if additional raw data had been made available to the review group.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The review authors strictly adhered to the prespecified methodology for conducting systematic reviews included in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). Two review authors screened all abstracts independently and in duplicate, and all identified papers were then assessed and had the risk of bias assessment conducted by at least two review authors.</P>
<P>After discussion, the review authors agreed that the placebo comparator arms employed by two studies were suitable for inclusion as they were considered to be non-active placebos (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK> (psychological therapies: cognitive therapy versus motivation/oral examination); <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK> (physical barriers: tongue protector + reinforced self-control instruction (RS-CI) versus RS-CI)).</P>
<P>Data from <LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK> were not included within the quantitative synthesis due to excessive attrition (19/24; 79%) in the study's placebo arm, or from <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK> due to attrition (7/30; 23%) in this cross-over study's first phase and their protocol requirement for participants who developed adverse effects to be withdrawn from the trial.</P>
<P>We decided it was inappropriate to use reported six-month data from <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK> and one-year data from <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>, as both studies only presented data at these time points from participants who had positively responded to treatment at their earlier assessment, and consequently comprised a highly biased subset of data.</P>
<P>Due to one of the included cross-over RCTs containing no washout period (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>), we only incorporated data from the first phase of their study within our analyses.</P>
<P>We identified that two studies reported different length scales from the same outcome assessment measure (OHIP-14 (Oral Health Impact Profile-14): <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK> scale 0 to 70, lower better; <LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK> scale 0 to 56, lower better). Despite the inconsistency in scale length, we used the length reported for each study rather than assuming that either one was incorrect.<BR/>
</P>
<P>Lastly, despite all studies initially assessing symptom relief by use of a continuous outcome metric, seven studies (<LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Alvarenga-da-Silva-2014" TYPE="STUDY">Alvarenga da Silva 2014</LINK>) transformed their data to report symptom relief categorically instead, which only permitted us to estimate their effect estimates dichotomously as risk ratios. Consequently, we had to present results from continuous and dichotomous data separately; as such, we were unable to estimate heterogeneity across the dietary supplements and topical treatments categories (except where permitted within subgroups), and were also unable to estimate subgroup differences.<BR/>
</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-11-03 18:22:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>This review largely concurs with the findings of two other systematic reviews of placebo-controlled RCTs:</P>
<UL>
<LI>
<LINK REF="REF-de-Moraes-2012" TYPE="REFERENCE">de Moraes 2012</LINK> (12 RCTs compared to this review's inclusion of 23 RCTs; includes <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK> and our excluded study <LINK REF="STD-Petruzzi-2004" TYPE="STUDY">Petruzzi 2004</LINK>), and</LI>
<LI>
<LINK REF="REF-Kisely-2016" TYPE="REFERENCE">Kisely 2016</LINK> (24 RCTs compared to this review's inclusion of 23 RCTs; includes <LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>; <LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>; <LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>; <LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>; <LINK REF="STD-Femiano-2000" TYPE="STUDY">Femiano 2000</LINK>; <LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>; <LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>; <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2009b" TYPE="STUDY">López-Jornet 2009b</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>; <LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>; <LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>; <LINK REF="STD-Sardella-2008" TYPE="STUDY">Sardella 2008</LINK>; <LINK REF="STD-Silvestre-2012" TYPE="STUDY">Silvestre 2012</LINK>; <LINK REF="STD-Spanemberg-2012" TYPE="STUDY">Spanemberg 2012</LINK>; <LINK REF="STD-Tammiala_x002d_Salonen-1999" TYPE="STUDY">Tammiala-Salonen 1999</LINK> and five of our excluded studies <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2010" TYPE="STUDY">Grémeau-Richard 2010</LINK>; <LINK REF="STD-L_x00f3_pez_x002d_Jornet-2013" TYPE="STUDY">López-Jornet 2013</LINK>; <LINK REF="STD-Miziara-2009" TYPE="STUDY">Miziara 2009</LINK>; <LINK REF="STD-Petruzzi-2004" TYPE="STUDY">Petruzzi 2004</LINK>; <LINK REF="STD-Toida-2009" TYPE="STUDY">Toida 2009</LINK>).</LI>
</UL>
<P>While neither <LINK REF="REF-de-Moraes-2012" TYPE="REFERENCE">de Moraes 2012</LINK> or <LINK REF="REF-Kisely-2016" TYPE="REFERENCE">Kisely 2016</LINK> undertook meta-analyses of included studies, both reviews concluded there was limited quality evidence to support the efficacy of any one treatment over another in the treatment of primary BMS. We also highlight agreement with their observations that few RCTs provide long-term follow-up (longer than three months), which we endorse for the sustained management of this chronic painful condition.</P>
<P>A systematic review (<LINK REF="REF-Cui-2016" TYPE="REFERENCE">Cui 2016</LINK>) concentrating specifically on clonazepam (a benzodiazepine) estimated short-term relief more conservatively than this review did (from the same three RCTs (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>; <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK>; <LINK REF="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TYPE="STUDY">Rodríguez de Rivera-Campillo 2010</LINK>) assessed by a visual analogue scale (VAS) (0 to 10, lower better); <LINK REF="REF-Cui-2016" TYPE="REFERENCE">Cui 2016</LINK>: mean difference (MD) -1.44, 95% confidence interval (CI) -2.06 to -0.82 versus this review's <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>: MD -1.84, 95% CI -2.14 to -1.54). However, we attribute this difference to <LINK REF="REF-Cui-2016" TYPE="REFERENCE">Cui 2016</LINK>'s selective use of interim data from <LINK REF="STD-Heckmann-2012" TYPE="STUDY">Heckmann 2012</LINK> (instead of the ultimately assessed outcome), standard deviation errors from <LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>'s data (up to four times larger, we assume from being incorrectly copied across), and their decision to pool topical and systemic benzodiazepines in a single group. Considering these differences, we maintain confidence in our larger estimate of effectiveness despite originating from very low-quality evidence.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-11-03 17:15:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-03 17:15:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Currently there is a dearth of high-quality research evidence to allow the development of clear guidance for those charged with treating burning mouth syndrome (BMS) patients. Clinicians may use the results and detailed data from this systematic review to assist in discussions with their BMS patients, about which treatment options to undertake in the management of their condition.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-11-03 12:59:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Further randomised controlled trials (RCTs), of longer duration (a minimum of three months follow-up) and high methodological quality, are required in order to establish the effective forms of treatment for patients suffering from BMS. Future high-quality research, which further assesses the treatments included in this review and incorporates novel BMS therapies, would very likely result in a change in clinical practice. Furthermore, treatments established in the management of other neuropathic pain conditions and psychological therapies should be considered for clinical trials in BMS.<BR/>
</P>
<P>Comparability of groups at baseline is of great importance, particularly with regard to intensity of symptoms, gender and psychological background. True randomisation with concealed allocation of treatment groups should provide comparable groups, although details of baseline characteristics should still be provided and an estimate of comparability undertaken. Given the subjectivity of the symptoms to be assessed, participants, healthcare providers and outcome assessors should be blinded to the intervention.</P>
<P>Visual analogue scales (VAS) or validated patient-reported outcome measures should be used for the assessment of pain intensity. A decision regarding how large a treatment effect constitutes an adequate outcome requires to be made. Most treatments for chronic pain aim for a 50% reduction in pain scores from baseline; however, it could be that this is too high and 30% would be more pragmatic. Farrar et al (<LINK REF="REF-Farrar-2000" TYPE="REFERENCE">Farrar 2000</LINK>) argue that use of consistent clinically important cut-off points for pain outcomes would not only enhance validity and comparability, but would also have more clinical applicability. Other outcome measures looking at improvements in quality of life, anxiety and depression are imperative, as the negative impact of this condition on mood and on daily life is potentially high. The development of a core outcome set as described by COMET (Core Outcome Measures in Effectiveness Trials Initiative; <A HREF="http://www.comet-initiative.org">www.comet-initiative.org</A>), may be a way of facilitating the production of valid and homogeneous outcome data from BMS clinical trials.</P>
<P>All participants included in a trial should be accounted for in the analysis of the results, with the analysis undertaken on an intention-to-treat basis. It should be acknowledged that the conduct and adequate funding of high-quality RCTs in this field will impact the volume of research undertaken due to funding agencies' limited resources. Larger studies are essential and multicentre studies may be one way of ensuring that the study power is great enough to yield statistically significant results.</P>
<P>More detailed reporting of the adverse effects of treatments are required, as tolerability is an important factor for patients when making treatment choices (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>).<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-03 23:39:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The review authors would like to thank the external referees who provided comments for each version of this review. Moreover, we would like to thank the study authors who responded to requests for further information (Desiree Cavalcanti (<LINK REF="STD-Cavalcanti-2009" TYPE="STUDY">Cavalcanti 2009</LINK>), Felice Femiano (<LINK REF="STD-Femiano-2002a" TYPE="STUDY">Femiano 2002a</LINK>), Edgardo López-D'alessandro (<LINK REF="STD-Lopez_x002d_D_x0027_alessandro-2011" TYPE="STUDY">Lopez-D'alessandro 2011</LINK>), Pia Lopez-Jornet (<LINK REF="STD-Cano_x002d_Carrillo-2014" TYPE="STUDY">Cano-Carrillo 2014</LINK>), Luis Alberto Moreno Lopez (<LINK REF="STD-Palacios_x002d_S_x00e1_nchez-2015" TYPE="STUDY">Palacios-Sánchez 2015</LINK>) and Alain Woda (<LINK REF="STD-Gr_x00e9_meau_x002d_Richard-2004" TYPE="STUDY">Grémeau-Richard 2004</LINK>)), and translators who assisted with foreign language studies (Mónica Ballesteros, Ming Jian, Maddalena Manfredi and May Wong). Joanna Zakrzewska undertook this work at University College London (UCL) Hospitals who received a proportion of funding from the UK National Institute for Health Research (NIHR) Biomedical Research Centre funding. The review authors would also like to thank members of Cochrane Oral Health's editorial base for their support, particularly Janet Lear (Group Administrator), Anne Littlewood (Information Specialist), Laura MacDonald (Managing Editor) and Luisa Fernandez-Mauleffinch (Managing Editor and Copy Editor).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-11-14 10:35:52 +0000" MODIFIED_BY="[Empty name]">
<P>Roddy McMillan: none known.<BR/>Heli Forssell: none known.<BR/>John AG Buchanan: John Buchanan has previously co-authored an evidence-based review for BMJ publications Clinical Evidence on burning mouth syndrome with Joanna M Zakrzewska.<BR/>Anne-Marie Glenny: none known. Anne-Marie Glenny is an editor with Cochrane Oral Health.<BR/>Joanna M Zakrzewska: Joanna M Zakrzewska has previously co-authored an evidence-based review for BMJ publications Clinical Evidence on burning mouth syndrome with John Buchanan.<BR/>Jo C Weldon: none known. Jo Weldon is a salaried member of staff of Cochrane Oral Health.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-03 14:33:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Development and co-ordination of the update: Roddy McMillan (RM).<BR/>Running electronic searches: Anne Littlewood (Cochrane Oral Health).<BR/>Communication with authors and organisations: RM and Jo Weldon (JW).<BR/>Screening titles, abstracts and full-text papers: RM, Joanna Zakrzewska (JZ), Anne-Marie Glenny (AMG), JW.<BR/>Reviewing papers: RM, Heli Forssell (HF), JZ, John Buchanan (JB), AMG, JW.<BR/>Extracting data: RM, HF, JZ, JB, JW.<BR/>Appraising quality/risk of bias: RM, HF, JZ, JB, AMG, JW.<BR/>Inputting data: RM, JW.<BR/>Data validation: AMG.<BR/>Analysis of data: JW, AMG.<BR/>Risk of bias analysis: RM, AMG.<BR/>Interpretation of data: JW, AMG.<BR/>Summary of findings tables: AMG, JW.<BR/>Writing the review: RM, HF, JW, AMG.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-11-03 14:51:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The current review has employed Cochrane's tool for assessing risk of bias in randomised trials (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). Papers identified in previous versions were reformatted using this new template. In keeping with current best practice (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), previously included controlled clinical trials were excluded in this update (<LINK REF="STD-Pisanty-1975" TYPE="STUDY">Pisanty 1975</LINK>), and a GRADE 'Summary of findings' table has been produced for each comparison. Adverse effects were included as an outcome measure in this version of the review, despite not formally being included as an outcome in the original protocol. After feedback, we determined the substantial effect of burning mouth syndrome upon patients' quality of life is of sufficient direct impact to justify upgrading quality of life from a secondary to a primary outcome. Due to heterogeneity in study follow-up periods and outcome assessment time points, we analysed outcome data as short-term (&#8804; 3 months from baseline) or long-term (&gt; 3 to &#8804; 6 months from baseline) for a manageable cut-off threshold. In accordance with Section 16.4.5 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011) (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), we utilised first period data only of cross-over trials which did not incorporate a washout period.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-11-14 12:04:45 +0000" MODIFIED_BY="Luisa Fernandez Mauleffinch">
<STUDIES MODIFIED="2016-11-03 22:41:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<INCLUDED_STUDIES MODIFIED="2016-11-03 18:27:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<STUDY DATA_SOURCE="PUB" ID="STD-Alvarenga-da-Silva-2014" MODIFIED="2016-11-03 18:16:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Alvarenga da Silva 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-03 18:16:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvarenga da Silva L, Siqueira JT, Teixeira MJ, Siqueira SR</AU>
<TI>The role of xerostomia in burning mouth syndrome: a case-control study</TI>
<SO>Arquivos de Neuro-psiquiatria</SO>
<YR>2014</YR>
<VL>72</VL>
<NO>2</NO>
<PG>91-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451894"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451893"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergdahl-1995a" MODIFIED="2016-05-11 09:53:11 +0100" MODIFIED_BY="[Empty name]" NAME="Bergdahl 1995a" YEAR="1995">
<REFERENCE MODIFIED="2016-05-11 09:53:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergdahl J, Anneroth G, Perris H</AU>
<TI>Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>5</NO>
<PG>213-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090505"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogetto-1999" MODIFIED="2016-05-11 10:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Bogetto 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-05-11 10:14:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogetto F, Bonatto Revello R, Ferro G, Maina L, Ravizza L</AU>
<TI>Psychopharmacological treatment of burning mouth syndrome (BMS). A study sample of 121 patients</TI>
<TO>Trattamento psicofarmacologico della burning mouth syndrome (BMS). Studio su di un campione di 121 pazienti</TO>
<SO>Minerva Psichiatrica</SO>
<YR>1999</YR>
<VL>40</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090507"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cano_x002d_Carrillo-2014" MODIFIED="2016-11-03 18:16:39 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Cano-Carrillo 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-03 18:16:39 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cano-Carrillo P, Pons-Fuster A, López-Jornet P</AU>
<TI>Efficacy of lycopene-enriched virgin olive oil for treating burning mouth syndrome: a double-blind randomised</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2014</YR>
<VL>41</VL>
<NO>4</NO>
<PG>296-305</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451895"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090509"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Carbone-2009" MODIFIED="2016-05-11 10:17:10 +0100" MODIFIED_BY="[Empty name]" NAME="Carbone 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-05-11 10:17:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S</AU>
<TI>Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study</TI>
<SO>European Journal of Pain</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>5</NO>
<PG>492-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238239"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090511"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cavalcanti-2009" MODIFIED="2016-05-11 10:17:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cavalcanti 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-05-11 10:17:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavalcanti DR, da Silveira FR</AU>
<TI>Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>3</NO>
<PG>254-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238240"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090513"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femiano-2000" MODIFIED="2016-05-11 10:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Femiano 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-05-11 10:19:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F, Gombos F, Scully C, Busciolano M, De Luca P</AU>
<TI>Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology</TI>
<SO>Oral Diseases</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>5</NO>
<PG>274-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238241"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090515"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Femiano-2002a" MODIFIED="2016-05-11 10:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Femiano 2002a" YEAR="2002">
<REFERENCE MODIFIED="2016-05-11 10:20:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Femiano F, Scully C. Burning mouth syndrome (bms): Double blind controlled study of alpha lipoic acid (thiotic acid) therapy. J Oral Pathol Med 2002;31:267-269.&lt;/p&gt;" NOTES_MODIFIED="2016-05-11 10:20:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F, Scully C</AU>
<TI>Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>5</NO>
<PG>267-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238242"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090517"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femiano-2002b" NAME="Femiano 2002b" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Femiano F. Burning mouth syndrome (BMS): An open trial of comparative efficacy of a-lipoic acid (thiotic acid) with other therapies. Minerva Stomatol 2002;51:105-109.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F</AU>
<TI>Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies</TI>
<SO>Minerva Stomatologica</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>9</NO>
<PG>405-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090520"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090519"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gr_x00e9_meau_x002d_Richard-2004" MODIFIED="2016-11-03 18:21:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Grémeau-Richard 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-11-03 18:21:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grémeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC, et al</AU>
<TI>Topical clonazepam in stomatodynia: a controlled study</TI>
<SO>Journal of Dental Research</SO>
<YR>2003</YR>
<VL>82</VL>
<NO>Spec Iss B</NO>
<PG>B-159 (Abstract No 1174)</PG>
<MD>incl</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451897"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-11-03 18:21:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grémeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC, et al</AU>
<TI>Topical clonazepam in stomatodynia: a randomised placebo-controlled study</TI>
<SO>Pain</SO>
<YR>2004</YR>
<VL>108</VL>
<NO>1-2</NO>
<PG>51-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451898"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451896"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heckmann-2012" MODIFIED="2016-05-11 10:25:26 +0100" MODIFIED_BY="[Empty name]" NAME="Heckmann 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-05-11 10:25:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T</AU>
<TI>A double-blind study on clonazepam in patients with burning mouth syndrome</TI>
<SO>Laryngoscope</SO>
<YR>2012</YR>
<VL>122</VL>
<NO>4</NO>
<PG>813-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090524"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lopez_x002d_D_x0027_alessandro-2011" MODIFIED="2016-11-03 18:22:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Lopez-D'alessandro 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-11-03 18:22:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-D'alessandro E, Escovich L</AU>
<TI>Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial</TI>
<SO>Medicina Oral, Patología Oral y Cirugía Bucal</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>5</NO>
<PG>e635-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451900"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451899"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_Jornet-2009b" MODIFIED="2016-07-07 16:33:54 +0100" MODIFIED_BY="Jo C Weldon" NAME="López-Jornet 2009b" YEAR="2009">
<REFERENCE MODIFIED="2016-05-11 10:37:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Leon-Espinosa S</AU>
<TI>Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study</TI>
<SO>Journal of Oral Rehabilitation</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>1</NO>
<PG>52-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451902"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451901"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_Jornet-2011" MODIFIED="2016-05-11 10:37:52 +0100" MODIFIED_BY="[Empty name]" NAME="López-Jornet 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-05-11 10:37:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Andujar-Mateos P</AU>
<TI>A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome</TI>
<SO>Oral Diseases</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>3</NO>
<PG>277-82</PG>
<MD>incl</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238248"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090530"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marino-2010" MODIFIED="2016-05-11 10:39:09 +0100" MODIFIED_BY="[Empty name]" NAME="Marino 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-05-11 10:39:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marino R, Torretta S, Capaccio P, Pignataro L, Spadari F</AU>
<TI>Different therapeutic strategies for burning mouth syndrome: preliminary data</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>8</NO>
<PG>611-6</PG>
<MD>incl</MD>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090532"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Palacios_x002d_S_x00e1_nchez-2015" MODIFIED="2016-11-03 18:23:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Palacios-Sánchez 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-11-03 18:23:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palacios-Sánchez B, Moreno-López LA, Cerero-Lapiedra R, Llamas-Martínez S, Esparza-Gómez G</AU>
<TI>Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial</TI>
<SO>Medicina Oral, Patología Oral y Cirugía Bucal</SO>
<YR>2015</YR>
<VL>20</VL>
<NO>4</NO>
<PG>e435-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090534"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" MODIFIED="2016-11-03 18:23:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Rodríguez de Rivera-Campillo 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-03 18:23:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodríguez De Rivera-Campillo ME, López-López J, Chimenos-Kustner E</AU>
<TI>Treatment of burning mouth syndrome with topical clonazepam</TI>
<TO>Tratamiento del Síndrome de Boca Ardiente con clonacepam tópico</TO>
<SO>Piel</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>6</NO>
<PG>263-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-11 10:42:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rodríguez de Rivera-Campillo E, López-López J, Chimenos-Küstner E</AU>
<TI>Response to topical clonazepam in patients with burning mouth syndrome: a clinical study</TI>
<SO>Bulletin de Groupement Europeen pour la Recherche Scientifique en Stomatologie et Odontologie</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>1</NO>
<PG>19-29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238250"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090536"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sardella-1999" MODIFIED="2016-05-11 11:02:54 +0100" MODIFIED_BY="[Empty name]" NAME="Sardella 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-05-11 11:02:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A</AU>
<TI>Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>6</NO>
<PG>683-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090539"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sardella-2008" MODIFIED="2016-05-11 11:07:32 +0100" MODIFIED_BY="[Empty name]" NAME="Sardella 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-05-11 11:07:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sardella A, Lodi G, Demarosi F, Tarozzi M, Canegallo L, Carrassi A</AU>
<TI>Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>7</NO>
<PG>395-401</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238252"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090541"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silvestre-2012" MODIFIED="2016-11-03 18:26:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Silvestre 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-11-03 18:26:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvestre FJ, Silvestre-Rangil J, Tamarit-Santafé C, Bautista D</AU>
<TI>Application of a capsaicin rinse in the treatment of burning mouth syndrome</TI>
<SO>Medicina Oral, Patología Oral y Cirugía Bucal</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>1</NO>
<PG>e1-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451905"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090545"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spanemberg-2012" MODIFIED="2016-05-11 11:10:25 +0100" MODIFIED_BY="[Empty name]" NAME="Spanemberg 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-05-11 11:10:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spanemberg JC, Cherubini K, de Figueiredo MA, Gomes AP, Campos MM, Salum FG</AU>
<TI>Effect of an herbal compound for treatment of burning mouth syndrome: randomized, controlled, double-blind clinical trial</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2012</YR>
<VL>113</VL>
<NO>3</NO>
<PG>373-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090547"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spanemberg-2015" MODIFIED="2016-11-03 18:27:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Spanemberg 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-11-03 18:27:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spanemberg JC, López López J, de Figueiredo MA, Cherubini K, Salum FG</AU>
<TI>Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: a randomized, controlled trial</TI>
<SO>Journal of Biomedical Optics</SO>
<YR>2015</YR>
<VL>20</VL>
<NO>9</NO>
<PG>098001</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451907"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451906"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tammiala_x002d_Salonen-1999" MODIFIED="2016-05-11 11:10:38 +0100" MODIFIED_BY="[Empty name]" NAME="Tammiala-Salonen 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-05-11 11:10:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tammiala-Salonen T, Forssell H</AU>
<TI>Trazodone in burning mouth pain: a placebo-controlled, double-blind study</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>83-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238256"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090549"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-11-03 22:25:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<STUDY DATA_SOURCE="PUB" ID="STD-Bai-2010" MODIFIED="2016-11-03 22:11:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Bai 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-03 22:11:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bai H, Yu P</AU>
<TI>Observation of effectiveness of electrical acupuncture on burning mouth syndrome</TI>
<SO>Journal of Clinical Acupuncture and Moxibustion</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>7</NO>
<PG>28-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451908"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090551"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bessho-1998" MODIFIED="2016-05-11 11:14:10 +0100" MODIFIED_BY="[Empty name]" NAME="Bessho 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-05-11 11:14:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bessho K, Okubo Y, Hori S, Murakami K, Iizuka T</AU>
<TI>Effectiveness of kampo medicine (sai-boku-to) in treatment of patients with glossodynia</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>6</NO>
<PG>682-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238258"/><IDENTIFIER TYPE="MEDLINE" VALUE="99085616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090553"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogetto-1997" MODIFIED="2016-11-03 22:14:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Bogetto 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-11-03 22:14:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogetto F, Ferro G, Maina G, Gandolfo S</AU>
<TI>Amisulpride vs paroxetine in the treatment of burning mouth syndrome (BMS)</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>27S (Abstract No 14-29)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451909"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090555"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campisi-1997" NAME="Campisi 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campisi G, Spadari F, Salvato A</AU>
<TI>Sucralfate in oral medicine. Our clinical findings</TI>
<TO>Il sucralfato in odontostomatologia. Nostra esperienza clinica</TO>
<SO>Minerva Stomatologica</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>6</NO>
<PG>297-305</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090558"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090557"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-1981" MODIFIED="2016-07-08 13:32:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ferguson 1981" YEAR="1981">
<REFERENCE MODIFIED="2016-07-08 13:32:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson MM, Carter J, Boyle P, Hart DM, Lindsay R</AU>
<TI>Oral complaints related to climacteric symptoms in oophrorectomized women</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1981</YR>
<VL>74</VL>
<NO>7</NO>
<PG>492-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451910"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090559"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forabosco-1992" MODIFIED="2016-11-03 22:14:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Forabosco 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-11-03 22:14:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forabosco A, Criscuolo M, Coukos G, Uccelli E, Weinstein R, Spinato S, et al</AU>
<TI>Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1992</YR>
<VL>73</VL>
<NO>5</NO>
<PG>570-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451911"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090561"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grechko-1996" NAME="Grechko 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;1.  Grechko V, G. BE. Use of transcutaneous electrical nerve stimulation in the complex treatment of glossalgia. Neuroscience &amp;amp; Behavioral Physiology 1996;26(6):584-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grechko VE, Borisova EG</AU>
<TI>Use of transcutaneous electrical nerve stimulation in the complex treatment of glossalgia</TI>
<SO>Neuroscience &amp; Behavioral Physiology</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>6</NO>
<PG>584-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090563"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gr_x00e9_meau_x002d_Richard-2010" MODIFIED="2016-07-11 16:28:55 +0100" MODIFIED_BY="Jo C Weldon" NAME="Grémeau-Richard 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-07-11 16:28:55 +0100" MODIFIED_BY="Jo C Weldon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A</AU>
<TI>Effect of lingual nerve block on burning mouth syndrome (stomatodynia): A randomised crossover trial</TI>
<SO>Pain</SO>
<YR>2010</YR>
<VL>149</VL>
<NO>1</NO>
<PG>27-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grushka-1998" NAME="Grushka 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grushka M, Epstein J, Mott A</AU>
<TI>An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, &amp; Endodontics</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>5</NO>
<PG>557-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090565"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1990" MODIFIED="2015-08-11 13:57:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hansen 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-08-11 13:57:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen HJ, Thorøe U</AU>
<TI>Low power laser biostimulation of chronic oro-facial pain. A double-blind placebo controlled cross-over study in 40 patients</TI>
<SO>Pain</SO>
<YR>1990</YR>
<VL>43</VL>
<NO>2</NO>
<PG>169-79</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090568"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090567"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-2011" MODIFIED="2015-02-02 21:02:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hirsch 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-02 21:02:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch AR, Ziad A, Kim AY, Lail NS, Sharma S</AU>
<TI>Pilot study: alleviation of pain in burning mouth syndrome with topical sucralose</TI>
<SO>Headache</SO>
<YR>2011</YR>
<VL>51</VL>
<NO>3</NO>
<PG>444-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090570"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090569"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2006" MODIFIED="2016-11-03 22:16:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Huang 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-11-03 22:16:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang J, Huo HY</AU>
<TI>Clinical observation of effectiveness of acupoint injection on 23 cases of BMS</TI>
<SO>Journal of Practical Traditional Chinese Internal Medicine</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451914"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090571"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2009" MODIFIED="2016-07-08 13:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-08 13:35:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang MZ, Zong JJ</AU>
<TI>Therapeutic efficacy of acupointinjection of vitamins B1 and B12 in the treatment of burning mouth syndrome</TI>
<SO>Acta Academiae Medicinae Jiangxi</SO>
<YR>2009</YR>
<VL>49</VL>
<PG>90-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238262"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090573"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hugoson-1991" MODIFIED="2016-05-11 11:17:11 +0100" MODIFIED_BY="[Empty name]" NAME="Hugoson 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-05-11 11:17:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hugoson A, Thorstensson B</AU>
<TI>Vitamin B status and response to replacement therapy in patients with burning mouth syndrome</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>1991</YR>
<VL>49</VL>
<NO>6</NO>
<PG>367-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090575"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ito-2010" MODIFIED="2016-05-11 11:18:01 +0100" MODIFIED_BY="[Empty name]" NAME="Ito 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-05-11 11:18:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ito M, Kimura H, Yoshida K, Kimura Y, Ozaki N, Kurita K</AU>
<TI>Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>2</NO>
<PG>79-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238264"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090577"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kho-2010" MODIFIED="2016-07-08 12:17:05 +0100" MODIFIED_BY="[Empty name]" NAME="Kho 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-07-08 12:17:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kho HS, Lee JS, Lee EJ, Lee JY</AU>
<TI>The effects of parafunctional habit control and topical lubricant on discomforts associated with burning mouth syndrome (BMS)</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>1</NO>
<PG>95&#8211;9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451915"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090579"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamey-1986" MODIFIED="2016-05-11 11:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Lamey 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-05-11 11:19:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamey PJ, Hammond A, Allam BF, McIntosh WB</AU>
<TI>Vitamin status of patients with burning mouth syndrome and the response to replacement therapy</TI>
<SO>British Dental Journal</SO>
<YR>1986</YR>
<VL>160</VL>
<NO>3</NO>
<PG>81-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238266"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090581"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" MODIFIED="2016-11-03 22:17:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Li 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-11-03 22:17:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li YQ, Luo HY</AU>
<TI>Observation of effectiveness of acupoint injection on burning mouth syndrome</TI>
<SO>Journal of Mudanjiang Medical College</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>6</NO>
<PG>34-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451916"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090583"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindholm-2015" MODIFIED="2016-08-10 15:23:26 +0100" MODIFIED_BY="Jo C Weldon" NAME="Lindholm 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-08-10 15:23:14 +0100" MODIFIED_BY="Jo C Weldon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm P, Lamusuo S, Taiminen T, Pesonen U, Lahti A, Virtanen A, et al</AU>
<TI>Right secondary somatosensory cortex - a promising novel target for the treatment of drug-resistant neuropathic orofacial pain with repetitive transcranial magnetic stimulation</TI>
<SO>Pain</SO>
<YR>2015</YR>
<VL>156</VL>
<NO>7</NO>
<PG>1276-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451918"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451917"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loldrup-1989" NAME="Loldrup 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loldrup D, Langemark M, Hansen HJ, Olesen J, Bech P</AU>
<TI>Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study</TI>
<SO>Psychopharmacology</SO>
<YR>1989</YR>
<VL>99</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090586"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090585"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_Jornet-2013" MODIFIED="2016-07-08 12:10:05 +0100" MODIFIED_BY="[Empty name]" NAME="López-Jornet 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-08 12:10:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Molino-Pagan D</AU>
<TI>Prospective, randomized, double-blind, clinical evaluation of aloe vera barbadensis, applied in combination with a tongue protector to treat burning mouth syndrome</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2013</YR>
<VL>42</VL>
<NO>4</NO>
<PG>295-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090587"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" MODIFIED="2016-11-03 22:20:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Lu 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-11-03 22:20:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu HR, Li HW</AU>
<TI>Therapeutic efficacy of acupointInjection of vitamins B1 and B12 in the treatment of burning mouth syndrome</TI>
<SO>Acta Academiae Medicinae Jiangxi</SO>
<YR>2002</YR>
<VL>42</VL>
<PG>74-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451920"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090589"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2006" MODIFIED="2016-05-11 11:20:52 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-05-11 11:20:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma GT</AU>
<TI>Acupoint injection of vitamin B1 and B12 in the treatment of burning mouth syndrome</TI>
<SO>Journal of Integrative Medicine</SO>
<YR>2006</YR>
<VL>14</VL>
<PG>254</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238270"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090591"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maina-2002" MODIFIED="2015-01-24 16:22:40 +0000" MODIFIED_BY="[Empty name]" NAME="Maina 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-01-24 16:22:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of ssrss and amisulpride in burning mouth syndrome: A single blind study. Journal of Clinical Pyschiatry 2002;63:38-43.&lt;/p&gt;" NOTES_MODIFIED="2015-01-24 16:22:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maina G, Vitalucci A, Gandolfo S, Bogetto F</AU>
<TI>Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090594"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090593"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miziara-2009" MODIFIED="2016-07-11 15:31:32 +0100" MODIFIED_BY="Jo C Weldon" NAME="Miziara 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-11 15:31:32 +0100" MODIFIED_BY="Jo C Weldon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miziara ID, Filho BC, Oliveira R, Rodrigues dos Santos RM</AU>
<TI>Group psychotherapy: an additional approach to burning mouth syndrome</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2009</YR>
<VL>67</VL>
<NO>5</NO>
<PG>443-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451922"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mo-2003" MODIFIED="2016-11-03 22:19:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Mo 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-03 22:19:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mo ZY, Liu J</AU>
<TI>Acupoint injection of vitamins B1 and B12 in the treatment of burning mouth syndrome</TI>
<SO>Journal of Stomatology</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>121</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451923"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palacios_x002d_Sanchez-2010" MODIFIED="2016-11-03 22:23:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Palacios-Sanchez 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-03 22:23:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palacios-Sanchez B, Moreno-Lopez LA, Esparza-Gomez G, Cerero-Lapiedra R, Llamas-Martinez S</AU>
<TI>Efficacy of ALA in the treatment of burning mouth syndrome</TI>
<SO>Oral Diseases</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>549 (Abstract No 148)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451924"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090597"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pellegrini-2010" MODIFIED="2016-11-03 22:23:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Pellegrini 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-03 22:23:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pellegrini VD, Silva EFP, Kato IT, Prates RA, Sugaya NN</AU>
<TI>Low level laser therapy in BMS patients: a preliminary report</TI>
<SO>Oral Diseases</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>550 (Abstract No 150)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090599"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2001" MODIFIED="2016-11-03 22:24:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Peng 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-11-03 22:24:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NOTES="&lt;p&gt;Peng J, Wu Y, Han W. Clinical efficacy of burning mouth syndrome treated by livial [chinese]. Bulletin of Hunan Medical University 2001;26:157-158.&lt;/p&gt;" NOTES_MODIFIED="2016-11-03 22:24:08 +0000" NOTES_MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng JY, Wu Y, Han W</AU>
<TI>Clinical efficacy of burning mouth syndrome treated by livial</TI>
<SO>Bulletin of Hunan Medical University</SO>
<YR>2001</YR>
<VL>26</VL>
<NO>2</NO>
<PG>157-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451926"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090601"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Petruzzi-2004" MODIFIED="2015-11-10 16:18:42 +0000" MODIFIED_BY="[Empty name]" NAME="Petruzzi 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-11-10 16:18:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R</AU>
<TI>Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2004</YR>
<VL>33</VL>
<NO>2</NO>
<PG>111-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3090604"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090603"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pisanty-1975" MODIFIED="2016-05-11 11:32:13 +0100" MODIFIED_BY="[Empty name]" NAME="Pisanty 1975" YEAR="1975">
<REFERENCE MODIFIED="2016-05-11 11:32:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pisanty S, Rafaely B, Polishuk W</AU>
<TI>The effect of steroid hormones on buccal mucosa of menopausal women</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1975</YR>
<VL>40</VL>
<NO>3</NO>
<PG>346-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090605"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qui-2010" MODIFIED="2016-11-03 22:24:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Qui 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-11-03 22:24:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiu HL 2010</AU>
<TI>Therapeutic efficacy of combined acupuncture and laser acupuncture in treating burning mouth syndrome</TI>
<SO>Chinese Journal of Physical Medicine and Rehabilitation</SO>
<YR>2010</YR>
<VL>32</VL>
<PG>229-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090607"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romeo-2010" MODIFIED="2016-05-11 11:35:00 +0100" MODIFIED_BY="[Empty name]" NAME="Romeo 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-05-11 11:35:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romeo U, Del Vecchio A, Capocci M, Maggiore C, Ripari M</AU>
<TI>The low level laser therapy in the management of neurological burning mouth syndrome. A pilot study</TI>
<SO>Annali di Stomatologia</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>1</NO>
<PG>14-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090609"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toida-2009" MODIFIED="2016-07-11 16:31:02 +0100" MODIFIED_BY="Jo C Weldon" NAME="Toida 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-11 16:30:50 +0100" MODIFIED_BY="Jo C Weldon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toida M, Kato K, Makita H, Long NK, Takeda T, Hatakeyama D, et al</AU>
<TI>Palliative effect of lafutidine on oral burning sensation</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>3</NO>
<PG>262-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451929"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451928"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vukoja-2011" MODIFIED="2016-05-11 11:35:12 +0100" MODIFIED_BY="[Empty name]" NAME="Vukoja 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-05-11 11:35:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vukoja D, Alajbeg I, Vu&#269;i&#263;evi&#263; Boras V, Brailo V, Alajbeg IZ, Andabak Rogulj A</AU>
<TI>Is effect of low-level laser therapy in patients with burning mouth syndrome result of a placebo?</TI>
<SO>Photomedicine and Laser Surgery</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>9</NO>
<PG>647-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238276"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090611"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woda-1998" MODIFIED="2016-05-11 11:35:27 +0100" MODIFIED_BY="[Empty name]" NAME="Woda 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-05-11 11:35:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woda A, Navez ML, Picard P, Gremeau C, Pichard-Leandri E</AU>
<TI>A possible therapeutic solution for stomatodynia (burning mouth syndrome)</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>4</NO>
<PG>272-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4238277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090613"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yong-2003" MODIFIED="2016-11-03 22:25:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Yong 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-11-03 22:25:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yong M, Zhu YM, Wu L, Wang YR</AU>
<TI>Point injection of vitamin B1 and B12 in burning mouth syndrome</TI>
<SO>Inner Mongolia Medical Journal</SO>
<YR>2003</YR>
<VL>35</VL>
<PG>493-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3090615"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-11-03 22:41:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-NCT02580734" MODIFIED="2016-11-03 22:32:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="NCT02580734" YEAR="2013">
<REFERENCE MODIFIED="2016-11-03 22:32:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02580734</AU>
<TI>Melatonin to treat burning mouth syndrome (BMS): a randomized, cross-over, placebo-controlled, triple-blind clinical trial</TI>
<SO>clinicaltrials.gov/show/NCT02580734</SO>
<YR>(first received 20 December 2013)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451932"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Umezaki-2016" MODIFIED="2016-11-03 22:41:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Umezaki 2016" YEAR="2016">
<REFERENCE MODIFIED="2016-11-03 22:41:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Umezaki Y, Badran BW, DeVries WH, Moss J, Gonzales T, George MS</AU>
<TI>The efficacy of daily prefrontal repetitive transcranial magnetic stimulation (rTMS) for burning mouth syndrome (BMS): a randomized controlled single-blind study</TI>
<SO>Brain Stimulation</SO>
<YR>2016</YR>
<VL>9</VL>
<NO>2</NO>
<PG>234-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4451934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4451933"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-11-03 23:28:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<ADDITIONAL_REFERENCES MODIFIED="2016-11-03 23:28:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<REFERENCE ID="REF-Albuquerque-2006" MODIFIED="2016-07-08 12:27:47 +0100" MODIFIED_BY="[Empty name]" NAME="Albuquerque 2006" TYPE="JOURNAL_ARTICLE">
<AU>Albuquerque RJC, de Leeuw R, Carlson CR, Okeson JP, Miller CS, Andersen AH</AU>
<TI>Cerebral activation during thermal stimulation of patients who have burning mouth disorder: An fMRI study</TI>
<SO>Pain</SO>
<YR>2006</YR>
<VL>122</VL>
<NO>3</NO>
<PG>223-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Almoznino-2016" MODIFIED="2016-10-12 13:59:12 +0100" MODIFIED_BY="[Empty name]" NAME="Almoznino 2016" TYPE="OTHER">
<AU>Almoznino G, Benoliel R, Sharav Y, Haviv Y</AU>
<TI>Sleep disorders and chronic craniofacial pain: characteristics and management possibilities</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2016 May 11 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2016-09-26 16:03:27 +0100" MODIFIED_BY="Jo C Weldon"><IDENTIFIER MODIFIED="2016-09-26 16:03:27 +0100" MODIFIED_BY="Jo C Weldon" TYPE="DOI" VALUE="10.1016/j.smrv.2016.04.005"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bergdahl-1995b" MODIFIED="2016-07-08 12:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bergdahl 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Bergdahl J, Anneroth G, Perris H</AU>
<TI>Personality characteristics of patients with resistant burning mouth syndrome</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>1</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergdahl-1999" NAME="Bergdahl 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bergdahl M, Bergdahl J</AU>
<TI>Burning mouth syndrome: prevalence and associated factors</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>8</NO>
<PG>350-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braud-2013" MODIFIED="2016-07-08 12:15:49 +0100" MODIFIED_BY="[Empty name]" NAME="Braud 2013" TYPE="JOURNAL_ARTICLE">
<AU>Braud A, Toure B, Agbo-Godeau S, Descroix V, Boucher Y</AU>
<TI>Characteristics of pain assessed with visual analog scale and questionnaire in burning mouth syndrome patients: a pilot study</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>3</NO>
<PG>235-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buchanan-2010" MODIFIED="2016-11-03 22:51:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Buchanan 2010" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan JA, Zakrzewska JM</AU>
<TI>Burning mouth syndrome</TI>
<SO>BMJ Clinical Evidence</SO>
<YR>2010</YR>
<VL>06</VL>
<PG>1301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaparro-2012" MODIFIED="2016-10-07 14:46:45 +0100" MODIFIED_BY="[Empty name]" NAME="Chaparro 2012" TYPE="COCHRANE_REVIEW">
<AU>Chaparro LE, Wiffen PJ, Moore RA, Gilron I</AU>
<TI>Combination pharmacotherapy for the treatment of neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-10-07 14:46:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-07 14:46:45 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008943.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cui-2016" MODIFIED="2016-10-12 14:00:36 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2016" TYPE="JOURNAL_ARTICLE">
<AU>Cui Y, Xu H, Chen F, Liu J, Jiang L, Zhou Y, et al</AU>
<TI>Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis</TI>
<SO>Oral Diseases</SO>
<YR>2016</YR>
<VL>22</VL>
<NO>6</NO>
<PG>503-11</PG>
<IDENTIFIERS MODIFIED="2016-07-11 15:28:40 +0100" MODIFIED_BY="Jo C Weldon"><IDENTIFIER MODIFIED="2016-07-11 15:28:40 +0100" MODIFIED_BY="Jo C Weldon" TYPE="DOI" VALUE="10.1111/odi.12422"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Moraes-2012" MODIFIED="2016-02-22 17:05:38 +0000" MODIFIED_BY="Jo C Weldon" NAME="de Moraes 2012" TYPE="JOURNAL_ARTICLE">
<AU>de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A</AU>
<TI>Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2012</YR>
<VL>41</VL>
<NO>4</NO>
<PG>281-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Moura-2009" MODIFIED="2016-07-08 12:27:17 +0100" MODIFIED_BY="[Empty name]" NAME="De Moura 2009" TYPE="JOURNAL_ARTICLE">
<AU>De Moura SA, de Sousa JM, Lima DF, Negreiros AN, Silva Fde V, da Costa LJ</AU>
<TI>Burning mouth syndrome (BMS): sialometric and sialochemical analysis and salivary protein profile</TI>
<SO>Gerodontology</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>3</NO>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2016-07-08 12:28:53 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eli-1994" NAME="Eli 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eli I, Baht R, Littner MM, Kleinhauz M</AU>
<TI>Detection of psychopathologic trends in glossodynia patients</TI>
<SO>Psychosomatic Medicine</SO>
<YR>1994</YR>
<VL>56</VL>
<NO>5</NO>
<PG>389-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eliav-2007" MODIFIED="2016-11-03 22:58:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Eliav 2007" TYPE="JOURNAL_ARTICLE">
<AU>Eliav E, Kamran B, Schaham R, Czerninski R, Gracely RH, Benoliel R</AU>
<TI>Evidence of chorda tympani dysfunction in patients with burning mouth syndrome</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2007</YR>
<VL>138</VL>
<NO>5</NO>
<PG>628-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrar-2000" MODIFIED="2015-04-18 21:29:12 +0100" MODIFIED_BY="[Empty name]" NAME="Farrar 2000" TYPE="JOURNAL_ARTICLE">
<AU>Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL</AU>
<TI>Defining the clinically important difference in pain outcome measures</TI>
<SO>Pain</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>3</NO>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finnerup-2015" MODIFIED="2016-06-27 17:08:26 +0100" MODIFIED_BY="Jo C Weldon" NAME="Finnerup 2015" TYPE="JOURNAL_ARTICLE">
<AU>Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al</AU>
<TI>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</TI>
<SO>Lancet Neurology</SO>
<YR>2015</YR>
<VL>14</VL>
<NO>2</NO>
<PG>162-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forssell-2002" NAME="Forssell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S</AU>
<TI>Sensory dysfunction in burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>1-2</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forssell-2012" MODIFIED="2016-11-03 22:59:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Forssell 2012" TYPE="JOURNAL_ARTICLE">
<AU>Forssell H, Teerijoki-Oksa T, Kotiranta U, Kantola R, Bäck M, Vuorjoki-Ranta TR, et al</AU>
<TI>Pain and pain behavior in burning mouth syndrome: a pain diary study</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>2</NO>
<PG>117-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fortuna-2013" MODIFIED="2016-07-08 12:30:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fortuna 2013" TYPE="JOURNAL_ARTICLE">
<AU>Fortuna G, Di Lorenzo M, Pollio A</AU>
<TI>Complex oral sensitivity disorder: a reappraisal of current classification of burning mouth syndrome</TI>
<SO>Oral Diseases</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>7</NO>
<PG>730-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-2007" MODIFIED="2016-08-04 11:23:13 +0100" MODIFIED_BY="Jo C Weldon" NAME="Foster 2007" TYPE="JOURNAL_ARTICLE">
<AU>Foster TS</AU>
<TI>Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy</TI>
<SO>Diabetes Educator</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>111-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galli-2016" MODIFIED="2016-10-12 14:07:04 +0100" MODIFIED_BY="[Empty name]" NAME="Galli 2016" TYPE="OTHER">
<AU>Galli F, Lodi G, Sardella A, Vegni E</AU>
<TI>Role of psychological factors in burning mouth syndrome: A systematic review and meta-analysis</TI>
<SO>Cephalalgia</SO>
<YR>2016 Apr 27 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2016-10-12 14:07:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-12 14:07:04 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1177/0333102416646769"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Granot-2005" MODIFIED="2016-07-08 12:31:37 +0100" MODIFIED_BY="[Empty name]" NAME="Granot 2005" TYPE="JOURNAL_ARTICLE">
<AU>Granot M, Nagler RM</AU>
<TI>Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints</TI>
<SO>Journal of Pain</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>9</NO>
<PG>581-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grushka-1987a" MODIFIED="2016-07-08 12:36:34 +0100" MODIFIED_BY="[Empty name]" NAME="Grushka 1987a" TYPE="JOURNAL_ARTICLE">
<AU>Grushka M, Katz RL, Sessle BJ</AU>
<TI>Spontaneous remission in burning mouth syndrome</TI>
<SO>Journal of Dental Research</SO>
<YR>1987</YR>
<VL>66</VL>
<NO>2</NO>
<PG>274</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grushka-1987b" MODIFIED="2015-05-19 21:11:41 +0100" MODIFIED_BY="[Empty name]" NAME="Grushka 1987b" TYPE="JOURNAL_ARTICLE">
<AU>Grushka M</AU>
<TI>Clinical features of burning mouth syndrome</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>1</NO>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hagelberg-2003" MODIFIED="2016-11-03 23:00:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Hagelberg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, et al</AU>
<TI>Striatal dopamine D1 and D2 receptors in burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>1-2</NO>
<PG>149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heckmann-2001" MODIFIED="2016-11-03 23:00:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Heckmann 2001" TYPE="JOURNAL_ARTICLE">
<AU>Heckmann SM, Heckmann JG, HiIz MJ, Popp M, Marthol H, Neundörfer B, et al</AU>
<TI>Oral mucosal blood flow in patients with burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>3</NO>
<PG>281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-11-03 23:01:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Higgins 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>889-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-11-03 23:04:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS MODIFIED="2015-01-26 20:32:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-IHS-2013" MODIFIED="2016-07-08 12:42:46 +0100" MODIFIED_BY="[Empty name]" NAME="IHS 2013" TYPE="JOURNAL_ARTICLE">
<AU>Headache Classification Subcommittee of the International Headache Society (IHS)</AU>
<TI>The international classification of headache disorders 3rd edition</TI>
<SO>Cephalalgia</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>9</NO>
<PG>629-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2016-11-03 23:04:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Just-2010" MODIFIED="2016-07-08 12:45:17 +0100" MODIFIED_BY="[Empty name]" NAME="Just 2010" TYPE="JOURNAL_ARTICLE">
<AU>Just T, Steiner S, Pau HW</AU>
<TI>Oral pain perception and taste in burning mouth syndrome</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4__x00e4_skel_x00e4_inen-1997" NAME="Jääskeläinen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jääskeläinen SK, Forssell H, Tenovuo O</AU>
<TI>Abnormalities of the blink reflex in burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>1997</YR>
<VL>73</VL>
<NO>3</NO>
<PG>455-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4__x00e4_skel_x00e4_inen-2001" MODIFIED="2016-11-03 23:05:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Jääskeläinen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jääskeläinen SK, Rinne JO, Forssell H, Tenovuo O, Kaasinen V, Sonninen P, et al</AU>
<TI>Role of the dopaminergic system in chronic pain - a fluorodopa-PET study</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>3</NO>
<PG>257-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00e4__x00e4_skel_x00e4_inen-2012" MODIFIED="2016-07-08 12:46:23 +0100" MODIFIED_BY="[Empty name]" NAME="Jääskeläinen 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jääskeläinen SK</AU>
<TI>Pathophysiology of primary burning mouth syndrome</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2012</YR>
<VL>123</VL>
<NO>1</NO>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-1999" MODIFIED="2011-11-23 15:56:08 +0000" MODIFIED_BY="[Empty name]" NAME="Jüni 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Witschi A, Bloch R, Egger M</AU>
<TI>The hazards of scoring the quality of clinical trials for meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1054-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-2014" MODIFIED="2016-07-08 12:47:42 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2014" TYPE="JOURNAL_ARTICLE">
<AU>Khan SA, Keaser ML, Meiller TF, Seminowicz DA</AU>
<TI>Altered structure and function in the hippocampus and medial prefrontal cortex in patients with burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>2014</YR>
<VL>155</VL>
<NO>8</NO>
<PG>1472-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kisely-2016" MODIFIED="2016-07-11 15:27:14 +0100" MODIFIED_BY="Jo C Weldon" NAME="Kisely 2016" TYPE="JOURNAL_ARTICLE">
<AU>Kisely S, Forbes M, Sawyer E, Black E, Lalloo R</AU>
<TI>A systematic review of randomized trials for the treatment of burning mouth syndrome</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2016</YR>
<VL>86</VL>
<PG>39-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohorst-2014" MODIFIED="2015-11-16 15:34:13 +0000" MODIFIED_BY="[Empty name]" NAME="Kohorst 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kohorst JJ, Bruce AJ, Torgerson RR, Schenk LA, Davis MDP</AU>
<TI>A population-based study of the incidence of burning mouth syndrome</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2014</YR>
<VL>89</VL>
<NO>11</NO>
<PG>1545-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohorst-2015" MODIFIED="2016-06-27 15:59:26 +0100" MODIFIED_BY="Jo C Weldon" NAME="Kohorst 2015" TYPE="JOURNAL_ARTICLE">
<AU>Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MD</AU>
<TI>The prevalence of burning mouth syndrome: a population-based study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2015</YR>
<VL>172</VL>
<NO>6</NO>
<PG>1654-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koike-2014" MODIFIED="2016-07-08 12:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="Koike 2014" TYPE="JOURNAL_ARTICLE">
<AU>Koike K, Shinozaki T, Hara K, Noma N, Okada-Ogawa A, Asano M, et al</AU>
<TI>Immune and endocrine function in patients with burning mouth syndrome</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>2</NO>
<PG>168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolkka_x002d_Palomaa-2016" MODIFIED="2016-07-08 12:50:16 +0100" MODIFIED_BY="[Empty name]" NAME="Kolkka-Palomaa 2016" TYPE="JOURNAL_ARTICLE">
<AU>Kolkka-Palomaa M, Jääskeläinen SK, Laine MA, Teerijoki-Oksa T, Sandell M, Forssell H</AU>
<TI>Pathophysiology of primary burning mouth syndrome with special focus on taste dysfunction: a review</TI>
<SO>Oral Diseases</SO>
<YR>2015</YR>
<VL>21</VL>
<NO>8</NO>
<PG>937-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korn-2002" MODIFIED="2016-07-27 14:34:50 +0100" MODIFIED_BY="Jo C Weldon" NAME="Korn 2002" TYPE="JOURNAL_ARTICLE">
<AU>Korn GP, Pupo DB, Quedas A, Filho IB</AU>
<TI>Correlation between xerostomia degree and sialometry in patients with Sjögren's Syndrome</TI>
<TO>Correlação entre o grau de xerostomia e o resultado da sialometria em pacientes com Síndrome de Sjögren</TO>
<SO>Revista Brasileira de Otorinolaringologia</SO>
<YR>2002</YR>
<VL>68</VL>
<NO>5</NO>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koszewicz-2012" MODIFIED="2016-07-08 12:51:18 +0100" MODIFIED_BY="[Empty name]" NAME="Koszewicz 2012" TYPE="JOURNAL_ARTICLE">
<AU>Koszewicz M, Mendak M, Konopka T, Koziorowska-Gawron E, Budrewicz S</AU>
<TI>The characteristics of autonomic nervous system disorders in burning mouth syndrome and Parkinson disease</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2012</YR>
<VL>26</VL>
<NO>4</NO>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lauria-2005" MODIFIED="2016-07-08 13:05:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lauria 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, et al</AU>
<TI>Trigeminal small-fibre sensory neuropathy causes burning mouth syndrome</TI>
<SO>Pain</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>3</NO>
<PG>332-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2015" MODIFIED="2016-07-08 13:06:24 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2015" TYPE="JOURNAL_ARTICLE">
<AU>Lee YC, Hong IK, Sy NA, Eun YG</AU>
<TI>Evaluation of salivary function in patients with burning mouth syndrome</TI>
<SO>Oral Diseases</SO>
<YR>2015</YR>
<VL>21</VL>
<NO>3</NO>
<PG>308-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2016-11-03 23:08:11 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Jornet-2008" MODIFIED="2016-07-08 13:08:28 +0100" MODIFIED_BY="[Empty name]" NAME="López-Jornet 2008" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Lucero-Berdugo M</AU>
<TI>Quality of life in patients with burning mouth syndrome</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>7</NO>
<PG>389-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Jornet-2009a" MODIFIED="2016-11-03 23:09:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="López-Jornet 2009a" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Leon-Espinosa S</AU>
<TI>Burning mouth syndrome, oral parafunctions, and psychological profile in a longitudinal case study</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>3</NO>
<PG>363-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Jornet-2013" MODIFIED="2016-10-31 10:50:11 +0000" MODIFIED_BY="Jo C Weldon" NAME="López-Jornet 2013" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Camacho-Alonso F, Molino-Pagan D</AU>
<TI>Prospective, randomized, double-blind, clinical evaluation of aloe vera barbadensis, applied in combination with a tongue protector to treat burning mouth syndrome</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2013</YR>
<VL>42</VL>
<NO>4</NO>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez_x002d_Jornet-2015" MODIFIED="2016-11-03 23:09:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="López-Jornet 2015" TYPE="JOURNAL_ARTICLE">
<AU>López-Jornet P, Lucero-Berdugo M, Castillo-Felipe C, Zamora Lavella C, Ferrandez-Pujante A, Pons-Fuster A</AU>
<TI>Assessment of self-reported sleep disturbance and psychological status in patients with burning mouth syndrome</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2015</YR>
<VL>29</VL>
<NO>7</NO>
<PG>1285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merksey-1994" MODIFIED="2016-11-03 23:10:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Merksey 1994" TYPE="BOOK">
<AU>Merksey H, Bogduk N</AU>
<SO>Classification of Chronic Pain</SO>
<YR>1994</YR>
<EN>2nd</EN>
<PB>International Association for the Study of Pain Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mueller-2003" MODIFIED="2016-11-03 23:11:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Mueller 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mueller C, Kallert S, Renner B, Stiassny K, Temmel AF, Hummel T, et al</AU>
<TI>Quantitative assessment of gustatory function in a clinical context using impregnated 'taste strips'</TI>
<SO>Rhinology</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>1</NO>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navazesh-1982" MODIFIED="2016-02-23 16:59:39 +0000" MODIFIED_BY="Jo C Weldon" NAME="Navazesh 1982" TYPE="JOURNAL_ARTICLE">
<AU>Navazesh M, Christensen CM</AU>
<TI>A comparison of whole mouth resting and stimulated salivary measurement procedures</TI>
<SO>Journal of Dental Research</SO>
<YR>1982</YR>
<VL>61</VL>
<NO>10</NO>
<PG>1158-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2013" MODIFIED="2016-11-03 23:22:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="NICE 2013" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence (NICE)</AU>
<TI>Neuropathic pain in adults: pharmacological management in non-specialist settings. Clinical guideline CG173</TI>
<SO>Available from www.nice.org.uk/guidance/cg173</SO>
<YR>(accessed prior to 24 May 2016)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penza-2010" MODIFIED="2016-11-03 23:23:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Penza 2010" TYPE="JOURNAL_ARTICLE">
<AU>Penza P, Majorana A, Lombardi R, Camozzi F, Bonadeo S, Sapelli P, et al</AU>
<TI>'Burning tongue' and 'burning tip': the diagnostic challenge of the burning mouth syndrome</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>6</NO>
<PG>528-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puhakka-2016" MODIFIED="2016-06-27 16:34:19 +0100" MODIFIED_BY="Jo C Weldon" NAME="Puhakka 2016" TYPE="JOURNAL_ARTICLE">
<AU>Puhakka A, Forssell H, Soinila S, Virtanen A, Röyttä M, Laine M, et al</AU>
<TI>Peripheral nervous system involvement in primary burning mouth syndrome - results of a pilot study</TI>
<SO>Oral Diseases</SO>
<YR>2016</YR>
<VL>21</VL>
<NO>8</NO>
<PG>338-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-2014" MODIFIED="2016-11-03 23:24:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Review Manager 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sardella-2006" MODIFIED="2016-07-08 13:11:01 +0100" MODIFIED_BY="[Empty name]" NAME="Sardella 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A</AU>
<TI>Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments</TI>
<SO>Oral Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>152-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scala-2003" MODIFIED="2016-07-04 16:44:39 +0100" MODIFIED_BY="Jo C Weldon" NAME="Scala 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA</AU>
<TI>Update on burning mouth syndrome: overview and patient management</TI>
<SO>Critical Reviews in Oral Biology and Medicine</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>4</NO>
<PG>275-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Souza-2011" MODIFIED="2016-07-08 13:12:54 +0100" MODIFIED_BY="[Empty name]" NAME="Souza 2011" TYPE="JOURNAL_ARTICLE">
<AU>Souza FT, Santos TP, Bernardes VF, Teixeira AL, Kümmer AM, Silva TA, et al</AU>
<TI>The impact of burning mouth syndrome on health-related quality of life</TI>
<SO>Health and Quality of Life Outcomes</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>9</NO>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stata-2015" MODIFIED="2016-11-01 15:55:26 +0000" MODIFIED_BY="[Empty name]" NAME="Stata 2015" TYPE="COMPUTER_PROGRAM">
<TI>Stata Data Analysis and Statistical Software: release 14</TI>
<YR>2015</YR>
<PB>StataCorp LP</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturgeon-2014" MODIFIED="2016-07-08 13:15:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sturgeon 2014" TYPE="JOURNAL_ARTICLE">
<AU>Sturgeon JA</AU>
<TI>Psychological therapies for the management of chronic pain</TI>
<SO>Psychology Research and Behavior Management</SO>
<YR>2014</YR>
<VL>10</VL>
<NO>7</NO>
<PG>115-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Svensson-1993" MODIFIED="2016-07-08 13:15:57 +0100" MODIFIED_BY="[Empty name]" NAME="Svensson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Svensson P, Bjerring P, Arendt-Nielsen L, Kaaber S</AU>
<TI>Sensory and pain thresholds to orofacial argon laser stimulation in patients with chronic burning mouth syndrome</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1993</YR>
<VL>9</VL>
<NO>3</NO>
<PG>207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taiminen-2011" MODIFIED="2016-11-03 23:27:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Taiminen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Taiminen T, Kuusalo L, Lehtinen L, Forssell H, Hagelberg N, Tenovuo O, et al</AU>
<TI>Psychiatric (axis I) and personality (axis II) disorders in patients with burning mouth syndrome or atypical facial pain</TI>
<SO>Scandinavian Journal of Pain</SO>
<YR>2011</YR>
<VL>2</VL>
<NO>4</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Waal-1990" MODIFIED="2016-11-03 23:27:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="van der Waal 1990" TYPE="BOOK">
<AU>van der Waal I</AU>
<SO>The Burning Mouth Syndrome</SO>
<YR>1990</YR>
<PB>Munksgaard</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woda-1999" MODIFIED="2016-07-08 13:19:50 +0100" MODIFIED_BY="[Empty name]" NAME="Woda 1999" TYPE="JOURNAL_ARTICLE">
<AU>Woda A, Pionchon P</AU>
<TI>A unified concept of idiopathic orofacial pain: Clinical features</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>3</NO>
<PG>172-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woda-2009" MODIFIED="2016-07-08 13:20:35 +0100" MODIFIED_BY="[Empty name]" NAME="Woda 2009" TYPE="JOURNAL_ARTICLE">
<AU>Woda A, Dao T, Grémeau-Richard C</AU>
<TI>Steroid dysregulation and stomatodynia (burning mouth syndrome)</TI>
<SO>Journal of Orofacial Pain</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>3</NO>
<PG>202-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yilmaz-2007" MODIFIED="2016-07-08 13:22:09 +0100" MODIFIED_BY="[Empty name]" NAME="Yilmaz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yilmaz Z, Renton T, Yiangou Y, Zakrzewska J, Chessell IP, Bountra C, et al</AU>
<TI>Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>9</NO>
<PG>864-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zakrzewska-1999" MODIFIED="2016-11-03 23:28:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NAME="Zakrzewska 1999" TYPE="BOOK_SECTION">
<AU>Zakrzewska JM, Hamlyn PJ</AU>
<TI>Facial pain</TI>
<SO>Epidemiology of Pain</SO>
<YR>1999</YR>
<PG>177-202</PG>
<ED>Crombie IK, Croft PR, Linton SJ, Le Resche L, Von Korff M</ED>
<PB>International Association for the Study of Pain Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-10-31 10:34:37 +0000" MODIFIED_BY="Jo C Weldon">
<REFERENCE ID="REF-Zakrzewska-2000" MODIFIED="2016-10-31 10:34:37 +0000" MODIFIED_BY="Jo C Weldon" NAME="Zakrzewska 2000" TYPE="COCHRANE_REVIEW">
<AU>Zakrzewska JM, Glenny A-M, Forssell H</AU>
<TI>Interventions for the treatment of burning mouth syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-10-07 14:49:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-07 14:49:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zakrzewska-2005" MODIFIED="2016-10-07 14:50:05 +0100" MODIFIED_BY="[Empty name]" NAME="Zakrzewska 2005" TYPE="COCHRANE_REVIEW">
<AU>Zakrzewska JM, Forssell H, Glenny AM</AU>
<TI>Interventions for the treatment of burning mouth syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-10-07 14:50:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-07 14:50:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002779.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-11-09 22:15:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Source of funding" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-11-09 12:51:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<CHAR_METHODS MODIFIED="2016-11-09 12:25:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 12:51:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>38 BMS patients</P>
<P>Group 1 mean age 66.32 SD 12.01, Group 2 mean age 58.42 SD 13.70 years (no overall age data provided)</P>
<P>Sex: 35 F:3 M (F 92%:M 8%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 12:41:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: topical treatments</B>
</P>
<P>Group 1: (n = 19) topical medication comprised of <B>urea 10%</B> to be applied at the oral cavity 3-4 times per day for 3 months</P>
<P>Group 2: (n = 19) <B>placebo</B> (5% sodium carboxymethylcellulose, 0.15% methyl paraben, and 10% glycerol in distilled water quantity sufficient to make 100 g) to be applied at the oral cavity 3-4 times per day for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 12:43:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"<B>EDOF-HC protocol</B> (Orofacial Pain Clinic - Hospital das Clinicas): a standardized orofacial pain questionnaire to detail the following: 1) chief complaint, 2) general pain characteristics (location, quality, duration, pain relief, pain triggering), 3) headache and/or body pain complaints, and 4) patient's medical history and comorbidities" at baseline and 3 months</P>
<P>
<B>Xerostomia questionnaire</B> at baseline and 3 months</P>
<P>Quantitative sensory testing (<B>QST</B>) at baseline and 3 months</P>
<UL>
<LI>salivary flow and gustative and olfactory thresholds</LI>
<LI>thermal detection thresholds for cold and warm sensations</LI>
<LI>mechanical detection thresholds for touch, vibration, and electrical perception</LI>
<LI>mechanical pain sensitivity, including superficial and deep pain thresholds</LI>
<LI>electrical pain threshold at the teeth</LI>
<LI>corneal reflex</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:12:29 +0100" MODIFIED_BY="[Empty name]">
<P>São Paulo State Research Foundation (FAPESP)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 12:48:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>All participants had been treated with 25-50 mg of amitriptyline within the last 3 months</P>
<P>The duration of pain was significantly longer in the study group (6.97, SD 4.93 years) compared to 5 placebo group (2.78, SD 2.61 years)</P>
<P>Insufficient results data were provided not sure how well validated all the QST are and whether there are age/gender related norms</P>
<P>SES: data reported on race, occupation, and marital status:</P>
<P>"Color: study group (n = 19) white 16, black 2, mulatto 1; control group (n = 19) white 16, black 1, mulatto 2; occupation: study group (n = 19) housekeeper 7, retired 6, domestic 2, seamstress 2, biomedical 1, unemployed 1; control group (n = 19) housekeeper 9, retired 5, unemployed 2, nanny 1, secretary 1, seller 1; marital status: study group (n = 19) married 8, widowed 6, single 4, divorced 1; control group (n = 19) married 8, widowed 7, single 3, divorced 1"<BR/>Conflict of interests: authors reported no conflict of interests exist<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 12:57:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Bergdahl-1995a">
<CHAR_METHODS MODIFIED="2016-11-09 12:50:47 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 12:51:47 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>30 BMS patients<BR/>Sex: 24 F:6 M (F 80%:M 20%)</P>
<P>24/30 (80%) were women with a mean age of 56 years (range: 40-69) and 6/30 (20%) were men with a mean age of 46 years (range: 38-57)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 12:55:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: psychological therapies</B>
</P>
<P>Group 1: (n = 15) "<B>therapy group</B>" (TG) - Phase 1: an introductory session consisting of a motivational input and an oral examination. The patients were given time to decide whether or not to participate in the study. Phase 2: evaluation of BMS intensity (pre-treatment). Phase 3: cognitive therapy (CT) for 12-15 sessions; 1 hour once a week. Phase 4: evaluation of BMS intensity and oral examination immediately after completed CT (post-treatment). Phase 5: evaluation of BMS intensity and oral examination 6 months after completed CT (6-month follow-up). 2 psychologists, dentist estimated outcome</P>
<P>Group 2: (n = 15) "<B>attention/placebo</B> <B>group</B>" (APG) - Phase 1: an introductory session consisting of a motivational input and an oral examination. The patients were given time to decide whether or not to participate in the study. Phase 2: evaluation of BMS intensity (pre-treatment). Phase 3: return visits 3 times during 12-15 weeks for evaluation of BMS intensity and oral examination. Phase 4: evaluation of BMS intensity and oral examination (post-treatment). Phase 5: evaluation of BMS intensity and oral examination 6 months later (6-month follow-up). 2 psychologists, dentist estimated outcome</P>
<P>Duration: 12 to 15 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 12:56:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>VAS</B> - graded 1-7, "graded from endurable to unendurable" pre-treatment, post-treatment, 6 months post-treatment - "All the patients evaluated their burning mouth intensity with the same dentist"</P>
<P>
<B>Global symptom reduction</B> post-treatment and 6/12 &#8211; not prespecified</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:08:49 +0100" MODIFIED_BY="[Empty name]">
<P>Swedish Dental Society and the Faculty of Odontology, Umeå University, Sweden</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 12:57:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Groups comparable at baseline</P>
<P>SES: not reported</P>
<P>Conflict of interests: not reported</P>
<P>Data analysis: ITT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 13:09:33 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Bogetto-1999">
<CHAR_METHODS MODIFIED="2016-11-09 12:58:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 12:59:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>121 BMS patients<BR/>Sex: 91 F:30 M (F 75%:M 25%)</P>
<P>Mean age 65.4 years (SD 10.6 years)<BR/>
</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 13:04:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: antidepressants and antipsychotics + benzodiazepines</B>
</P>
<P>Group 1: (n = 24) <B>paroxetine</B> 20 mg/day</P>
<P>Group 2: (n = 23) <B>amitriptyline</B> 25 mg/day</P>
<P>Group 3: (n = 26) <B>clordemetildiazepam </B>1 mg/day</P>
<P>Group 4: (n = 24) <B>amisulpride</B> 50 mg/day</P>
<P>Group 5: (n = 24) <B>placebo</B>
</P>
<P>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 13:06:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Hamilton Anxiety Rating Scale (<B>HARS</B>) (clinician-rated)</P>
<P>Montgomery&#8211;Åsberg Depression Rating Scale (<B>MADRS</B>)</P>
<P>Clinical Global Impression I (<B>CGI I</B>) scale (clinician-rated)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:08:56 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 13:09:33 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>All participants were given a 2-week washout period from prior medication prior to being randomised</P>
<P>SES: participants' average number of schooling years reported (5.7 years (SD 2.3) (min 0 - max 13))<BR/>Conflict of interests: not reported<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 13:22:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<CHAR_METHODS MODIFIED="2016-11-09 13:12:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 13:12:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>60 BMS patients</P>
<P>Sex: 48 F:12 M (F 80%:M 20%)</P>
<P>Mean age 63.3, SD 12.9 years</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 13:13:50 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 30) extra virgin olive oil (VOO) with <B>lycopene</B> 300 ppm: applied as a spray to the mouth, to be swallowed afterwards: 1.5 mL 3 times a day for 12 weeks</P>
<P>Group 2: (n = 30) identical <B>placebo </B>formulation: as above &#8211; "consisted of a formulation (water and dye) identical to that of the study product but without the active agents"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 13:21:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>VAS "pain"</B>: "A visual analogue scale (VAS) was used to evaluate symptoms at the start of treatment (Day 0) and after 12 weeks of treatment. In this way, the difference between baseline and endpoint scores numerically expresses any symptomatic improvement (0 = none and 10 = extreme). The subjects were asked to mark a vertical line through a 10 cm horizontal line to indicate their level of symptoms. The scores for pain were classified into: slight (&#8804; 3.3), moderate (3.4&#8211;6.6), and severe (&#8805; 6.7)"</P>
<P>
<B>VAS "burning"</B>: "A visual analogue scale (VAS) was used to evaluate symptoms at the start of treatment (Day 0) and after 12 weeks of treatment. In this way, the difference between baseline and endpoint scores numerically expresses any symptomatic improvement (0 = none and 10 = extreme). The subjects were asked to mark a vertical line through a 10 cm horizontal line to indicate their level of symptoms. The scores for pain were classified into: slight (&#8804; 3.3), moderate (3.4&#8211;6.6), and severe (&#8805; 6.7)"</P>
<P>General health assessment - 36-Item Short Form Health Survey (<B>SF-36</B>) at baseline &#8211; 12 weeks</P>
<P>Oral Health Impact Profile-14 (<B>OHIP-14</B>) at baseline &#8211; 12 weeks</P>
<P>The Hospital Anxiety and Depression (<B>HAD</B>) scale at baseline &#8211; 12 weeks</P>
<P>"<B>Lipid profile blood test</B>" at 12 weeks</P>
<P>"<B>Patient-rated benefit and satisfaction</B>" - Not stated how this was measured</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-09 13:22:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Study authors reported no funding received</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 13:22:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Outcome measures and their use were partly very confusing</P>
<P>SF-36 normally compared to norms for age and gender</P>
<P>SES: not reported<BR/>Conflict of interests: study authors reported no conflict of interests exist<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 13:44:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Carbone-2009">
<CHAR_METHODS MODIFIED="2016-11-09 13:30:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 13:30:33 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>66 BMS patients</P>
<P>Sex: 54 F:12 M (F 82%:M 18%)</P>
<P>Of the 52 patients who completed the trial, mean age was reported as 67.3 years (SD 11.9)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 13:42:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 22) 400 mg <B>alpha lipoic acid (ALA) and vitamins</B> B (1, 2, 6, 12), C, E, and folic acid (vitamin B9) - 1 pill twice/day by mouth 30 minutes after food for 8 weeks followed by phase II which was a 2-month follow-up period without therapy (Tiobec, produced by Laborest)</P>
<P>Group 2: (n = 22) 400 mg <B>alpha lipoic acid </B>- 1 pill twice/day by mouth 30 minutes after food for 8 weeks followed by phase II which was a 2-month follow-up period without therapy (produced by Laborest as standalone ALA specifically for this trial)</P>
<P>Group 3: (n = 22) <B>placebo</B> pill 1 pill twice/day 30 minutes after food (containing dicalcium phosphate, microcrystalline cellulose, hydroxipropylmethyl cellulose, silicon dioxide, vegetal magnesium stearate, shellac and stearic acid) for 8 weeks. Followed by phase II which was a further 2-month follow-up period without 'therapy'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 13:43:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Proportion of participants achieving a <B>50% improvement</B> in BMS symptoms from baseline to T3 and T4, measured by the <B>VAS</B> score. Each participant was examined by the same examiner (blinded to treatment) at the beginning of therapy (T0), 2 weeks (T1) and 4 weeks (T2) after the start of treatment, at the end of treatment (T3), and after 2 months of follow-up (T4)<BR/>Quality of pain experienced by participants was also assessed using the <B>McGill Pain Questionaire</B>. Similarly, each participant was examined by the same examiner (blinded to treatment) at the beginning of therapy (T0), at 2 weeks (T1) and at 4 weeks (T2) after the start of treatment, at the end of treatment (T3), and after 2 months of follow-up (T4)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:09:29 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 13:44:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The study authors query whether all participants should have been treated with a 7-day course of antifungal therapy to eradicate subclinical candidosis. Current clinical practice would consider this unnecessary and irrelevant if the diagnosis is BMS. Is 8 weeks treatment sufficient time to provide a definitive answer?</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 14:16:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Cavalcanti-2009">
<CHAR_METHODS MODIFIED="2016-11-09 13:48:10 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled cross-over RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:11:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>38 BMS patients</P>
<P>Sex: 34 F:4 M (F 89%:M 11%)</P>
<P>Mean age 63.1 years (range: 36&#8211;78)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:13:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 17) 200 mg <B>alpha lipoic acid</B> (ALA) capsules 3 times daily for 30 days. A 20-day washout period followed before participants received placebo (cellulose starch 100 mg), administered in identical capsules 3 times daily for a further 30 days. Participants who reported any improvement with the proposed treatment were contacted after 60 days to assess maintenance or loss of the results (follow-up)</P>
<P>Group 2: (n = 14) <B>placebo</B> (cellulose starch 100 mg), administered in identical capsules 3 times daily for 30 days. A 20-day washout period followed before 200 mg of ALA capsules 3 times daily for a further 30 days. Participants who reported any improvement with the proposed treatment were contacted after 60 days to assess maintenance or loss of the results (follow-up)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 14:14:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Extent of reduction of symptoms based on <B>VAS</B>: rating of burning was evaluated by measurements of the VAS, ranging from 0 (no burning) to 100 mm (maximum burning), before and after each cycle (i.e. before the beginning of the treatment (baseline T0) and at follow-up visits: after completing the first cycle of 30 days (T1), at the end of washout period of 20 days (T2) and at the end of the second cycle of 30 days (T3))</P>
<P>Self-reported description of improvement Global Perceived Effect (<B>GPE</B>). Adapted from Femiano and colleagues and scored by the participant according to a 5-point scale, ranging from: 1 = worse; 0 = no change; +1 = slight improvement; +2 = decided improvement; +3 = no burning anymore (resolution) after each cycle</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:09:41 +0100" MODIFIED_BY="[Empty name]">
<P>São Paulo State Research Foundation (FAPESP)</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 14:16:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Participants taking antidepressants, possibly anxiolytics, angiotensin-converting enzyme inhibitors and hormone replacement therapy were included in the study population &#8211; although they appeared to be distributed evenly across the arms</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 14:28:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Femiano-2000">
<CHAR_METHODS MODIFIED="2016-11-09 14:23:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:23:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>42 BMS patients<BR/>Median age 63 years (range 43 to 78)<BR/>Sex: 32 F:10 M (F 76%:M 14%)<BR/>20 had removable prostheses</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:24:25 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 21) <B>alpha lipoic acid and vitamins</B> B (1, 2, 6, 12), C, E, and folic acid (vitamin B9) 600 mg/day for 20 days, followed by 200 mg/day for 10 days (Tiobec, produced by Laborest)</P>
<P>Group 2: (n = 21) <B>placebo</B> cellulose starch 100 mg/day for 30 days</P>
<P>Duration: 30 days</P>
<P>As a second stage study, the original controls were then treated with the active regimen for 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 14:27:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"All patients were reviewed at 15-day intervals"; <B>bespoke BMS symptomology change scale</B>: "change in symptomatology scored as Worsening - Unchanged +/- Slight improvement + Decided improvement + + Resolution + + +" - unclear as to exactly how these data were recorded and by whom</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 14:28:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Unvalidated outcome measure used<BR/>Comparability of groups at baseline is unclear</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 14:34:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Femiano-2002a">
<CHAR_METHODS MODIFIED="2016-11-09 14:30:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Placebo-controlled parallel RCT (unclear where study was conducted or whether single or multicentre)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:31:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>60 BMS patients<BR/>Median age 45 years (range 22 to 68)<BR/>Sex: 42 F:18 M (F 70%:M 30%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:31:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 30) <B>alpha lipoic acid and vitamins</B> B (1, 2, 6, 12), C, E, and folic acid (vitamin B9) in 200 mg oral pills, 3 times a day for 8 weeks (Tiobec, produced by Laborest)</P>
<P>Group 2: (n = 30 ) <B>placebo</B> cellulose starch 100 mg/day, 3 times a day</P>
<P>Duration: 2 months (note: those showing improvement in symptoms at 2 months given a further month of treatment and followed for 1 year)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 14:34:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Bespoke BMS symptomology change scale</B> - change in symptomatology scored as: Worsening - Unchanged +- Slight improvement + Decided improvement ++ Resolution +++</P>
<P>"Results at 1 year follow-up for changes in burning symptomatology in all subjects who showed an improvement at 2 months, as shown in Table 2, using alpha lipoic acid (test) or placebo control (starch)" &#8211; categories = No change, Slight deterioration, Significant deterioration</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 14:34:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Outcome measures were confusing and unvalidated<BR/>Comparability of groups at baseline unclear</P>
<P>It is unclear whether other ALA studies published by this study author around the same time used the same participants or not</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 14:46:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Femiano-2002b">
<CHAR_METHODS MODIFIED="2016-11-09 14:37:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:38:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>80 BMS patients<BR/>Median age 63 years (range 30 to 74)<BR/>Sex: 48 F:32 M (F 60%:M 40%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:42:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements + topical treatments + cholinergics</B>
</P>
<P>Group 1: (n = 20) <B>bethanechol </B>(urecholine) 5 mg oral dose every 8 hours between meals</P>
<P>Group 2: (n = 20) <B>lactoperoxidase </B>oral solution (Biotene oral rinse) topically 5-6 times daily</P>
<P>Group 3: (n = 20) <B>alpha lipoic acid and vitamins</B> B (1, 2, 6, 12), C, E, and folic acid (vitamin B9) in 200 mg oral pills, 3 times a day (every 8 hours) for 60 days (Tiobec, produced by Laborest)</P>
<P>Group 4: (n = 20)<B> placebo </B>- xylitol 3% in distilled water (no further details provided)</P>
<P>Study conducted over 60 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 14:44:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Bespoke BMS symptomology change scale</B> scored as: Worsening, Unchanged, Slight improvement, Decided improvement, Resolution &#8211; unclear as to how this was assessed</P>
<P>Weekly "assessments" performed &#8211; further details not provided. Unclear whether symptomatology or side effects were assessed at every visit</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 14:46:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>16/80 participants reported to have "used anxiolytic drugs to control the BMS" &#8211; these were allocated equally amongst the study arms</P>
<P>2 participants were reported in results section to be ongoing with anxiolytics during trial</P>
<P>Unusually high number of male participants included within the study cohort</P>
<P>It is unclear whether other ALA studies published by the author around the same time used the same participants or not</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 14:52:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<CHAR_METHODS MODIFIED="2016-11-09 14:48:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Multicentre (6 centres), placebo-controlled parallel RCT (open-label study continued for 6 months following initial 14-day study &#8211; data not included in this analysis)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:49:01 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>48 patients with "stomatodynia" ("isolated complaint of chronic pain in the oral mucosa with normal clinical examination, with duration of pain greater than 4 months")<BR/>Mean age 65 years SD 2.1<BR/>Sex: 44 F:4 M (F 92%:M 8%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:49:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: benzodiazepines</B>
</P>
<P>Group 1: (n = 24) <B>clonazepam </B>tablet 1 mg to be sucked without swallowing for 3 minutes, 3 times a day (after each meal) for 2 weeks</P>
<P>Group 2: (n = 24) <B>placebo</B> tablet to be sucked without swallowing for 3 minutes, 3 times a day (after each meal) for 2 weeks</P>
<P>Duration: 2 weeks intervention, 6-month open follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 14:52:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Numerical Pain Scale</B> (0-10): "The primary criterion used to evaluate drug efficacy was the difference in pain intensity score observed for each subject before and after 14 days of treatment (NS 0 &#8211; NS 2)" - mean pain intensity (0 "no pain" to 10 "maximal pain imaginable")</P>
<P>"As a secondary outcome criterion, the immediate effects of clonazepam were evaluated by comparing, between the active treatment and control groups, the average of the differences (NS 0 &#8211; NS 1) in pain intensity score before and 5 min after topical 5 application"</P>
<P>Compliance and adverse events were also recorded</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-09 14:52:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"The authors thank Laboratoire Roche for clonazepam and placebo tablets, C Cadène and the association 'Langue de feu' for their help, and the Teaching Hospital of Clermont-Ferrand for financial and administrative support"<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 14:52:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Groups comparable at baseline - baseline anxiety or depression status were not known</P>
<P>The active treatment was continued for all participants for 6 months after the initial trial finished. It would have been interesting to note if there were any adverse events upon withdrawal of the active treatment</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 15:06:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Heckmann-2012">
<CHAR_METHODS MODIFIED="2016-11-09 14:57:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 14:58:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>20 BMS patients</P>
<P>Overall ages not presented - Group 1 (clonazepam): from text - mean 67.5 (range 49-89) / from table - mean 65.0 SD: 12.4. Group 2 (placebo): from text - mean 65.4 (49-78) / from table - mean 62.9 SD: 8.7</P>
<P>Sex: 13 F:7 M (F 65%:M 35%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 14:58:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: benzodiazepines</B>
</P>
<P>Group 1: (n = 10) <B>clonazepam</B> 0.5 mg capsules - 1 daily</P>
<P>Group 2: (n = 10) <B>placebo </B>capsules - 1 daily</P>
<P>Duration: 9 weeks</P>
<P>"As the intake of clonazepam can cause dependency, the medication was tapered off at the end of study in those subjects who had received verum. They took drops (0.1 mg clonazepam per drop) for a period of 10 days starting with five drops; this dose was reduced by one drop every 2 days"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 15:06:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Beck Depression Inventory (BDI)</B> &#8211; 2 weeks before treatment, beginning of treatment, 3 weeks after starting treatment, at end of treatment and 2 weeks after end of treatment</P>
<P>
<B>Zerssen Mood Scale</B> &#8211; 2 weeks before treatment, beginning of treatment, 3 weeks after starting treatment, at end of treatment and 2 weeks after end of treatment</P>
<P>
<B>Taste test score</B> (0-16): "Taste test. For quantitative assessment of gustatory function, a standardized validated test based on filter papers impregnated with tastants was used. Strips with the basic tastes sweet, sour, salty, and bitter (in four concentrations each) were applied onto the extended tongue, which was then taken back into the closed mouth. Before application of each taste strip, patients rinsed their mouths with water. Following presentation of the strip, patients were asked to identify the taste from a list of four descriptors (sweet, sour, salty, and bitter). The sum of correct identifications was used for further statistical analysis" - performed 2 weeks before treatment and at end of treatment and 2 weeks after end of treatment (methods fully detailed in <LINK REF="REF-Mueller-2003" TYPE="REFERENCE">Mueller 2003</LINK>: scale 0-16 (each taste component 0-4), higher better)</P>
<P>
<B>Smell test score</B>: "Smell test. The odour identification part of the Sniffin'- Sticks test battery were used to screen for changes in olfactory function. Following presentation of a common odour, subjects were each asked to identify it from a list of descriptors. The sum of correct identifications was used for further analysis" - performed 2 weeks before treatment and at end of treatment and 2 weeks after end of treatment</P>
<P>"<B>Salivary flow rate</B>. The salivary flow rate was measured using a cotton swab. It was weighed and placed onto the patient's tongue for 1 minute. After that, the cotton swab was weighed again and the resulting difference was used to calculate salivary flow rate" - performed 2 weeks before treatment and at end of treatment and 2 weeks after end of treatment (methods fully detailed in <LINK REF="REF-Navazesh-1982" TYPE="REFERENCE">Navazesh 1982</LINK>: weight scale, higher better. Swab method is 1 of 4 methods (draining, spitting, suction, swab) compared to calculate salivary flow. (Note <LINK REF="REF-Navazesh-1982" TYPE="REFERENCE">Navazesh 1982</LINK> authors state swab method is least reliable and most variable of the 4 options)</P>
<P>
<B>Numerical pain ratings scale</B> (0-10): "<B>Pain ratings.</B> Patients rated the sensation of burning pain in the mouth on a scale ranging between 0 and 10, with 0 indicating no pain and 10 indicating maximum possible pain" - performed 2 weeks before treatment and at end of treatment and 2 weeks after end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-09 15:02:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Study authors reported no funding was received</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 15:03:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>SES: not reported<BR/>Conflict of interests: authors reported no conflict of interests exist<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:09:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<CHAR_METHODS MODIFIED="2016-11-09 15:09:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 15:19:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>120 BMS patients</P>
<P>Mean age 14.1 SD 57.5 years, median: 57</P>
<P>Sex: 94 F:26 M (F 78%:M 22%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 15:36:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: anticonvulsants + dietary supplements</B>
</P>
<P>Group 1: (n = 20) 600 mg daily <B>alpha lipoic acid </B>- for 2 months (Ciagen 600, produced by Craveri). Supplement includes excipients (sodium lauryl sulfate 30.00 mg; 329.50 mg lactose monohydrate; cornstarch 115.50 mg; croscarmellose sodium ( AC-DI-SOL) 72.00 mg; colloidal silicon dioxide (Aerosil 200) 5.50 mg; 35.00 mg magnesium stearate; povidone K-30 12.50 mg; methocel E15 25.08 mg; 10.05 mg lactose monohydrate; 0.39 mg titanium dioxide; polyethylene glycol 6000 0.78 mg; yellow iron oxide 3.68 mg)</P>
<P>Group 2: (n = 20) 300 mg daily <B>gabapentin</B> (GABA)</P>
<P>Group 3: (n = 20) 600 mg daily <B>alpha lipoic acid </B>(ALA) + 300 mg daily <B>gabapentin</B> (GABA)</P>
<P>Group 4: (n = 60) 100 mg daily starch and cellulose <B>placebo</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:09:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Number of sites affected</B> - "evaluated the presence of burning through a numerical scale especially created for this work, describing the burning from 0 to 4, where the 0 value corresponded to the absence of burning, the 1 value to the presence of burning in a single area of the tongue, the 2 value to two distinctive areas (tongue and gums, tongue and lips or tongue and palate), the 3 value to three areas and the 4 value corresponded to burning spread throughout the mouth. This specific designed scale, which considered the geographical distribution of burning in different areas of the mouth, allowed us to distinguish improvements or deteriorations of burning sensation in the various assessments"</P>
<P>"<B>Evaluation of the effects</B>&#8230; the day before the start of treatment and thirty and sixty days, respectively. To evaluate the changes that occurred with the taking of the different drugs, it was established that the improvements (positive changes) involved the passage of a certain level or numerical category of burning to a lower one, the deteriorations (negative changes) involved an increase of a certain level of burning to a higher one and the total resolution indicated the total absence of burning, that is to say the transition from any higher value to zero value. In this way four categories were obtained for the analysis of the 5 results: Category 1: with negative changes (deterioration), Category 2: no changes; Category 3: with positive changes (improvements) and Category 4: with total recovery"</P>
<P>Change in quality of life (QoL) was assessed at baseline only (consequently unable to assess change) by use of 2 surrogate (measuring anxiety and depression) scales: - anxiety: Hamilton Anxiety Rating Scale (HARS) - baseline only; and - anxiety/depression: Hospital Anxiety and Depression (HAD) scale - baseline only</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:10:47 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 15:22:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The dosage of gabapentin given is not therapeutic as an anticonvulsant</P>
<P>Outcome evaluation was based on the numerical scale which was based on the number of sites affected. Thus only 1 (not validated) outcome measure was used in the study</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 15:52:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<CHAR_METHODS MODIFIED="2016-11-09 15:50:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 15:50:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>60 BMS patients</P>
<P>Mean age 64.37 SD 11.61 years</P>
<P>Sex: 54 F:6 M (F 90%:M 10%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 15:51:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 23) 800 mg in oral pills per day for 8 weeks: each containing <B>alpha lipoic acid </B>(0.05 mg) <B>+ adjunctive lycopene </B>(100 mg)<B> + green tea extract </B>(40%, 50 mg) (Thioderm, produced by Sesderma)</P>
<P>Group 2: (n = 16) <B>placebo</B> - cellulose tablets of the same appearance, shape, texture and colour as the treatment for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 15:52:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Pain intensity as recorded on a 10 cm <B>VAS</B>. The scores for pain were classified into: slight (&#8804; 3.3), moderate (3.4&#8211;6.6) and severe (&#8805; 6.7). Pain scores were recorded before treatment (day 0) and at 1 and 2 months (only participants completing treatment protocol for the 2 months were included i.e. n = 39)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:10:59 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 15:52:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:02:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<CHAR_METHODS MODIFIED="2016-11-09 15:54:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 15:57:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>50 BMS patients</P>
<P>Mean age 61.18, SD 12.27 (range 37-84)</P>
<P>Sex: 46 F:4 M (F 92%:M 8%)</P>
<P>Inclusion and diagnostic criteria appropriate - exclusion of all "patients with known neurological disorders and those previously treated, even irregularly, with antidepressants, anticonvulsants, other psychotropic drugs, or psychological therapy" represents exclusion of a significant proportion of the BMS population, hence reducing applicability to all BMS patients (i.e. possible reduced external validity)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 15:58:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: physical barriers</B>
</P>
<P>Group 1: (n = 25) <B>control</B> - "Patients were informed in detail about their illness, and were instructed not to rub their tongue against their teeth and/or dentures. A self-control technique was used to this effect, the patients being given 10 printed habit-modifying reminder points to be placed in visible place"</P>
<P>Group 2: (n = 25) <B>tongue protector </B>- same as group 1 with tongue protector: "The protector consisted of a transparent, low-density polyethylene sheath covering the tongue from 4 the tip to the posterior third. These tongue protectors were single-use devices measuring 0.1 mm in thickness, with a standard size (67 mm in length and 66 mm wide), and were custom manufactured by our group. Each patient received a kit with the protectors and the reminder points for treatment"; "Instructions were provided on their use &#8211; the protector being worn during the daytime for period of 2 months. We recommended use of the protector 15 min/three times a day"</P>
<P>Duration of intervention: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:01:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Oral symptoms <B>VAS</B> (0: no pain, 10: most severe pain experienced): "Patients were asked to indicate the mean pain intensity for the 2 weeks preceding the consultation. The difference between baseline and the endpoint scores numerically expressed symptoms variation" - measured at baseline and 2 months</P>
<P>Hospital Anxiety and Depression scale (<B>HAD</B>) - measured at baseline and 2 months</P>
<P>Oral Health Impact Profile-49 (<B>OHIP-49</B>) - measured at baseline and 2 months</P>
<P>36-Item Short Form Health Survey (<B>SF-36</B>) - measured at baseline and 2 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:02:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The biological plausibility of the active treatment is not clear</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:14:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Marino-2010">
<CHAR_METHODS MODIFIED="2016-11-09 16:04:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 16:11:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>56 BMS patients</P>
<P>Mean age 62 years (SD 9.8)</P>
<P>Sex: 46 F:10 M (F 82%:M 18%)</P>
<P>Inclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 16:13:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements + topical treatments</B>
</P>
<P>Group 1: (n = 14) thrice daily oral rinses with <B>capsaicin</B>, 250 mg of red pepper emulsion in 50 ml of water for 8 weeks followed by 8-week post-treatment observation</P>
<P>Group 2: (n = 14) <B>alpha lipoic acid and vitamins</B> B (1, 2, 6, 12), C, E, and folic acid (vitamin B9) in 400 mg oral pills, twice a day for 60 days (Tiobec, produced by Laborest)</P>
<P>Group 3: (n = 14) <B>lysozyme lactoperoxidase oral rinse</B> (Biotene; GlaxoSmithKline Consumer Healthcare; GlaxoSmithKline S.P.A., Verona, Italy), 5 times a day for 8 weeks followed by 8-week post-treatment observation</P>
<P>Group 4: (n = 14) 0.05 g of boric acid dissolved in 100 ml of distilled water (<B>placebo</B>), thrice a day for mouthwash for 8 weeks followed by 8-week post-treatment observation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:13:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Severity of burning mouth sensation was assessed at the beginning and at the end of both the studies by means of a subjective <B>VAS</B> ranging from 0 (no burning mouth sensation) to 10 (severe burning mouth sensation)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:14:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Tiobec contains vitamin C, B1, 2, 6, 12, PP, folic acid, E (this is not mentioned in the paper)</P>
<P>No side effects reported - unexpected given the nature of capsaicin</P>
<P>SES: not reported<BR/>Conflict of interests: study authors report no conflict of interests exist<BR/>Data analysis: unclear<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:20:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<CHAR_METHODS MODIFIED="2016-11-09 16:16:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, parallel-arm, placebo-controlled RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 16:16:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>60 BMS patients</P>
<P>Mean age: 62.13 years (range 36-86)</P>
<P>Sex: 55 F:5 M (F 92%:M 8%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 16:18:10 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 30) 600 mg (3 x 200 mg every 8 hours) in oral pills per day for 8 weeks: each containing <B>alpha lipoic acid </B>(0.05 mg) <B>+ adjunctive lycopene </B>(100 mg)<B> + green tea extract </B>(40%, 50 mg) (Thioderm, produced by Sesderma)</P>
<P>Group 2: (n = 30) <B>placebo</B> - similar looking cellulose tablets to group 1 intervention, for 8 weeks (provided by ALA manufacturer)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:19:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Symptom relief, surrogately measured by <B>VAS</B> (scale 0-10, but expressed dichotomously in reporting) to measure change in symptoms, at baseline, 1 month and 2 months</P>
<P>Depression by Beck Depression Inventory (<B>BDI</B>), at baseline (unknown if recorded latterly)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:11:22 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported, although all treatment (intervention and placebo) provided by Sesderma Laboratories</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:20:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Adverse effects not reported despite stating a priori that their occurrence would be recorded</P>
<P>Baseline mean symptom intensity presented for all participants, rather than each group separately. May be baseline imbalance</P>
<P>Depression reported by 54% of participants (32/59)</P>
<P>Use of medication: antidepressants/anxiolytics 53%; antihypertensives 25%; thyroid treatment 12%; other medication 43%</P>
<P>SES: not reported<BR/>Conflict of interests: study authors report no conflict of interests exist<BR/>Data analysis: per-protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:26:50 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<CHAR_METHODS MODIFIED="2016-11-09 16:24:25 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 16:24:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>66 BMS patients</P>
<P>Mean age 64.9 years (range 48&#8211;85)</P>
<P>Sex: 64 F:2 M (F 97%:M 3%)</P>
<P>Inclusion and diagnostic criteria appropriate</P>
<P>Baseline characteristics for each group provided in graphs and table were difficult to interpret &#8211; no obvious differences between groups at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 16:26:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: benzodiazepines</B>
</P>
<P>Group 1: (n = 33) <B>topical clonazepam</B> - "Each patient was given a sealed envelope containing 32 tablets of 0.5 mg of clonazepam. They were instructed to take a single tablet at the first sign of discomfort in the morning. The tablet should be dissolved in the mouth for three minutes, and then the remaining saliva should be spat out. The patient should then note his or her sensations and the evolution of the symptoms. If there was improvement, the procedure was to be repeated when the symptoms reappeared. Patients were advised not to exceed four tablets a day (that is, a total dose of 2 mg of clonazepam)"</P>
<P>Group 2: (n = 33) <B>placebo</B> - "lactose tablets, of the same shape and size as those given to Group A. Their instructions were the same as those given to Group A"</P>
<P>The amount of tablets used varied between participants</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-31 23:01:35 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>VAS</B> from 0 to 10 (no scale descriptors provided) &#8211; baseline, 1 month, 6 months</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:11:32 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:26:50 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>No email correspondence details provided &#8211; therefore, we could not contact authors to determine VAS descriptors</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:36:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Sardella-1999">
<CHAR_METHODS MODIFIED="2016-11-09 16:31:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 16:35:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>30 BMS patients<BR/>Mean age 69 years (range 54-85)<BR/>Sex: 26 F:4 M (F 87%:M 13%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 16:35:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: topical treatments</B>
</P>
<P>Group 1: (n = 10) <B>benzydamine hydrochloride</B> 0.15% oral rinse, 15 ml rinse 3 times a day for 4 weeks</P>
<P>Group 2: (n = 10) <B>placebo</B> oral rinse 3 times a day for 4 weeks</P>
<P>Group 3: (n = 10) <B>no treatment</B>
</P>
<P>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:36:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Change in severity of symptoms <B>VAS</B> (0 = no symptoms, 8 = a severe burning sensation) before and after treatment scored as: "ineffective" (same dot value for the symptoms at the 2 visits), "partially effective" (reduction in dot value of the symptoms), "effective" (complete absence of symptoms)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:11:42 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:36:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Groups comparable at baseline</P>
<P>Unvalidated outcome measure used<BR/>Study only double-blind for groups 1 and 2</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 16:59:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Sardella-2008">
<CHAR_METHODS MODIFIED="2016-11-09 16:38:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 16:55:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>43 BMS patients</P>
<P>Mean age 64.9 SD 4.7 years</P>
<P>Sex: 35 F:4 M (reported per protocol) (F 90%:M 10%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 16:56:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 21) <B>hypericum perforatum</B> extract 300 mg capsules (hypericin 0.31%, hyperforin 3.0%) 3 times a day for 12 weeks</P>
<P>Group 2: (n = 22) <B>placebo </B>capsules "identically appearing" 3 times a day for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 16:59:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>10 cm <B>VAS</B> consisting of a horizontal line marked from 0 (no pain) to 10 (the worst pain ever experienced) measured at first visit (t0) and at 3 follow-up visits (after 4 (t28), 8 (t56), and 12 (t84) weeks)</P>
<P>
<B>Number of oral mucosa sites with reported burning symptoms </B>measured at first visit (t0) and at 3 follow-up visits (after 4 (t28), 8 (t56), and 12 (t84) weeks)</P>
<P>
<B>Non-standardised assessment of quality of life </B>- self-reported descriptions in response to "simple questions (i.e. did you feel irritable/depressed/worry? or did oral burning sensations interfere with your daily activities? or have you had difficult in concentrating on things as reading or watching a TV movie?)"</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-09 16:59:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"This study has been supported by a grant of the University of Milan (FIRST, Fondo Interno per la Ricerca Scientifica e Tecnologica, no 12-1-5201001-540). We also thank Body Spring (Ancona, Italy) that kindly supplied both hypericum extract and placebo"</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 16:59:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 21:26:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Silvestre-2012">
<CHAR_METHODS MODIFIED="2016-11-09 21:23:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled cross-over RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 21:23:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>30 BMS patients</P>
<P>Mean age 72.65 SD 12.10 years (range 40-90 years)</P>
<P>Sex: 19 F:4 M (reported per protocol) (F 83%:M 17%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 21:25:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: topical treatments</B>
</P>
<P>Group 1: (n = 30) <B>capsaicin </B>- 0.02% capsaicin rinse administered 3 times a day &#8211; applied for 30 seconds in volumes of 15 ml &#8211; 1 week; "After this first week of treatment, the patients completed a one-week washout period (no rinses, only regular dental hygiene in the form of tooth brushing), after which they were assigned to the opposite group for a further week of treatment"; "During this cross-over period, treatment and the scoring of discomfort were carried out in the same way as in the first week, but administering the opposite oral rinse". No details of whether this was before or after meals</P>
<P>Group 2: (n = 30) <B>placebo </B>- "Placebo" rinse (unspecified preparation) - applied for 30 seconds in volumes of 15 ml &#8211; 1 week; "After this first week of treatment, the patients completed a one-week washout period (no rinses, only regular dental hygiene in the form of tooth brushing), after which they were assigned to the opposite group for a further week of treatment"; "During this cross-over period, treatment and the scoring of discomfort were carried out in the same way as in the first week, but administering the opposite oral rinse". No details of whether this was before or after meals</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 21:26:30 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>VAS</B> - "discomfort at different times during the study (0 cm = no discomfort, 10 cm = unbearable or maximum discomfort)" &#8211; measured "morning before treatment in both the capsaicin group (AM1) and in the placebo group (BM1). The VAS score was then again recorded in the afternoon of the first day of treatment in both groups (AA1 and BA1) and at the end of one week of treatment in both groups, in the morning (AM7 and BM7) and in the afternoon (AA7 and BA7)"</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:12:20 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 21:26:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>No baseline characteristics provided for each study arm</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: Per protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 21:44:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Spanemberg-2012">
<CHAR_METHODS MODIFIED="2016-11-09 21:28:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 21:29:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>72 BMS patients</P>
<P>Mean ages - Group 1: 63.6 SD 9.61 (range 41&#8211;79); Group 2: 61.5 SD 6.76 (range 46&#8211;73)</P>
<P>Sex: 53 F:7 M (reported per protocol) (F 88%:M 12%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 21:30:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: dietary supplements</B>
</P>
<P>Group 1: (n = 38) <B>'Catuama'</B> herbal compound - 310 mg capsules - Paullinia cupana ('guarana': 125 mg), Trichilia catigua ('catuaba': 87.5 mg), Zingiber officinalis ('ginger root': 10 mg), and Ptychopetalum olacoides ('potency wood': 87.5 mg) - 2 capsules a day, before lunch and dinner, for 8 weeks after the first evaluation</P>
<P>Group 2: (n = 34) <B>placebo</B> capsules containing magnesium silicate, with the same colour and shape as those taken by the group test - 2 capsules a day, before lunch and dinner, for 8 weeks after the first evaluation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 21:44:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Visual numeric scale (<B>VNS</B>) consists of a ruler divided into 11 equal parts, numbered successively from 0 (without symptoms) to 10 (maximum intensity of the symptoms). At baseline, 4, 8, and 12 weeks after the treatment onset. The assessment at 12 weeks was carried out 30 days after the end of treatment</P>
<P>Faces scale (<B>FS</B>): "the individual classified the intensity of their symptoms according to the expression shown 4 in each pictured face. The expression of happiness corresponds to 0 (without symptoms) and the expression of maximum unhappiness to 5 (maximum intensity of the symptoms)". At baseline, 4, 8, and 12 weeks after the treatment onset. The assessment at 12 weeks was carried out 30 days after the end of treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:12:10 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 21:32:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>No data provided as to how quickly one would expect the active treatment to work and how long it works for - presumably a prolonged benefit was expected as the study looked at outcomes 4 weeks after cessation of treatment</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 22:03:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Spanemberg-2015">
<CHAR_METHODS MODIFIED="2016-11-09 21:43:10 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 21:43:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>78 BMS patients<BR/>Mean age 62.8 years</P>
<P>Sex: 67 F:11 M (F 86%:M 14%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 22:00:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: electromagnetic radiation</B>
</P>
<P>Group 1: (n = 20) <B>infrared weekly laser</B>: 1 session weekly for 10 weeks (10 sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.028 cm²), aluminium gallium arsenide (GaAlAs), 830 nm wavelength, 100 mW output, continuous emissions, 3.57 W/cm², 5 J energy p/point, 176 J/cm² radiant exposure, applied 50 seconds p/point) + OHI (mucosal hydration and irritant avoidance (spicy/citric food, alcohol, tobacco))</P>
<P>Group 2: (n = 20) <B>infrared laser 3 times per week</B>: 3 sessions weekly for 3 weeks (9 sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.028 cm²), GaAlAs, 830 nm wavelength, 100 mW output, continuous emissions, 3.57 W/cm², 5 J energy p/point, 176 J/cm² radiant exposure, applied 50 seconds p/point) + OHI (as above)</P>
<P>Group 3: (n = 19) <B>red laser 3 times per week</B>: 3 sessions weekly for 3 weeks (9 sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.028 cm²), aluminium gallium indium phosphide (InGaAlP), 685 nm wavelength, 35 mW output, continuous emissions, 1.25 W/cm², 2 J energy p/point, 72 J/cm² radiant exposure, applied 58 seconds p/point) + OHI (as above)</P>
<P>Group 4: (n = 19) <B>placebo laser 3 times per week</B>: 3 sessions weekly for 3 weeks (9 sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.028 cm²), plastic-tipped with rubber interior to block radiation emission, duration of application per point not reported) + OHI (as above)</P>
<P>Duration: Groups 2-4 - used in this review: 3 weeks; Group 1 - data not used within this review due to no comparable placebo group: 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 22:02:19 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>VAS</B> and visual numeric scale (<B>VNS</B>): "Both scales were applied to check whether patients would be consistent in their responses" at baseline, 3 weeks (end of treatment) and 11 weeks (2 months after treatment cessation) using 100 mm VAS scale (endpoints were 0 = no pain, 100 = worst pain possible) and VNS scale (endpoints were 0 = no pain, 10 = worst pain possible)</P>
<P>Oral Health Impact Profile-14 (<B>OHIP-14</B>) (Portuguese language version) at baseline and 3 weeks (end of treatment)</P>
<P>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-11-09 22:02:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; process number 4906-13-6), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) - all in Brazil</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 22:03:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: ITT</P>
<P>QoL not assessed at 11-week follow-up, only immediately after cessation of treatment (3 weeks)</P>
<P>Note: While VAS (0-100 mm) and VNS (0-10) were both assessed to ensure response consistency, VAS was used in this review's analyses due to the greater precision in reported results and reassurance from the study authors: "In both scales, the patients were consistent in their responses, presenting Pearson correlation coefficient &gt; 0.9"<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-11-09 22:09:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<CHAR_METHODS MODIFIED="2016-11-09 22:04:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single centre, placebo-controlled parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-09 22:04:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>37 BMS patients<BR/>Mean age 58.6 years (range 39 to 71)</P>
<P>Sex: 37 F (F 100%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 22:05:30 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: antidepressants and antipsychotics</B>
</P>
<P>Group 1: (n = 18) <B>trazodone</B> 200 mg daily</P>
<P>Group 2: (n = 19) <B>placebo</B>
</P>
<P>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-09 22:06:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>VAS</B> at 0, 2, 4 and 8 weeks using 100 mm VAS scale (endpoints were 0 = no pain, 100 = worst pain possible)</P>
<P>Short McGill Pain Questionnaire (<B>MPQ</B>) at baseline and 8 weeks - "intensity and character of the pain were further defined by the use of the Finnish version of the McGill Pain Questionnaire"<BR/>Beck Depression Inventory (<B>BDI</B>)</P>
<P>Global assessment at 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-05-18 08:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>Finnish Dental Society</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-09 22:09:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Groups differed at baseline with regard to pain intensity</P>
<P>Number of dropouts was higher in those who were depressed</P>
<P>SES: not reported<BR/>Conflict of interests: not reported<BR/>Data analysis: per protocol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALA = alpha lipoic acid; BMS = burning mouth syndrome; F = female; ITT = intention-to-treat; M = male; OHI = oral hygiene instruction; ppm = parts per million; QoL = quality of life; RCT = randomised controlled trial; SD = standard deviation; SES = socioeconomic status; VAS = visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-11-09 22:52:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-11-03 14:57:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Bai-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 14:57:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Does not use a placebo group - electric acupuncture therapy versus oral oryzanol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-02 21:48:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bessho-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-02 21:48:14 +0000" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - compares Kampo medicine with diazepam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-31 14:45:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogetto-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-31 14:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Amisulpride versus paroxetine - conference abstract only - insufficient detail provided to confirm that participants had burning mouth syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:15:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Campisi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:15:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Does not use a placebo group - compares 2 different forms of sucralfate - 20% suspension versus 1 g chewable tablet</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:01:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Ferguson-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:01:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - single-centre, double-blind CCT of 145 oophorectomised patients comparing mestranol with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:01:07 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Forabosco-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:01:07 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - the diagnosis of BMS was uncertain in this study, all subjects included in the study with BMS symptoms received the same intervention (hormone replacement therapy)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-02 21:48:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grechko-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-02 21:48:55 +0000" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - compares electrical stimulation therapy with standard methods of treatment (novocaine blockade, analgesics, etc.)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:01:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Grushka-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:01:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - all 30 subjects received clonazepam (starting dose was 0.25 mg daily, with an increase in dose of 0.25 mg on a weekly basis if symptoms continued)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:04:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:04:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Inappropriate design - only immediate assessment, no clinical application. "The spontaneous burning was measured with a visual analogue scale (VAS) just before and 15 min after injection"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:04:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Hansen-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:04:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not true cross-over; not all participants received both interventions. Mixed diagnosis; unable to separate out results for BMS sufferers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:15:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Hirsch-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:15:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - pilot study reporting 3 cases of open-label application of topical sucralose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:05:25 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Huang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:05:25 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Does not use a placebo group - acupoint injection of vitamin B<SUB>1 </SUB>and B<SUB>12 </SUB>versus oral oryzanol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:06:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Huang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:06:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Does not use a placebo group - acupoint injection of vitamin B<SUB>1 </SUB>and B<SUB>12 </SUB>versus oral oryzanol and vitamin B<SUB>2</SUB> complex</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:07:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Hugoson-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:07:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - participants grouped according to presence of BMS symptoms or vitamin deficiency or both. Only those with both symptoms and vitamin deficiency received therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:07:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Ito-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:07:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - open-label case series in 22 patients with BMS who were given varying doses of milnacipram over a 12-week period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:07:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Kho-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:07:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - not primary BMS, some participants had anaemia, diabetes mellitus and hyposalivation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:08:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Lamey-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:08:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Participants initially divided according to whether they were vitamin deficient or not. The non-vitamin deficient group were randomly allocated to various vitamin replacement regimens, although results are not broken down according to regimen</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:11:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:11:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Unable to locate a copy of the original article from any location worldwide after repeated search through the British Library's Inter-Library Loans service</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:14:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Lindholm-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:14:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>The trial included participants with various neuropathic orofacial pain conditions. Data for BMS sufferers (n = 5; 31%) could not be separated out from other types of pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:16:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Loldrup-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:16:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Participants randomly allocated to 1 of 3 groups: clomipramine, mianserin or placebo. The trial included patients with pain of no known organic origin. Data for BMS sufferers could not be separated out from other types of pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:16:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Lu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:16:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Does not use a placebo group - acupoint injection of vitamin B<SUB>1 </SUB>and B<SUB>12 </SUB>versus oral oryzanol and vitamin B complex</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:17:01 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:17:01 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Comparison between tongue protector and tongue protector plus aloe vera gel - therefore study is not placebo-controlled, as the tongue protector is considered to be an active treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:17:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Ma-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:17:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Unable to locate a copy of the original article from any location worldwide after repeated search through the British Library's Inter-Library Loans service</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-02 21:50:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maina-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-02 21:50:05 +0000" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - compares SSRIs (paroxetine 20 mg/day or sertraline 50 mg/day) with amisulpride 50 mg/day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:18:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Miziara-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:18:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Inappropriate design - placebo group outcome assessed after 1 month while intervention group outcome assessed after 3 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:18:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Mo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:18:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Unable to locate a copy of the original article from any location worldwide after repeated search through the British Library's Inter-Library Loans service</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:19:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Palacios_x002d_Sanchez-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:19:14 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Insufficient details to permit entry to review as only conference abstract available (no inclusion/exclusion criteria or diagnostic classifications) and possibly not a randomised study - alpha lipoic acid versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:19:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Pellegrini-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:19:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Insufficient details to permit entry to review as only conference abstract available (no inclusion/exclusion criteria or diagnostic classifications)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-02 21:50:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-02 21:50:19 +0000" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - compares livial (a synthetic hormone) with oryzanol and vitamin E</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:20:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Petruzzi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:20:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Error in MEDLINE reference. Not an RCT, sample were alternately assigned to arms. Clarification received from lead author</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:21:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Pisanty-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:21:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT. Also insufficient data provided to determine whether participants had BMS or other diagnoses causing such symptoms - estrone 10,000 U and estrone 50,000 U ointments versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-31 14:17:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qui-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-31 14:17:08 +0100" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - compares laser acupuncture versus acupoint injection of vitamin B<SUB>1 </SUB>and B<SUB>12 </SUB>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:21:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Romeo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:21:13 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - no control group, case series - laser therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-09 22:52:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Toida-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-09 22:52:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not primary BMS, methods state all participants were being treated for gastritis for 4 months and had oral burning for at least a month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:22:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Vukoja-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:22:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Letter to the editor, insufficient details on diagnostic classification, methods or outcomes - laser therapy versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-11-03 15:23:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Woda-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-03 15:23:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Not an RCT - all 25 subjects received clonazepam (0.5 or 1 mg) 2 or 3 times daily</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-31 14:18:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-31 14:18:46 +0100" MODIFIED_BY="[Empty name]">
<P>Does not use a placebo group - acupoint injection of vitamin B<SUB>1</SUB> and B<SUB>12</SUB> combined with oral oryzanolum versus oral oryzanolum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BMS = burning mouth syndrome; CCT = controlled clinical trial; RCT = randomised controlled trial; SSRIs = selective serotonin reuptake inhibitors.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Source of funding" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-11-03 15:47:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-NCT02580734">
<CHAR_METHODS MODIFIED="2016-11-03 15:47:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Placebo-controlled, triple-blinded cross-over RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-03 15:45:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>20 BMS patients<BR/>Mean age: Unknown until published (eligible age range 18 to 90)</P>
<P>Sex: Distribution unknown until published</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-03 15:45:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: Dietary supplements</B>
</P>
<P>Group 1: (n = 20) <B>Melatonin</B> 12 mg daily (3 mg capsules taken 4 times p/day)</P>
<P>Group 2: (n = 20) <B>Placebo </B>(capsules taken 4 times p/day)</P>
<P>Duration: 5 months (2 months, followed by 1 month washout, and then final 2 months)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-03 15:46:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<UL>
<LI>Pain intensity at 2 months (assessed by VAS, verbal intensity score and numerical rating scale)</LI>
<LI>QoL (assessed by SF-36 (36-Item Short Form Health Survey))</LI>
<LI>QoL surrogate: Anxiety (assessed by Hamilton Anxiety Rating Scale (HAM-A))</LI>
<LI>Adverse effects</LI>
</UL>
<P>Outcomes not of interest to this review</P>
<UL>
<LI>Sleep (assessed by Epworth Sleepiness Scale (ESS) and sleep scale from the Medical Outcomes Study (MOS))</LI>
<LI>Serum melatonin levels (measured by blood sample)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-15 12:37:44 +0100" MODIFIED_BY="Jo C Weldon">
<P>Unknown until published</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-03 15:46:30 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Study currently unpublished</P>
<P>Contact: Andrea Sardella (andrea.sardella@unimi.it)</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" STUDY_ID="STD-Umezaki-2016">
<CHAR_METHODS MODIFIED="2016-11-03 15:47:05 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>Single-centre, placebo-controlled, single-blinded parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-11-03 15:48:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>26 BMS patients<BR/>Mean age 63.9 years (SD 9.56)</P>
<P>Sex: 24F:2M (F92%:M8%)</P>
<P>Inclusion/exclusion and diagnostic criteria appropriate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-09 22:56:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>
<B>Intervention category: Electromagnetic radiation</B>
</P>
<P>Group 1: (n = 14) High-frequency <B>transcranial magnetic stimulation </B>(TMS): 10 daily sessions (1 session p/day for 5 days, 2 days untreated and then a further 5 days of 1 session p/day) totalling 30,000 single-pulse stimulations at 10 Hz (MagVenture MagPro x100 Stimulator - MagVenture Inc., Denmark; Cool-B65 A/P figure 8 coil, positioned over left dorsolateral prefrontal cortex (DLPFC) at medial frontal 10-20 system EEG-electrode location (F3); unconnected ECT electrodes placed under coil - Natus Neurology, Middleton, Wisconsin)</P>
<P>Group 2: (n = 12) <B>Placebo</B>: 10 daily sessions (1 session p/day for 5 days, 2 days untreated and then a further 5 days of 1 session p/day) totalling 30,000 single-pulse stimulations (MagVenture MagPro x100 Stimulator - MagVenture Inc., Denmark; shielded Cool-B65 A/P figure 8 coil, positioned over left DLPFC at location F3; connected ECT electrodes placed under coil to stimulate when TMS was triggered - Natus Neurology, Middleton, Wisconsin)</P>
<P>Duration: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-03 15:55:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<UL>
<LI>Pain intensity at baseline, daily during days 1-14, follow-up at day 15, 1 month and 2 months (assessed by VAS)</LI>
<LI>Functional impairment at baseline, days 8 and 15, 1 month and 2 months (assessed by Short Form McGill Pain Questionnaire (SFMPQ); Brief Pain Inventory (BPI); Patient Health Questionnaire (PHQ-9); Patients' Global Impression of Change (PGIC); Clinical Global Impression for global improvement scale (CGI-I))</LI>
<LI>Adverse effects</LI>
</UL>
<P>Outcomes not of interest to this review</P>
<UL>
<LI>Patients' assumed treatment group (TMS or placebo; assessed at end of treatment)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-15 14:29:32 +0100" MODIFIED_BY="Jo C Weldon">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2016-11-03 18:01:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>No numbers (tables 1-3), means or SDs (text and figures 2-3) associated with the study's results were available in the published study paper. Until this information is obtained we are unable to incorporate this study within our analyses</P>
<P>Quotation: "SSRIs were prescribed for around 40% of the patients, but these did not adequately relieve the BMS pain. Although 30% of the patients had a prior history of depression, none currently met diagnostic criteria for depression"</P>
<P>Comment: Unclear if SSRIs were prescribed before the trial commenced, or during the trial as a co-intervention</P>
<P>SES: Not reported<BR/>Conflict of interests: Not reported<BR/>Data analysis: Per-protocol (according to Figure 1). 6 participants did not complete the assigned intervention duration due to competing commitments which allowed them to attend only 2 sessions (of 10 scheduled) each. Group 1: 2 patients abandoned study; Group 2: 4 patients left study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>BMS = burning mouth syndrome; F = female; M = male; QoL = quality of life; RCT = randomised controlled trial; SD = standard deviation; SES = socioeconomic status; SSRIs = selective serotonin reuptake inhibitors; VAS = visual analogue scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-11-09 22:10:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-11-09 22:09:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 12:49:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Quotation: "The subjects were randomly divided into two groups"</P>
<P>Comment: insufficient information to make a judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 12:57:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Quotation: "divided at random into equal groups"</P>
<P>Comment: no details provided of exactly how this was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:09:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Quotation: "...patients were subdivided in 5 groups using a random criteria..."</P>
<P>Comment: the method used to generate the randomisation is not reported in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:17:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Quotation: "Randomization was performed using the website http://randomization.com to assign participants to either the intervention group or the placebo group"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:44:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quotation: "Randomization was performed using computer-generated random number tables in order to assign patients to receive one of the three 8-week standardized treatments"</P>
<P>Comment: satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:17:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Quotation: "appropriate random-number generator software (available at www.graphpad.com/quickcalcs/RandMenu.csm)"</P>
<P>Comment: appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:28:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Quotation: "randomly divided into two groups (Test and Control) each of 21 subjects, matched for age and sex"</P>
<P>Comment: unclear as to how the randomisation was conducted and what was meant by "matched"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:35:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Quotation: "divided at random for two groups of patients"</P>
<P>Comment: no detail provided about how randomisation was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:46:33 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Quotations: "This BMS cohort was then randomly divided into 4 groups"; "matched for age and sex"</P>
<P>Comment: no detail provided about how randomisation was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:52:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Quotation: "Randomisation was performed in blocks of eight by the hospital pharmacy"</P>
<P>Comment: third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:06:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Quotations: "performed by an independent individual using a specialized software program (RANDLIST; DatInf, Tübingen, Germany)"; "enrolment numbers were established, and the subjects to be investigated were randomized in such a way as to form five groups made up of four participants each (i.e., two were assigned clonazepam and two were assigned a placebo)"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:41:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Quotation: "The 120 patients were randomly divided into 6 groups of 20 members each"</P>
<P>Comment: unclear as to how the randomisation was conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:52:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Quotation: "Having met the eligibility criteria, participants were randomly divided into two groups according to a list made by simple randomization block design, generated using a randomization table. A simple block randomization list with a block size of four was prepared by a team member not involved in the recruitment and follow-up of the patients"</P>
<P>Comment: satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:02:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Quotation: "&#8230;were randomly allocated to one of the two arms of the study. The random allocation sequence was generated using software available online at&#8230;"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:14:50 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Quotation: "Patients were single-blindly randomised by means of computer-generated random number"</P>
<P>Comment: probably undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:20:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Quote: "patients were randomly allocated to one of the two different sequence groups"</P>
<P>Comment: no detail provided about sequence generation method used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:26:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Quotation: "table of random numbers was used in order to ensure the randomization of the treatments"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:36:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Quotation: "Each patient was assigned to one of 3 management modalities (A, B or C) through use of a table of random numbers. To avoid subgroups of different sizes, a block randomization was used"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 17:00:11 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Quotation: "random allocation sequence was generated using online software available at http://graphpad.com/quickcalcs/randomise1.cfm"</P>
<P>Comment: appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 21:26:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Quotation: "The patients were randomized to two groups"</P>
<P>Comment: not enough information to make a judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 21:32:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Quotation: "The herbal and placebo were stored in identical vials and properly coded to blind both researcher and patients. The researcher chose the vial by lot and thus were patients randomly allocated to treatment groups"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:03:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Quotation: "randomly allocated into four groups"</P>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:09:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Quotation: "Randomization was performed in blocks of 6 by the manufacturer of the drug (Orion)"</P>
<P>Comment: third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-11-09 22:09:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 12:49:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Comment: nothing stated about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 12:57:33 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Comment: no details provided on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:09:47 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Comment: no details provided on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:23:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Quotation: "A code for randomization was kept in an opaque envelope in a safe environment and was not consulted until the end of the study"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:44:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Comment: allocation concealment was not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:18:47 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Quotation: "After determining the eligibility and obtaining the consent, to guarantee the blinding, the researcher sent the patient's study number to the pharmacist, who then allocated patients"</P>
<P>Comment: participants and investigators enrolling participants could not foresee assignment because pharmacy-controlled central allocation was used to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:28:46 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Comment: allocation concealment was not discussed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:39:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Comment: nothing stated about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:46:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Comment: no detail given regarding allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:53:07 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Quotations: "Randomisation was performed in blocks of eight by the hospital pharmacy"; "Experimentors were blinded to patient allocation"</P>
<P>Comment: appropriate method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-28 21:49:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Comment: randomisation and blinding was conducted by an independent person</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:42:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Quotations: "The support staff of our service made a draw with 6 balls to link the groups with the cycles of treatment"; "allocation that was always masked to both patients and researcher"</P>
<P>Comment: assumption that "support staff" were independent to investigators &#8211; seems unlikely that allocation concealment would be compromised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:52:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Quotation: "Randomization allocation concealment was performed by sending the randomization numbers in sealed envelopes to the investigator responsible for giving the assigned treatment after each eligible patient was enrolled"</P>
<P>Comment: satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:02:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Comment: nothing stated about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:15:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Quotation: "Patients were single-blindly randomised by means of computer-generated random number tables"<BR/>Comment: study is single-blind hence allocation was not concealed to investigators. Participants and investigators enrolling participants appear not to have been able to foresee assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:20:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-31 22:48:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Comment: nothing stated about allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:55:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Comment: nothing stated about allocation concealment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 14:47:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Quotation: "To guarantee allocation concealment, the researchers deciding on patient eligibility did not know the sequence, and a researcher who was not involved in patient enrolment assigned the patients to one of the two arms"</P>
<P>Comment: concealed allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-01 20:32:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Comment: no mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-01 21:24:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Comment: as above, likely that allocation was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:03:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Comment: not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:09:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Quotations: "The randomization code was not opened during the trial"; "The examiner could not guess the treatment of the subjects"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-11-09 22:10:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01 CMP-004.01 CMP-002.01 CMP-003.01 CMP-003.02 CMP-003.04 CMP-003.03 CMP-005.01 CMP-005.02 CMP-005.03 CMP-005.04 CMP-005.05 CMP-007.01 CMP-007.02 CMP-008.01 CMP-009.01 CMP-009.02 CMP-009.03">
<NAME>Blinding of participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.01 CMP-004.01 CMP-002.01 CMP-003.01 CMP-003.02 CMP-003.04 CMP-003.03 CMP-005.01 CMP-005.02 CMP-005.03 CMP-005.04 CMP-005.05 CMP-007.01 CMP-007.02 CMP-008.01 CMP-009.01 CMP-009.02 CMP-009.03">
<NAME>Blinding of outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 12:49:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Quotation: "double-blind clinical trial"</P>
<P>Comment: no further information, although placebo administered as for intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 12:49:47 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Quotation: "double-blind clinical trial"</P>
<P>Comment: no further information, although placebo administered as for intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 12:57:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Quotation: "All the patients evaluated their burning mouth intensity with the same dentist"</P>
<P>Comment: the study was unblinded to the participants.There was no mention of blinding - given that both arms employed completely different treatment modalities, it is unlikely that it would be possible to blind the participants or investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 12:58:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Quotation: "All the patients evaluated their burning mouth intensity with the same dentist"</P>
<P>Comment: the study was unblinded to the participants.There was no mention of blinding - given that both arms employed completely different treatment modalities, it is unlikely that it would be possible to blind the participants or investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 13:09:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Quotation: "open label"</P>
<P>Comment: open study hence participants not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 13:09:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Quotation: "open label"</P>
<P>Comment: open study hence assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 13:25:39 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Quotations: "A randomized, double-blind and placebo-controlled study design was adopted"; "Both patients and researchers were blind to treatment assignment (treatment/placebo)"; "The placebo consisted of a formulation (water and dye) identical to that of the study product but without the active agent"; "The products were coded by an operator external to the study in identical opaque containers (without any brand name)"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 13:26:00 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Quotations: "In all cases, data were collected by a single researcher blind to the group to which each patient belonged"; "Data were analysed by a third party blinded to the allocation results"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 13:45:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quotations: "Double blind"; "The medication (pills) was distributed in identical containers. During treatment, neither the physician nor the patients knew which of the three medications they were using"</P>
<P>Comment: satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 13:45:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quotation: "Each patient was examined by the same examiner (blind to treatment)"</P>
<P>Comment: satisfactory &#8211; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 14:19:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Quotations: "placebo-controlled double-blind crossover trial"; "Patients started with 200 mg of ALA or placebo (cellulose starch 100 mg), administered in identical capsules three times daily for 30 days"</P>
<P>Comment: blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken. Side effects from ALA may have led to participants being suspicious that they might be taking the active treatment &#8211; results suggest no significant difference in reported adverse events between groups, hence unlikely that adverse events introduced significant bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 14:20:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Quotations: "placebo-controlled double-blind crossover trial"; "Patients started with 200 mg of ALA or placebo (cellulose starch 100 mg), administered in identical capsules three times daily for 30 days"</P>
<P>Comment: blinding of key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 14:28:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Quotation: "open controlled clinical study"</P>
<P>Comment: described as an open-label study hence non-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 14:28:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Quotation: "open controlled clinical study"</P>
<P>Comment: described as an open-label study hence non-blinded - how reported outcome was recorded (i.e. self-reported by patient or by clinician) is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 14:35:30 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Quotation: "using lipoic acid as test, and cellulose starch as control, where neither the patient nor doctor could distinguish the substance used"</P>
<P>Comment: appropriate placebo control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 14:35:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Quotation: "The patients were clinically assessed every 15 days, and symptomatology was recorded"..."neither the patient nor doctor could distinguish the substance used"</P>
<P>Comment: blinded outcome assessment, although how reported outcomes were recorded (i.e. self-reported by patient or by clinician) is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 14:46:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Quotation: "This open controlled study of &#945;-lipoic acid"</P>
<P>Comment: the study is described as open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 14:47:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Quotation: "This open controlled study of &#945;-lipoic acid"</P>
<P>Comment: the study is described as open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 14:53:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Quotations: "Experimentors were blinded to patient allocation"; "All the tablets looked identical"</P>
<P>Comment: side effects could potentially unblind participants, however, no significant difference in side effects reported between 2 arms. Unblinding mentioned: "After unblinding, five patients identified as clonazepam receivers .... "&#8211; however, this was after the initial trial period of 14 days</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 14:53:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Quotations: "Experimentors were blinded to patient allocation"; "All the tablets looked identical"</P>
<P>Comment: patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 15:07:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Quotations: "The bottles were sealed and labelled with the study code and the enrolment number"; "When the study was complete, unblinding was carried out by an independent individual"</P>
<P>Comment: it is unclear to the review authors at what point was the "study complete"; was it at the end of treatment or at the final session 5 visit? According to the data provided, the participants were unblinded for the outcomes taken during the final (session 5)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 15:07:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Quotation: "When the study was complete, unblinding was carried out by an independent individual"</P>
<P>Comment: according to above comment, the investigators were still blinded at the session 5 assessment point. Again there was uncertainty about when exactly study completion occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 15:43:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Quotation: "through the use of capsules of similar size and appearance so that just the support staff was the one who recorded the information until the end of the treatment (blind)"</P>
<P>Comment: "similar size and appearance" - unlikely that formulations were identical, as weights were different and they may not look the same. Unclear how preparations were provided to participants and in what packaging. Placebo only group involved 1 tablet while group 3 had 2 tablets to take &#8211; hence unblinding group 3 that they were on the combined treatment arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-07-07 15:24:57 +0100" MODIFIED_BY="Jo C Weldon" RESULT="YES" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Comment: patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 15:53:23 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Quotations: "double blind"; "as placebo, cellulose tablets of the same appearance shape, texture and colour as the treatment" [were used]</P>
<P>Comment: satisfactory</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 15:53:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Quotations: "double blind"; "as placebo, cellulose tablets of the same appearance shape, texture and colour as the treatment"</P>
<P>Comment: satisfactory; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-01-28 21:15:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Comment: nothing stated about blinding of participants or study personnel. The treatment modalities differed vastly from each other, hence unblinding participants and the investigator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-02-02 13:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Comment: nothing stated about blinding of participants or study personnel. The treatment modalities differed vastly from each other, hence unblinding participants and the investigator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 16:15:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Comment: no blinding attempted or possible - mouthwashes (capsaicin) and Biotene gel are being compared against a systemic option (ALA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-07-07 15:25:51 +0100" MODIFIED_BY="Jo C Weldon" RESULT="YES" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Comment: patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 16:21:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Comment: described as a "double-blind placebo-controlled study", but no further detail provided. Provision of identical placebo treatment by manufacturer would have allowed blinding of participants and outcome assessors, but not confirmed in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 16:21:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Comment: described as a "double-blind placebo-controlled study", but no further detail provided. Provision of identical placebo treatment by manufacturer would have allowed blinding of participants and outcome assessors, but not confirmed in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 16:28:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Quotations: "double blind study"; "Each patient was given a sealed envelope containing 32 tablets of 0.5 mg of clonazepam"; "Group B: 33 patients, placebo group. They were given 32 lactose tablets, of the same shape and size as those given to Group A"</P>
<P>Comment: from information provided, blinding method appears appropriate - adverse effects (only reported in active arm &#8211; "sleepiness in 5 patients of the clonazepam group, which did not require the clinicians to suspend the treatment") and some participants in active arm reported sensation of effervescent and numbness for up to 3 hours &#8211; possible unblinding of participants due to side effects of clonazepam</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 16:28:43 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Quotations: "double blind study"; "Each patient was given a sealed envelope containing 32 tablets of 0.5 mg of clonazepam"; "Group B: 33 patients, placebo group. They were given 32 lactose tablets, of the same shape and size as those given to Group A"</P>
<P>Comment: blinded outcome assessment; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 16:37:03 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Quotation: "This study was a double-blind, randomized, longitudinal investigation"</P>
<P>Comment: nothing further stated about the blinding procedure. Group C was a no treatment control group, thus knew which group they have been allocated, and were not blinded to treatment, however this treatment arm not relevant to this review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 16:37:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Quotation: "This study was a double-blind"</P>
<P>Comment: nothing further stated about the blinding procedure; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 17:00:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Quotations: "double-blind, placebo-controlled study"; "Patients were randomized to receive indistinguishable 300-mg capsules of H. perforatum extract (hypericin 0.31%, hyperforin 3.0%; Test Group) or placebo (Control Group)"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-07-07 15:27:15 +0100" MODIFIED_BY="Jo C Weldon" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Quotation: "double-blind, placebo-controlled study"</P>
<P>Comment: patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-02-01 20:33:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Comment: likely unblinding of participants due to burning sensation of capsaicin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-07-07 15:30:30 +0100" MODIFIED_BY="Jo C Weldon" RESULT="NO" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Comment: likely unblinding of participants due to burning sensation of capsaicin; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 21:32:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Quotation: "All patients were evaluated by the same investigator, who had no information about the medicine codes. The blinding was maintained throughout the trial"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 21:33:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Quotation: "All patients were evaluated by the same investigator, who had no information about the medicine codes. The blinding was maintained throughout the trial"</P>
<P>Comment: blinded outcome assessment; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 22:03:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Quotation: "the present randomized, blind, placebo-controlled study"</P>
<P>Comment: although not explicitly reported, it is assumed participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 22:03:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Quotation: "the present randomized, blind, placebo-controlled study"</P>
<P>Comment: not reported who was blinded, however only patient-reported outcomes assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-11-09 22:10:11 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Quotations: "Identical capsules of trazodone and of passive placebo were packed in the same way"; "nothing suggested that the blinding had not remained intact for the patients"; "Seven subjects in the trazodone group and 2 in the placebo group failed to finish the trial because of side effects, mainly because of dizziness"</P>
<P>Comment: probably achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2016-11-09 22:10:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Quotation: "The examiner could not guess the treatment of the subjects"</P>
<P>Comment: blinded outcome assessment; patient-reported outcomes only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-11-09 22:10:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 12:50:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Quotation: "Among the 38 patients that were included in this sample, 25 (65.9%) returned for the re-evaluation (12 from the study and 13 from the control group)"</P>
<P>Comment: no further details were provided &#8211; inadequate data provided on dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 12:58:25 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Comment: it was not stated if all participants completed the study/no mention of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 13:11:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Group 1 paroxetine 9/24 (37.5%) dropouts</P>
<P>Group 2 amitriptyline 14/23 (60.8%) dropouts</P>
<P>Group 3 clordemetildiazepam 11/26 (42.3%) dropouts</P>
<P>Group 4 amisulpride 1/24 (4.2%) dropouts</P>
<P>Group 5 placebo 19/24 (79.2%) dropouts</P>
<P>Explanation provided by study authors - possible reasons for dropouts: "patients with BMS tend to change medical doctor frequently, side effects of drug tested apart from amisulpride that is characterized by few side effects"</P>
<P>Comment: insufficient details on why participants dropped out - reason for missing outcome data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 13:26:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Quotations: "4/30 patients in the treatment group left the study; 6/30 patients in the placebo group left the study"; "Patients were lost from the sample due to lack of compliance" (both groups)</P>
<P>Comment: dropouts not accounted for in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 13:46:29 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Quotation: "Fourteen patients did not complete the study and were excluded from the efficacy sample. No side effects were reported as being a reason for withdrawal from the trial: 10 patients dropped out because of lack of compliance, and four patients because of lack of efficacy. No significant difference in the rate of dropout was observed among the three groups (p = 0.079, v2-test)" Intention-to-treat was also considered</P>
<P>Comment: reasons for dropouts were described overall, but not for each arm. 10 participants "dropped out" due to a "lack of compliance" &#8211; it is unclear exactly what "lack of compliance" meant and how these 10 were spread across each of the study arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 14:22:12 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Comment: 38 BMS patients commenced the trial. 2 appear to have been lost to follow-up and 5 discontinued the interventions. 4 of them did not complete the proposed treatment because of the symptoms that they felt were due to treatment (these adverse effects were listed). 4 participants were excluded from the analysis. Proportions appear similar across the 2 groups</P>
<P>Data from flow diagram (stating 2 participants in each arm were excluded from the analysis) did not match details in text (which stated 7 patients had their data excluded from analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 14:29:16 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Comment: no dropouts or missing data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 14:35:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Comment: according to the results presented, no dropouts occurred</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 14:47:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Quotation: no dropouts reported. No missing data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 14:56:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Quotations: "At fourteen days: Two Group A patients discontinued intervention because of side effects. One group B patient discontinued intervention because of side effects". ITT analysis performed &#8211; assumption "that the three patients who did not complete the study were not modified by the treatment". The pain intensity outcome at 5 minutes only reported on active arm "n = 22" and placebo arm "n = 23" i.e. suggesting that the 3 dropouts occurred within the first 5 minutes of the study. No ITT analysis was provided for the 5 minute outcome. Unclear if this was a simple error in notation or otherwise</P>
<P>Comment: no real imbalance in dropouts and number of them unlikely to influence result</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 15:07:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Comment: all prespecified outcomes were reported in the prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 15:43:45 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Comment: no dropouts were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 15:53:51 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Comment: 7/30 missing from intervention group (1 due to gastrointestinal side effects, other 6 reasons not given); 14/30 missing from control group (authors suggest that withdrawal may have been due to lack of efficacy of placebo)</P>
<P>Proportions of dropouts different across 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-28 21:16:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Commnent: no missing outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 16:15:42 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Comment: dropouts were fully reported &#8211; they only occurred after phase 1 (active treatment) was completed. Although attrition rate was high, missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 16:22:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>54 patients (90%) complete trial (Group 1 n = 25; Group 2 n = 29); however, rationale for losses not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 16:28:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Comment: no dropouts or missing data reported - over a 6-month study period one would expect some to drop out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 16:37:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Quotation: ".. all patients completed the study period"</P>
<P>Comment: no dropouts reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 17:00:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Comment: all dropouts and missing data accounted for</P>
<P>Proportions similar across groups</P>
<P>Reasons similar across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 21:27:24 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Quotation: "where indicated, those subjects who developed adverse effects were removed from the study"</P>
<P>Comment: removal of participants who have had adverse events from the analysis is likely to introduce significant bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 21:33:55 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Quotation: "6 withdrew from the study for reasons unrelated to the treatment" &#8211; 5 in active, 1 in control &#8211; no reasons stated. Lost to follow-up - 8 in active arm, 4 in control. According to flow chart &#8211; 13 in active arm and 5 in control arm dropped out</P>
<P>Comment: the paper states that 8 in active and 4 in control arms were not evaluated. Hence, there is a mismatch between dropouts and evaluated participants which is not explained. Higher attrition in active arm with inadequate data provided as to why this was</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 22:03:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Quotation: "All the patients in the sample (n = 78) completed the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-09 22:10:56 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Comment: reasons for dropouts were reported appropriately. Unclear as to how these data were handled &#8211; no mention of numbers analysed for the outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-11-09 22:04:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 12:50:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Comment: no appropriate outcome data were reported despite being assessed &#8211; study authors only commented on whether there was any significant differences or not with P values</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-25 19:39:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Comment: the prespecified outcome measure was reported appropriately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:12:10 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Comment: outcomes reported in prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:28:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>Not all prespecified outcomes reported in the results (e.g. tolerability, compliance with treatment)<BR/>All reported outcomes not specified in the methods (e.g. patient-rated benefit and satisfaction)</P>
<P>Definition of outcome "evolution of pain symptoms" unclear; numbers of participants in each of these groups are not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:47:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Comment: full McGill Pain Questionnaire data not provided but alluded to and partially described</P>
<P>Quotation: "The McGill Pain Questionnaire scores showed some improvements compared to the baseline measurements (Friedman test), but significant differences among the three groups were never observed (Kruskall&#8211;Wallis test). In particular, the affective, and the mixed affective/evaluative subscales slightly improved in Group C (Friedman test: p = 0.004 and 0.022, respectively); conversely, the evaluative subscale improved in all three groups (Friedman test: Group A, p = 0.007; Group B, p = 0.003; Group C, p = 0.046)"</P>
<P>Comment: no baseline characteristic data were presented (only P values of statistical tests), full McGill Pain Questionnaire data not provided (again only P values)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:22:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Comment: standard deviations not reported; data by treatment cycle obtained from study authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-25 19:56:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Comment: all outcomes were reported in the prespecified format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:37:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Quotation: "patients were clinically assessed every 15 days, and symptomatology was recorded"</P>
<P>Comment: the above was prespecified but no data were provided in results</P>
<P>Quotation: "without notable adverse effects"</P>
<P>Comment: no prespecified method of assessing adverse effects was provided and above comment suggests some adverse effects were reported, but no data provided in results</P>
<P>Quotation: "The study was concluded with a re-evaluation of the results 1 year after commencement of the trial"</P>
<P>Comment: the study only analysed results for the participants who "showed an improvement at 2 months", despite the methods section suggesting "Patients that reported any amelioration within 4 months (12 of Control group and 29 of Test group) were given further therapy for 1 month, with a protocol identical to that used previously". Therefore the methods and results do not correlate with each other. One should expect that all participants should be followed up at 1 year, not only the responders</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:47:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Comment: no data provided for BMS symptoms during trial (e.g. at week 4) only after trial completion scores were given. "All patients reported increased salivation" was reported in Group 1 - but this was not a prespecified outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:54:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Comment: all outcomes reported in prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:08:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Comment: side effects were not mentioned as a prespecified outcome and were not adequately reported in the outcomes ("The drugs were tolerated very well by all participants"; "does not cause major side effects"). This comment would suggest that some side effects were noted, but not formally reported. One would expect side effects from clonazepam and should be able to expect that side effects would be more thoroughly reported, as side effects may have unblinded participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:49:11 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Quotation: "adverse effects that appeared were very mild"</P>
<P>Comment: clarification sought from contact author who provided adverse effect data. No baseline characteristics were presented for each arm of the study. Baseline anxiety and depression was presented for all participants but not for each arm. Outcome data were not presented in the prespecified way &#8211; graphs were presented which were difficult to interpret as the actual data values were not presented. The study authors combined "positive changes" with "full recovery" data for the active arms and "no change" with "worsened" data with the placebo &#8211; these outcomes should have been presented separately as combining them is very misleading. No useable data were presented for month 1, only month 2. Clarification sought from contact author who provided missing data from month 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:53:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Comment: all prespecified outcomes were reported appropriately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:02:48 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Comment: all prespecified outcomes were reported in the prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:15:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Comment: prespecified outcomes were reported appropriately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:22:28 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Comment: secondary outcomes (depression and adverse effects) not reported after receipt of treatment:</P>
<P>depression reported at baseline, but unknown if recorded latterly, as appears to only have been used as a covariate within the authors' logistic regression analyses</P>
<P>Adverse effects not reported despite stating a priori that their occurrence would be recorded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-31 22:57:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>All prespecified outcomes were reported in the prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:37:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Comment: outcome reported in prespecified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-28 22:38:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Comment: all primary outcomes were presented in the prespecified format</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 21:27:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Comment: VAS scores data were not presented appropriately &#8211; graph only showing capsaicin group with no raw data values (i.e. no means, standard deviations or ranges provided). Paper suggested quantitative data would be presented as median and range &#8211; unclear why this was as the distribution of the VAS data was not stated (i.e. no mention that it was non-normally distributed)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-01 21:28:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>All prespecified outcomes were reported in the prespecified manner</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:04:04 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Comment: adverse events were not reported despite being indicated to have been assessed in the final session</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-01 17:45:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Comment: prespecified outcomes were reported but not completely &#8211; although VAS measurement on speaking, eating and suffering &#8211; no data provided &#8211; only mention that there was no significant differences between the groups. McGill pain score raw data not provided, reported to be no significant difference in standard deviations for VAS and Beck data only shown graphically with no raw data provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-11-09 22:04:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-04 21:36:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alvarenga-da-Silva-2014">
<DESCRIPTION>
<P>Comment: no other sources of bias were identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-03 16:04:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergdahl-1995a">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 11:58:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bogetto-1999">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 13:29:38 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Cano_x002d_Carrillo-2014">
<DESCRIPTION>
<P>The baseline data provided for the arms are incomplete, however, given appropriate randomisation method balance/imbalance less of a concern</P>
<P>Participants occasionally using anxiolytics to induce sleep were accepted - results as to the use of anxiolytics within the cohort were not given, thus it is not known whether groups were comparable at baseline with regards to anxiolytics. There were also errors noted in the presented outcome data (tables 3 and 4) - however the corrected data were obtained from the study authors after contacting them</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-25 21:34:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carbone-2009">
<DESCRIPTION>
<P>Comment: no other obvious risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 14:22:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Cavalcanti-2009">
<DESCRIPTION>
<P>Comment: errors in reporting within paper (flow diagram, and n values), although clarified by authors in correspondence; data received from study authors revealed a baseline imbalance in relation to the VAS scores between the 2 study arms however randomisation process conducted appropriately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 12:30:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Femiano-2000">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:42:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Femiano-2002a">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:42:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Femiano-2002b">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:45:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004">
<DESCRIPTION>
<P>Comment: baseline anxiety levels were not assessed -hence the spread of baseline anxiety between the study arms was not known. Bearing in mind that clonazepam is an anxiolytic drug which was noted to have a systemic uptake within the participants, the presence of baseline anxiety is a potential confounder and should have been taken into account (potential omitted variable bias)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:51:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Heckmann-2012">
<DESCRIPTION>
<P>Comment: discrepancy between baseline ages of participants when comparing text and table data </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 15:49:44 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011">
<DESCRIPTION>
<P>Comment: possible selection bias caused by exclusion criteria &#8211; "patients using more than 3 systemically daily drugs, those ones taking psychotropic and antihypertensives drugs as well as patients with serious psychiatric conditions previously diagnosed were excluded"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:50:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b">
<DESCRIPTION>
<P>Comment: baseline inequalities in gender and age are present, however randomisation appropriate </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:03:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011">
<DESCRIPTION>
<P>Quotation: "Patients occasionally using anxiolytics to induce sleep were accepted"</P>
<P>Comment: no data provided on baseline use of anxiolytics between groups &#8211; prespecified as inclusion criteria but not reported upon. Important data as could induce baseline inequality or act as confounder</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-02 13:52:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marino-2010">
<DESCRIPTION>
<P>Commnent: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:24:07 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015">
<DESCRIPTION>
<P>Comment: no baseline data presented; given lack of detail regarding randomisation process substantial inequalities at baseline cannot be ruled out</P>
<P>Wide use of medication by participants, and over half reporting depression</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:31:36 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010">
<DESCRIPTION>
<P>Quotations: "Three clinicians, with extensive experience in oral medicine, examined the patients"; "They were again scheduled for visits after 1 month and 6 months, which allowed the clinicians to monitor their evolution"; "Both groups of patients showed improvement, which was partially due to the psychotherapy. The management of patients with BMS should be focused on two aspects. On one hand, clinicians could treat the symptoms; on the other hand, they could use basic psychotherapy customized to each person, which can be carried out in our dental office. The aforementioned psychotherapy is focused on listening to the patient, emphasizing affectivity, security and tranquility, and transmitting the feeling that we know exactly what the patient is going through as well as the difficulties we face in giving him/her solutions to his/her problems. Our personal experience has shown us that, if we manage to calm the patient with our attitude, the possibility of improvement increases; this is particularly true in patients who are relatively stable from an emotional point of view"</P>
<P>Comment: the above statements suggest that there was additional treatment in the form of psychological intervention for each participant, undertaken by 3 different clinicians. No mention of standardisation of consultations or calibration of clinicians, hence possible confounding factor in terms of "psychotherapy" provided in a non-standardised/uncalibrated way. Unclear if adverse events were recorded by investigators (see above) &#8211; possible unblinding of investigating clinicians, as a result of this which could influence the consultation and "psychotherapy" provided to each participant</P>
<P>Quotation: "None of the patients was treated in the last month before their inclusion in the study"</P>
<P>Comment: despite the above quotation, the authors reported most participants were taking adjuvant medications (e.g. antidepressants, anxiolytics) during the study. Therefore the former statement is misleading and inaccurate, as most would consider antidepressants and anxiolytics to be active treatments for BMS. No data were provided on type of drugs used, any dose changes during the study period &#8211; hence unclear whether there were confounder inequalities between groups during the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 16:37:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Sardella-1999">
<DESCRIPTION>
<P>Comment: insufficient data provided on baseline characteristics of participants. Baseline symptom severity VAS data were given for each individual participant. The mean VAS scores differed between treatment arms (Group A = 6.7, Group B = 6.1 and Group C = 5.7 ). It is unclear whether there were any significant differences regarding the symptom severity at the baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-28 22:39:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sardella-2008">
<DESCRIPTION>
<P>Comment: no other obvious risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 21:28:15 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="YES" STUDY_ID="STD-Silvestre-2012">
<DESCRIPTION>
<P>Comment: given that participants had a mean of 5 years duration of BMS, 1 week treatment duration is very short</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 21:34:20 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="UNKNOWN" STUDY_ID="STD-Spanemberg-2012">
<DESCRIPTION>
<P>Quotation: "Two patients who took the test substance reported exacerbation of the symptoms in the first week of treatment, but this was also observed in 4 patients in the control group"</P>
<P>Comment: the text above is contradicted by the flow chart which states 3 patients in each arm reported exacerbation of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-11-09 22:04:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" RESULT="NO" STUDY_ID="STD-Spanemberg-2015">
<DESCRIPTION>
<P>Comment: baseline inequality in OHIP and VNS present between infrared and placebo groups</P>
<P>Study authors did not assess OHIP-14 at 11-week follow-up, but did assess VAS and VNS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-28 20:55:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tammiala_x002d_Salonen-1999">
<DESCRIPTION>
<P>Comment: no other risks of bias were noted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-02-05 17:13:58 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01 CMP-004.01 CMP-002.01 CMP-003.01 CMP-003.02 CMP-003.04 CMP-003.03 CMP-005.01 CMP-005.02 CMP-005.03 CMP-005.04 CMP-005.05 CMP-007.01 CMP-007.02 CMP-008.01 CMP-009.01 CMP-009.02 CMP-009.03">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-02-05 17:13:58 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01 CMP-004.01 CMP-002.01 CMP-003.01 CMP-003.02 CMP-003.04 CMP-003.03 CMP-005.01 CMP-005.02 CMP-005.03 CMP-005.04 CMP-005.05 CMP-007.01 CMP-007.02 CMP-008.01 CMP-009.01 CMP-009.02 CMP-009.03">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-11-09 12:39:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-11-09 12:38:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1">
<TITLE MODIFIED="2016-11-07 13:09:27 +0000" MODIFIED_BY="[Empty name]">Antidepressants versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Antidepressants compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>antidepressants (trazodone)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Antidepressants</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean VAS pain score</U>
<BR/>(Scale 0-10: lower better)</P>
</TD>
<TD>
<P>4.66</P>
</TD>
<TD>
<P>
<B>1.26 higher </B>(0.24 lower to 2.76 higher)</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD>
<P>37<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Only trazodone was assessed by a single study<BR/>No data were available to estimate long-term symptom relief<BR/>No data were available to estimate the effect of other antidepressants</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL):</B> short-term (&#8804; 3 months) - <U>Mean Beck Depression Inventory score</U>
 (Scale 0-63: lower better)</P>
</TD>
<TD COLSPAN="3">
<P>This single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but there was no evidence of a difference between groups</P>
</TD>
<TD>
<P>37</P>
<P>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Single study assessing trazodone</P>
<P>No data were available to estimate long-term change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="3">
<P>There was evidence of an increase in dizziness (RR 11.61, 95% CI 1.66 to 81.04) and drowsiness (RR 4.75, 95% CI 1.18 to 19.07) in people treated with antidepressants</P>
</TD>
<TD>
<P>37<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>Only trazodone was assessed by a single study</P>
<P>No data were available to estimate the harms of other antidepressants</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>OIS:</B> optimal information size; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio; <B>VAS: </B>visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on mean placebo group pain score at short-term (&#8804; 3 months) follow-up; downgraded once due to risk of bias: unclear risk of attrition and reporting biases; downgraded once due to indirectness: concerns relating to applicability, only 1 type of antidepressant assessed, effects of other antidepressants may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>2</SUP>Downgraded once due to unclear risk of attrition and reporting biases; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability (only 1 type of antidepressant assessed, effects of other antidepressants may differ); downgraded once due to imprecision: OIS not met.<BR/>
<SUP>3</SUP>Downgraded once due to risk of bias: unclear risk of attrition and reporting biases; downgraded once due to indirectness: concerns relating to applicability, only 1 type of antidepressant assessed, effects of other antidepressants may differ; downgraded twice due to imprecision: OIS not met, and narrative report did not permit estimation of effect or 95% CI.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-11-09 12:38:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2">
<TITLE MODIFIED="2016-11-07 13:09:41 +0000" MODIFIED_BY="[Empty name]">Anticonvulsants versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Anticonvulsants compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>anticonvulsants (gabapentin: +/- alpha lipoic acid (ALA))</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Anticonvulsants</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Bespoke geographical burning distribution numerical scale</U> (0-4) (Dichotomised)</P>
</TD>
<TD>
<P>150 per 1000</P>
</TD>
<TD>
<P>600 per 1000<BR/>(313 to 1000)</P>
</TD>
<TD>
<P>RR 4.00<BR/>(2.09 to 7.67)</P>
</TD>
<TD>
<P>100<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>No data were available to estimate long-term symptom relief</P>
<P>Only gabapentin (+/- adjunctive ALA) was assessed by a single study</P>
<P>No data were available to estimate the effect of other anticonvulsants</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL)</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="3">
<P>There was evidence of an increase in drowsiness (RR 31.95, 95% CI 1.84 to 553.64) in people treated with gabapentin alone (1 RCT, 80 participants). This effect was not found for people treated with gabapentin + adjunctive ALA (1 RCT, 80 participants), nor was there evidence of an increase in mild headaches</P>
</TD>
<TD>
<P>100</P>
<P>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Only gabapentin (+/- adjunctive ALA) was assessed by a single study<BR/>No data were available to estimate the harms of other anticonvulsants</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>OIS:</B> optimal information size; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on control estimate at short-term (&#8804; 3 months) follow-up: total of control participants experiencing symptom relief, divided by total number of participants in control group multiplied by 100; downgraded twice due to high risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticonvulsant assessed, effects of other anticonvulsants may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>2</SUP>Single 4-armed study (totalling 120 people), with 3 of 4 groups included in this comparison (placebo group: 60 people; gabapentin group: 20 people; gabapentin + ALA group: 20 people), the remaining group (ALA: 20 people) and placebo group (60 people) are included within <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>; downgraded twice due to high risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticonvulsant assessed, effects of other anticonvulsants may differ; downgraded once due to imprecision: OIS not met.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-11-09 12:38:40 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3">
<TITLE MODIFIED="2016-11-07 13:09:59 +0000" MODIFIED_BY="[Empty name]">Benzodiazepines versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Benzodiazepines compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>benzodiazepines (topical/systemic clonazepam)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Benzodiazepines</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean VAS pain score</U>
<BR/>(Scale 0-10: lower better)</P>
</TD>
<TD>
<P>4.76</P>
</TD>
<TD>
<P>
<B>1.89 lower </B>(2.19 to 1.59 lower)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>111<BR/>(2 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>There was evidence of a difference between subgroups between the 2 subgroups: systemic and topical clonazepam<BR/>
</P>
<P>Short-term relief is estimated from 2 <B>topical clonazepam</B> studies. Long-term symptom relief (&gt; 3 to &#8804; 6 months) was <B>1.39 lower</B> (1.96 to 0.83 lower) than the placebo group (1 RCT, 66 participants)</P>
<P/>
<P>No evidence of short-term symptom relief from a single study assessing <B>systemic clonazepam</B> (&#8804; 3 months): mean VAS score in both placebo and intervention groups was 4.5 (MD <B>0.00 lower</B>, 95% CI 1.86 lower to 1.86 higher) (1 RCT, 20 participants)</P>
<P>
<BR/>
</P>
<P>No data were available to estimate the effect of other benzodiazepines</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL):</B> short-term (&#8804; 3 months) - <U>Mean depression score</U>
 (Scale 0-4: lower better)</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>
<B>0.20 lower </B>(0.95 lower to 0.55 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>20<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Single study assessing systemic clonazepam<BR/>No data were available to estimate long-term change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean taste test score</U> (Scale 0-16: higher better)</P>
</TD>
<TD>
<P>12.3</P>
</TD>
<TD>
<P>
<B>1.00 lower</B> (3.11 lower to 1.11 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>20<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>Single study assessing systemic clonazepam<BR/>
</P>
<P>No data were available to estimate long-term change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="4">
<P>There was no difference in the adverse events reported (drowsiness: 2 RCTs, 114 participants; dry mouth, spasmophilia, or euphoric behaviour: 1 RCT, 48 participants) for people treated with benzodiazepines</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>Both studies used topical clonazepam</P>
<P>We were unable to estimate the harms of systemic clonazepam as adverse events were not reported by its study<BR/>No data were available to estimate the harms of other benzodiazepines</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>MD:</B> mean difference; <B>OIS:</B> optimal information size; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio; <B>VAS: </B>visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on mean placebo group pain score at short-term (&#8804; 3 months) follow-up; downgraded once due to studies being assessed at unclear risk of bias across multiple domains; downgraded once due to inconsistency: substantial heterogeneity (I<SUP>2 </SUP>= 56%); downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam - irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>2</SUP>Assumed placebo risk based on mean placebo group depression score at short-term (&#8804; 3 months) follow-up; downgraded once due to high risk of selective reporting bias; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of benzodiazepine (clonazepam - irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>3</SUP>Assumed placebo risk based on mean placebo group taste score at short-term (&#8804; 3 months) follow-up; downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam - irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded once due to high risk of selective reporting bias; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>4</SUP>Downgraded once due to studies being assessed at unclear risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of benzodiazepine (clonazepam - irrespective of mode of administration) assessed, effects of other benzodiazepines may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-11-09 12:38:50 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4">
<TITLE MODIFIED="2016-11-07 13:31:51 +0000" MODIFIED_BY="[Empty name]">Cholinergics versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Cholinergics compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>cholinergics (bethanechol)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Cholinergics</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Bespoke BMS symptomology change scale</U> (Dichotomised)</P>
</TD>
<TD>
<P>150 per 1000</P>
</TD>
<TD>
<P>750 per 1000<BR/>(39 to 1000)</P>
</TD>
<TD>
<P>RR 5.00<BR/>(0.26 to 98.00)</P>
</TD>
<TD>
<P>40<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>No data were available to estimate long-term symptom relief<BR/>Only bethanechol was assessed by a single study<BR/>No data were available to estimate the effect of other cholinergics</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL)</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="3">
<P>This single study narratively reported adverse effect data. 4 participants (20%) in the bethanechol arm reported adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain). Reported data did not present the distribution of these outcomes by participant</P>
</TD>
<TD>
<P>40<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Only bethanechol was assessed by a single study<BR/>No data were available to estimate the harms of other cholinergics</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>BMS:</B> burning mouth syndrome; <B>CI:</B> confidence interval; <B>OIS:</B> optimal information size; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>No placebo group participants experienced pain relief in the single study assessing cholinergics. Consequently, in order to calculate the corresponding risk, the assumed placebo risk for cholinergics is based on the assumed placebo risk for anticonvulsants, as detailed in <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; downgraded twice: risk of bias concerns across multiple domains (allocation, blinding, selective reporting and absence of baseline data); downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticholinergic assessed, effects of other cholinergics may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>2</SUP>Downgraded twice: risk of bias concerns across multiple domains (allocation, blinding, selective reporting and absence of baseline data); downgraded once due to indirectness: concerns relating to applicability, only 1 type of anticholinergic assessed, effects of other cholinergics may differ; downgraded twice due to imprecision: OIS not met, and narrative report did not permit estimation of effect or 95% CI.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-11-09 12:39:09 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="5">
<TITLE MODIFIED="2016-11-07 13:39:07 +0000" MODIFIED_BY="[Empty name]">Dietary supplements versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TH COLSPAN="7">
<P>
<B>Dietary supplements</B> <B>compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>dietary supplements (ALA with (+ vitamins, + lycopene + green tea extract) or without adjunctive active ingredients; hypericum perforatum (St John's Wort); 'Catuama' herbal compound; lycopene)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Dietary supplements</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
</TD>
<TD COLSPAN="3">
<P>There is insufficient or contradictory evidence regarding the benefit of any of the evaluated dietary supplements over placebo to evaluate short-term symptom relief</P>
</TD>
<TD>
<P>628<BR/>(12 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Interventions evaluated for short-term symptom relief included:</P>
<UL>
<LI>ALA without adjunctive active ingredients (3 RCTs)</LI>
<LI>ALA with vitamins (5 RCTs)</LI>
<LI>ALA with lycopene and green tea extract (2 RCTs)</LI>
<LI>hypericum perforatum (St John's Wort) (1 RCT)</LI>
<LI>'Catuama' herbal compound (1 RCT)</LI>
<LI>lycopene (1 RCT)</LI>
</UL>
<P>The mean VAS pain score (scale 0-10: lower better) for <B>long-term symptom relief </B>(&gt; 3 to &#8804; 6 months) was <B>0.89 lower</B> (2.37 lower to 0.59 higher) for people treated with ALA (with or without adjunctive vitamins) than the placebo group (2 RCTs, 94 participants)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL):</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean OHIP-14 score</U> (Scale 0-70: lower better)</P>
</TD>
<TD>
<P>17.38</P>
</TD>
<TD>
<P>
<B>0.93 higher</B> (3.14 lower to 5.00 higher)</P>
</TD>
<TD ROWSPAN="3">
<P>-</P>
</TD>
<TD ROWSPAN="3">
<P>50<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>Single study assessing short-term QoL, anxiety and depression compared lycopene with placebo</P>
<P/>
<P>No data were available to estimate long-term change in QoL, or its surrogate markers: anxiety or depression</P>
<P/>
<P>No data were available to estimate the effect of other dietary supplements; however, 1 study (43 patients), comparing hypericum perforatum extract with placebo, evaluated QoL from patient self-reports and narratively indicated that both intervention and placebo participants were better able to cope at trial completion</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in QoL - anxiety:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean HAD anxiety score</U> (Scale 0-21: lower better)</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P>
<B>2.85 lower</B> (5.28 to 0.42 lower)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in QoL - depression:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean HAD depression score</U> (Scale 0-21: lower better)</P>
</TD>
<TD>
<P>6.25</P>
</TD>
<TD>
<P>
<B>1.87 lower</B> (4.23 lower to 0.49 higher)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="4">
<UL>
<LI>For people treated with ALA (with or without adjunctive active ingredients), there was evidence of an increase in headache occurrence (RR 10.87, 95% CI 1.36 to 87.03; 2 RCTs, 118 participants) or gastrointestinal complaints (RR 4.00, 95% CI 1.21 to 13.27; 3 RCTs, 138 participants). There was no difference in blood pressure (1 RCT, 38 participants) or intermittent facial skin rash (1 RCT, 80 participants)</LI>
<LI>For people treated with ALA (with or without adjunctive active ingredients) or 'Catuama' herbal compound, there was no difference in drowsiness (2 RCTs, 110 participants)</LI>
<LI>For people treated with 'Catuama' herbal compound (1 RCT, 72 participants), there was no difference in exacerbation of symptoms, insomnia or weight gain</LI>
<LI>1 RCT (60 participants, ALA with adjunctive vitamins) reported no "notable adverse effects", and another RCT (40 participants, ALA with adjunctive vitamins) narratively reported 4 intervention participants (20%) experienced heartburn, before correction by administration of ranitidine (150 mg)</LI>
<LI>Severe headache resulting from hypericum perforatum extract use caused 1 participant (5%) to discontinue treatment (1 RCT, 43 participants)</LI>
<LI>4 RCTs (224 participants, ALA (with or without adjunctive active ingredients) and lycopene) narratively reported that no adverse effects occurred</LI>
</UL>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>ALA:</B> alpha lipoic acid; <B>CI:</B> confidence interval; <B>HAD:</B> Hospital Anxiety and Depression scale; <B>OHIP-14:</B> Oral Health Impact Profile-14; <B>OIS: </B>optimal information size; <B>RCT:</B> randomised controlled trial; <B>RR:</B> risk ratio; <B>VAS:</B> visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; 1 RCT (<LINK REF="STD-Carbone-2009" TYPE="STUDY">Carbone 2009</LINK>) contributes to 2 subgroups: ALA with vitamins and ALA without adjunctive active ingredients.<BR/>
<SUP>2</SUP>Assumed placebo risk based on mean placebo group QoL score at short-term (&#8804; 3 months) follow-up; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded once due to indirectness: concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>3</SUP>Assumed placebo risk based on mean placebo group anxiety score at short-term (&#8804; 3 months) follow-up; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>4</SUP>Assumed placebo risk based on mean placebo group depression score at short-term (&#8804; 3 months) follow-up; downgraded once due to high risk of bias relating to selective reporting and lack of baseline data; downgraded twice due to indirectness: use of surrogate measure, and also concerns relating to applicability, only 1 type of dietary supplement assessed, effects of other dietary supplements may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>5</SUP>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; downgraded once for imprecision: wide CIs estimated around effect sizes.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2016-11-09 12:39:22 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="6">
<TITLE MODIFIED="2016-11-07 14:13:44 +0000" MODIFIED_BY="[Empty name]">Electromagnetic radiation versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Electromagnetic radiation compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>electromagnetic radiation (low-level laser therapy)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>
<B>Electromagnetic radiation</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B>
</P>
<P>short-term (&#8804; 3 months)</P>
<P>- <U>Mean VAS score</U> (Scale 0-100: lower better)</P>
</TD>
<TD>
<P>62.84</P>
</TD>
<TD>
<P>
<B>30.36 lower</B> (44.22 to 16.50 lower)</P>
</TD>
<TD ROWSPAN="2">
<P>-</P>
</TD>
<TD ROWSPAN="2">
<P>58<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="2">
<P>No data were available to estimate long-term symptom relief<BR/>Only low-level laser therapy (infrared laser and red laser) was assessed by a single study<BR/>No data were available to estimate the effect of other types of electromagnetic radiation (e.g. transcranial magnetic stimulation)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL):</B>
</P>
<P>short-term (&#8804; 3 months)</P>
<P>- <U>Mean OHIP-14 score</U> (Scale 0-56: lower better)</P>
</TD>
<TD>
<P>13.39</P>
</TD>
<TD>
<P>
<B>5.24 lower</B> (7.38 to 3.09 lower)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported the occurrence of adverse events</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>OHIP-14:</B> Oral Health Impact Profile-14; <B>OIS: </B>optimal information size; <B>RCT:</B> randomised controlled trial; <B>VAS:</B> visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on mean placebo group pain score at short-term (&#8804; 3 months) follow-up; downgraded once due to the single study being assessed at unclear risk of bias across multiple domains and high risk of bias relating to other bias; downgraded once due to indirectness: concerns relating to applicability, only 1 type of electromagnetic radiation assessed, effects of other types of electromagnetic radiation may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>2</SUP>Assumed placebo risk based on mean placebo group QoL score at short-term (&#8804; 3 months) follow-up; downgraded once due to the single study being assessed at unclear risk of bias across multiple domains and high risk of bias relating to other bias; downgraded once due to indirectness: concerns relating to applicability, only 1 type of electromagnetic radiation assessed, effects of other types of electromagnetic radiation may differ; downgraded once due to imprecision: OIS not met.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2016-11-09 12:39:32 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="7">
<TITLE MODIFIED="2016-11-07 14:30:41 +0000" MODIFIED_BY="[Empty name]">Physical barriers versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TH COLSPAN="7">
<P>
<B>Physical barriers compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>physical barriers (tongue protector)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Physical barriers</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B>
<BR/>short-term (&#8804; 3 months)<BR/>- <U>Mean VAS pain score</U> (Scale 0-10: lower better)</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>
<B>1.10 lower</B> (2.14 to 0.06 lower)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>50<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Single study assessing tongue protectors<BR/>No data were available to estimate long-term symptom relief</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL):</B> short-term (&#8804; 3 months)<BR/>- <U>Mean OHIP-49 score</U> (Scale 0-196: lower better)</P>
</TD>
<TD>
<P>53.72</P>
</TD>
<TD>
<P>
<B>9.20 lower</B> (26.90 lower to 8.50 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD ROWSPAN="3">
<P>50<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="3">
<P>Single study assessing tongue protectors<BR/>No data were available to estimate long-term change in QoL, or its surrogate markers: anxiety or depression</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in QoL - anxiety:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean HAD anxiety score</U> (Scale 0-21: lower better)</P>
</TD>
<TD>
<P>11.04</P>
</TD>
<TD>
<P>
<B>0.16 higher</B> (3.19 lower to 3.51 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in QoL - depression:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean HAD depression score</U> (Scale 0-21: lower better)</P>
</TD>
<TD>
<P>8.92</P>
</TD>
<TD>
<P>
<B>0.64 lower</B> (3.98 lower to 2.70 higher)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="3">
<P>The single study narratively reported that no adverse events occurred from the use of tongue protectors</P>
</TD>
<TD>
<P>50<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>HAD:</B> Hospital Anxiety and Depression scale; <B>OHIP-49:</B> Oral Health Impact Profile-49; <B>OIS: </B>optimal information size; <B>RCT:</B> randomised controlled trial; <B>VAS:</B> visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on mean placebo group pain score at short-term (&#8804; 3 months) follow-up; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>2</SUP>Assumed placebo risk based on mean placebo group quality of life score at short-term (&#8804; 3 months) follow-up; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect.<BR/>
<SUP>3</SUP>Assumed placebo risk based on mean placebo group anxiety score at short-term (&#8804; 3 months) follow-up; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect; downgraded once due to indirectness: use of surrogate measure.<BR/>
<SUP>4</SUP>Assumed placebo risk based on mean placebo group depression score at short-term (&#8804; 3 months) follow-up; downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no effect; downgraded once due to indirectness: use of surrogate measure.<BR/>
<SUP>5</SUP>Downgraded twice due to serious concerns of risk of bias, relating to blinding and potential confounding influence of participants in receipt of anxiolytics; downgraded once due to imprecision: OIS not met.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2016-11-09 12:39:41 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="8">
<TITLE MODIFIED="2016-11-07 14:43:19 +0000" MODIFIED_BY="[Empty name]">Psychological therapies versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Psychological therapies compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>psychological therapies (cognitive therapy)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH VALIGN="MIDDLE">
<P>
<B>Psychological therapies</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> long-term (&gt; 3 to &#8804; 6 months)</P>
<P>- <U>Mean VAS pain score</U> (Scale 1-7: lower better)</P>
</TD>
<TD>
<P>4.6</P>
</TD>
<TD>
<P>
<B>3.20 lower </B>(4.22 to 2.18 lower)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>30<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Single study assessing cognitive therapy<BR/>No data was available to estimate short-term symptom relief<BR/>No data was available to estimate the effect of other psychological therapies</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL)</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported change in taste</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported change in feeling of dryness</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included study reported the occurrence of adverse events</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>OIS: </B>optimal information size; <B>RCT:</B> randomised controlled trial; <B>VAS:</B> visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Assumed placebo risk based on mean placebo group pain score at long-term (&gt; 3 to &#8804; 6 months) follow-up; downgraded twice due to serious concerns of risk of bias, relating to blinding and lack of baseline data; downgraded once due to indirectness: concerns relating to applicability, only 1 type of psychological therapy assessed, effects of other psychological therapies may differ; downgraded once due to imprecision: OIS not met.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-09" MODIFIED="2016-11-09 12:39:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="9">
<TITLE MODIFIED="2016-11-07 14:48:51 +0000" MODIFIED_BY="[Empty name]">Topical treatments versus placebo for treating people with burning mouth syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TH COLSPAN="7">
<P>
<B>Topical treatments compared with placebo for treating burning mouth syndrome</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>people diagnosed with burning mouth syndrome</P>
<P>
<B>Settings: </B>secondary care</P>
<P>
<B>Intervention: </B>topical treatments (benzydamine hydrochloride oral rinse, lactoperoxidase oral rinse (Biotene), topical urea (10%), capsaicin oral rinse)</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="MIDDLE">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Topical treatments</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Symptom relief:</B> short-term (&#8804; 3 months)</P>
</TD>
<TD COLSPAN="3">
<P>There is insufficient or contradictory evidence regarding the benefit of any of the evaluated topical treatments over placebo to evaluate short-term symptom relief</P>
</TD>
<TD>
<P>150</P>
<P>(4 RCTs)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Interventions evaluated for short-term symptom relief included:</P>
<UL>
<LI>benzydamine hydrochloride oral rinse (1 RCT)</LI>
<LI>lactoperoxidase oral rinse (Biotene) (2 RCTs)</LI>
<LI>topical urea (10%) (1 RCT)</LI>
<LI>capsaicin oral rinse (1 RCT)</LI>
</UL>
<P>The mean VAS pain score (scale 0-10: lower better) for <B>long-term symptom relief </B>(&gt; 3 to &#8804; 6 months) was <B>2.60 lower</B> (5.11 to 0.09 lower) for people treated with capsaicin oral rinse than the placebo group (1 RCT, 18 participants)<BR/>No evidence of long-term symptom relief from a single study assessing lactoperoxidase oral rinse (Biotene): mean VAS score in intervention group was 1.50 lower than people treated with placebo (3.91 lower to 0.91 higher) (1 RCT, 18 participants)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in quality of life (QoL)</B>
</P>
</TD>
<TD COLSPAN="6">
<P>No included studies reported change in QoL</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in taste:</B> short-term (&#8804; 3 months)</P>
<P>- <U>Mean Quantitative Sensory Testing (QST) score: gustative threshold</U> (Scale: unknown)</P>
</TD>
<TD COLSPAN="3">
<P>A single study narratively reported that there was no difference in short-term gustation thresholds</P>
</TD>
<TD>
<P>38</P>
<P>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>Single study assessing topical urea (10%)<BR/>No data were available to estimate long-term change in taste<BR/>No data were available to estimate the effect of other topical treatments</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Change in feeling of dryness: </B>
</P>
<P>short-term (&#8804; 3 months)</P>
<P>- <U>Xerostomia questionnaire</U> (Scale 1-5: lower better)</P>
</TD>
<TD COLSPAN="3">
<P>A single study narratively reported that there was no difference in short-term xerostomia questionnaire assessment before or after treatment</P>
</TD>
<TD>
<P>38</P>
<P>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>Single study assessing topical urea (10%)<BR/>No data were available to estimate long-term change in feeling of dryness<BR/>No data were available to estimate the effect of other topical treatments</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects</B>
</P>
</TD>
<TD COLSPAN="3">
<P>A single study narratively reported that no adverse events occurred from the use of benzydamine hydrochloride oral rinse</P>
</TD>
<TD>
<P>20<BR/>(1 RCT)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>No data were available to estimate the effect of other topical treatments</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>OIS: </B>optimal information size; <B>RCT:</B> randomised controlled trial; <B>VAS:</B> visual analogue scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Downgraded twice due to high risk of bias across multiple domains; downgraded twice due to inconsistency between, and within, subgroups; downgraded once due to imprecision: OIS not met; 1 RCT (<LINK REF="STD-Marino-2010" TYPE="STUDY">Marino 2010</LINK>) contributes to 2 subgroups: capsaicin oral rinse and lactoperoxidase oral rinse (Biotene).<BR/>
<SUP>2</SUP>Downgraded twice due to high risk of bias relating to attrition and selective reporting; downgraded once due to indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>3</SUP>Downgraded twice due to high risk of bias relating to attrition and selective reporting; downgraded once for indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met.<BR/>
<SUP>4</SUP>Downgraded once due to unclear risk of bias across multiple domains; downgraded once due to indirectness: concerns relating to applicability, only 1 type of topical therapy assessed, effects of other topical therapies may differ; downgraded once due to imprecision: OIS not met.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-11-09 13:07:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-11-07 10:48:42 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-11-07 10:06:28 +0000" MODIFIED_BY="[Empty name]">Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies</TITLE>
<TABLE COLS="3" ROWS="24">
<TR>
<TH VALIGN="MIDDLE">
<P>Study ID</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Diagnosis description</P>
</TH>
<TH VALIGN="MIDDLE">
<P>Duration of disease</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Alvarenga da Silva 2014</B>
</P>
</TD>
<TD>
<P>"..patients with BMS diagnosed according to the International Association for the Study of Pain (IASP) guidelines. They underwent laboratory tests and a careful examination to exclude other causes of burning mouth. The exclusion criteria were other facial pain syndromes, other causes of abnormal salivation, other neuropathies or primary diseases associated with burning mouth"</P>
</TD>
<TD>
<P>Mean duration of BMS (+/- SD):</P>
<P>topical urea 10% (n = 19) 6.97 years (+/- 4.93);</P>
<P>placebo (n = 19) 2.78 years (+/- 2.61)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bergdahl 1995a</B>
<BR/>
</P>
</TD>
<TD>
<P>"The patients were odontologically and medically examined and treated according to the protocol for the management of patients with BMS proposed by Bergdahl et al, including complete anamnesis, general medical and odontological examination, laboratory investigation and an epicutaneous patch test. [...] All the odontologically and medically diagnosed diseases were treated, but the treatment had no influence on the burning sensations and therefore these patients were labelled as suffering from resistant BMS"</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bogetto 1999</B>
<BR/>
</P>
</TD>
<TD>
<P>(Translated from Italian) "Inclusion criteria: diagnosis of BMS, according to the criteria provided by the literature [six references]"</P>
</TD>
<TD>
<P>(Translated from Italian) "The total average duration of the disorder was 2.7 ( +/- 3.2 ) years"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cano-Carrillo 2014</B>
<BR/>
</P>
</TD>
<TD>
<P>"Inclusion criteria for participating in the study were as follows: a clinical history of continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than 6 months, without paroxysms, and independent of the nervous pathway; an absence of clinical abnormalities that might account for the symptoms; and normal blood test findings (complete blood count, blood glucose, serum, iron and transferrin levels, serum vitamin B12, and folate. Patients with pain attributable to other conditions (angiotensin-converting enzyme inhibitor use, candidiasis, lichenoid reactions, sores, tongue atrophy, etc.) were excluded"</P>
</TD>
<TD>
<P>"The majority of patients had severe burning sensation and had suffered from BMS over a long period"</P>
<P>(Inclusion criteria required continuous symptoms for longer than 6 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Carbone 2009</B>
<BR/>
</P>
</TD>
<TD>
<P>"The study was prospectively performed on patients with previously untreated BMS referred to the Oral Medicine Section of the University of Turin [...], approximately 90 patients reporting oral symptoms suggestive of BMS were screened for participation [...].</P>
<P>Consistent with Gremeau-Richard et al (2004), the inclusion criteria were the presence of an isolated complaint of chronic pain in the oral mucosa with a normal clinical examination, and pain present for more than 4 months, which was continuous throughout all or part of the day, with no paroxysms and not following a nerve trajectory.<BR/>Candida infection was ruled out and any organic conditions that could be considered as causative factors for similar oral symptoms were ruled out in all subjects by laboratory examinations (e.g. full blood cell count, and serum levels of iron, ferritine, folate, vitamin B12, and glucose)"</P>
</TD>
<TD>
<P>Not reported</P>
<P>(Inclusion criteria required continuous symptoms for longer than 4 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cavalcanti 2009</B>
<BR/>
</P>
</TD>
<TD>
<P>"Subjects [...] who reported a history of oral burning pain for more than 6 months and absence of oral findings were assessed for eligibility.[...] The patients underwent detailed clinical evaluation and laboratory tests [complete blood cell count; blood glucose level; serum iron and ferritin levels; serum vitamin B12; folic acid levels; salivary flow rate measurement; exfoliative cytology; detection of local abnormalities] to exclude possible local and &#8260; or systemic causes for oral burning"</P>
</TD>
<TD>
<P>"The mean duration of BMS was 37.43 months (range 6-132 months)"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2000</B>
<BR/>
</P>
</TD>
<TD>
<P>"Only BMS patients with objective evidence of a normal-looking oral mucosa, with absence of identifiable oral mucosal pathological lesions, with normal salivary secretion (.15 ml/15 min unstimulated and .1 ml min<SUP>-1</SUP> after 5% citric acid stimulation), and with normal laboratory results [refers to earlier quote: "full blood count, serum ferritin, vitamin B<SUB>12</SUB>, SGOT, SGPT, serum total IgE (PRIST) and IgE specific for methacrylate, corrected whole blood folate and random blood sugars"] were included. [...] The final patient group thus consisted of persons with BMS and neither clinical nor laboratory evidence of organic disease"</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002a</B>
<BR/>
</P>
</TD>
<TD>
<P>"..patients, diagnosed with BMS from a history of constant burning discomfort in the anterior tongue, lower lip or hard palate, for more than two months, with no relevant drug or medical history, were examined for evidence of clinical oral mucosal lesions and alterations in laboratory parameters (whole blood folate, serum vitamin B<SUB>12</SUB>, serum ferritin, serum glucose, thyroid hormone levels) that could be responsible for the BMS. A final study subgroup of 60 subjects with BMS [...] was identified with no clinical or laboratory evidence of disease"</P>
</TD>
<TD>
<P>Not reported</P>
<P>(Inclusion criteria required continuous symptoms for longer than 2 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002b</B>
<BR/>
</P>
</TD>
<TD>
<P>"The study population consisted of persons with BMS as defined elsewhere [reference indicates <LINK REF="REF-van-der-Waal-1990" TYPE="REFERENCE">van der Waal 1990</LINK>] and with neither clinical nor laboratory evidence of organic disease. [...] the final test subjects were BMS patients only with objective evidence of a normal-looking oral mucosa, with absence of identifiable oral mucosal pathological lesions, with normal salivary secretion and with normal laboratory results"</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Grémeau-Richard 2004</B>
<BR/>
</P>
</TD>
<TD>
<P>"..patients with stomatodynia were screened for participation [...]. The inclusion criteria were the presence of an isolated complaint of chronic pain in the oral mucosa with a normal clinical examination. Pain was present for more than 4 months, was continuous throughout all or part of the day, with no paroxysms and did not follow a nerve trajectory. Patients presenting with an organic condition that could be considered as a causative factor such as diabetes or anaemia were not included. Such local or systemic conditions were sought with laboratory examinations only when suspected from the clinical approach (e.g. blood cell count, serum iron folate level or detection of Candida). Also, patients with abnormal neurological conditions and those regularly treated on a daily basis by anti-depressants, anti-convulsants, other psychotropic drugs or psychological therapy were also excluded from this study. [...] Reliability for diagnosis of stomatodynia had been assessed in a previous study involving the same experimentors"<BR/>
</P>
</TD>
<TD>
<P>Not reported</P>
<P>(Inclusion criteria required continuous symptoms for longer than 4 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Heckmann 2012</B>
<BR/>
</P>
</TD>
<TD>
<P>"Twenty-three patients suffering from BMS were referred to the oral pain clinic of Erlangen University Dental School. [...] Inclusion was restricted to idiopathic cases. [...] the patients received a physical examination of their oral cavity including a test for possible pathological infections with candida"</P>
</TD>
<TD>
<P>Mean duration of disease:<BR/>clonazepam (n = 10) 2.8 years (SD 1.9); placebo (n = 10) 3.6 years (SD 2.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Lopez-D'alessandro 2011</B>
<BR/>
</P>
</TD>
<TD>
<P>"..patients with idiopathic BMS of more than three months duration. [...] Patients with deficiencies of folic acid, vitamin B, carriers of anemias of any kind and patients with Sjögren syndrome were also excluded"</P>
</TD>
<TD>
<P>Not reported</P>
<P>(Inclusion criteria required continuous symptoms for longer than 3 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2009b</B>
<BR/>
</P>
</TD>
<TD>
<P>"..patients attending our service with symptomatology compatible with BMS were invited to participate [...]. Inclusion criteria to participate in the study were presentation of a clinical history of continuous symptomatology of oral burning or pain, daily or almost daily, during all or part of the day for more than 6 months evolution, without paroxysms, and independent of the nervous pathway; likewise, no clinical abnormality that would justify the symptomatology. Furthermore, the patients had to present a normal blood analysis (completed blood cell counts, blood glucose levels, serum iron and transferrin levels, serum Vit B<SUB>12</SUB> and folate) [...]. Patients with pain attributable to other entities (candidiasis, lichenoid reactions, sores, etc.) were excluded"</P>
</TD>
<TD>
<P>"The average time suffering BMS was 3 years, with a minimum of 6 months and a maximum of 5 years"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2011</B>
<BR/>
</P>
</TD>
<TD>
<P>"Inclusion criteria for participating in the study were a clinical history of continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than 6 months, without paroxysms, and independent of the nervous pathway. Likewise, the included patients presented no clinical abnormalities that could account for the symptoms. Furthermore, the patients had to present normal blood test findings (complete blood count, blood glucose, serum iron and transferrin levels, serum vitamin B12, and folate) [...]. Patients with pain attributable to other conditions (angiotensin-converting enzyme inhibitor use, candidiasis, lichenoid reactions, sores, tongue atrophy, etc.) were excluded"</P>
</TD>
<TD>
<P>Not reported</P>
<P>(Inclusion criteria required continuous symptoms for longer than 6 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Marino 2010</B>
<BR/>
</P>
</TD>
<TD>
<P>"..patients who referred [...] for otherwise idiopathic BMS [...].They all complained of a burning, stinging or painful sensation in the mouth in the absence of alterations in the appearance of the oral mucosa or any local or systemic diseases. [...] exclusion criteria were: (i) evidence of any local disorders that may be responsible for the burning mouth sensation, such as infection by Candida species, parafunctional habits, temporomandibular joint disorders, allergic contact stomatitis, benign migratory glossitis and lichen planus"</P>
<P>"Inclusion criteria: Symptoms of diffuse burning pain of the tongue and &#8260; or oral mucosa associated or unassociated with subjective oral dryness or loss or alteration of taste or sensation; Burning pain almost every day; Normal-looking mucosa in the region of burning; Absence of systemic disorders or laboratory alterations known to be associated with orofacial pain; Daily bilateral oral burning (or pain-like sensation); Pain is unremitting for at least 4&#8211;6 months [...] Exclusion criteria: Presence of specific local etiologic evidence for the burning (e.g. disease of the oral mucosa, hyposalivation); Presence of specific systemic etiologic evidence for the burning (e.g. diabetes, anemia); Use of medications known to be associated with oral burning and &#8260; or alteration of taste or sensation"</P>
</TD>
<TD>
<P>"The mean time from symptom onset to enrolment was 18 months"</P>
<P>(Inclusion criteria required continuous symptoms for longer than 4 months)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Palacios-Sánchez 2015</B>
<BR/>
</P>
</TD>
<TD>
<P>"Diagnosis was made during the first screening phase. [...] patients over 18 years of age clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome (<LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>) [...] Exclusion criteria included: patients whose burning sensation could be related to local alterations [...] All patients were assessed for salivary flow rates, at rest and stimulated, complete blood count and biochemistry values, including ferritin, vitamin B<SUB>12</SUB> and folic acid levels. [...] According to Lamey and Lewis's BMS classification, 38 patients (63.3%) belonged to type I, 17 patients (28.3%) to type II, and only 5 patients (8.3%) to type III"</P>
</TD>
<TD>
<P>"The evolution time of symptomatology varied between 4 months and 20 years"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Rodríguez de Rivera-Campillo 2010</B>
<BR/>
</P>
</TD>
<TD>
<P>"..adults with BMS [...]. Some patients attended the clinic to receive dental or medical treatment, while others were referred by colleagues after unsuccessful treatments. All subjects reported oral burning in the absence of apparent oral lesions. [...] We excluded patients with disorders in the oral mucosa that could explain the symptoms, those who were receiving treatment for BMS [...]"</P>
</TD>
<TD>
<P>Duration of disease (all patients (n = 66)): &lt; 6 months n = 4 (6%); 6-12 months n = 12 (18%); &gt; 12 months n = 50 (76%)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 1999</B>
<BR/>
</P>
</TD>
<TD>
<P>"The criterion for admission was the diagnosis of "idiopathic" or "essential" burning mouth syndrome. We use this term to refer to all forms of burning sensation in the mouth, including complaints described as stinging sensation or pain, in association with an oral mucosa that appears clinically normal in the absence of local or systemic diseases or alterations; these include nutritional and hematologic deficiencies, diabetes mellitus, the presence of Candida albicans or candidiasis infection, xerostomia, denture design faults, parafunctional habits, contact allergy to dental materials, oral lichen planus, and geographic tongue.</P>
<P>To identify the "essential" BMS cases, the patients' medical and dental histories were carefully taken, particular attention being paid to the characteristics of the complaint (type, localization, duration), the clinical oral inspection performed, and the laboratory evaluations requested. In particular, the laboratory data included complete blood cell counts, blood glucose levels, serum iron and transferrin levels, and serum vitamin B<SUB>12 </SUB>and folate levels.</P>
<P>Furthermore, patch testing for allergy to dental material was performed, a tongue and palate smear for the detection of Candida was taken, and salivary gland flow rates, resting and stimulated, were determined. When altered parameters were detected, an appropriate therapy was proposed. [...] Patients experiencing symptomatic improvement after correction of their deficiencies were excluded from the investigations, the assumption being made that they did not have "essential" BMS.</P>
<P>This clinical design led to the identification of 30 patients with "essential" BMS. [...] With reference to the classification suggested by Lamey and Lewis,13 BMS type II was present in 16 patients (53%), BMS type III in 10 patients (33%), and BMS type I in the remaining 4 patients (14%)"</P>
</TD>
<TD>
<P>"The duration of the syndrome was a matter of months or even years, with a mean duration before the beginning of the clinical trial of 18 months"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 2008</B>
<BR/>
</P>
</TD>
<TD>
<P>"Subjects referred [...] who reported a history of oral burning pain for at least 6 months and who lacked oral findings were considered for this study. [...] Demographic and medical questionnaires asking for information related to the presence of current systemic diseases and on-going medications were administered.<BR/>To confirm the diagnosis of essential BMS, the patients underwent a standard set of evaluations to exclude local or systemic conditions that could be considered causative factors for an oral burning sensation (salivary flow rates; laboratory tests [complete blood cell counts, blood glucose levels, serum iron and transferrin levels, serum vitamin B12 folate levels]; isolation of Candida species; detection of parafunctional activities)"</P>
</TD>
<TD>
<P>Mean duration of BMS (+/- SD):</P>
<P>hypericum perforatum (n = 19) 28.8 months (+/- 8.9);</P>
<P>placebo (n = 19) 32.4 months (+/- 9.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Silvestre 2012</B>
<BR/>
</P>
</TD>
<TD>
<P>"BMS was diagnosed according to the current criteria, and the discomfort had been present on a daily basis for at least 6 months (<LINK REF="REF-Scala-2003" TYPE="REFERENCE">Scala 2003</LINK>). [...] excluded from the study [...] were those [...] patients with oral mucosal lesions that might explain the burning sensation"</P>
</TD>
<TD>
<P>"The mean duration of the disease was 5.43 ± 3.23 years (range 1-14 years). Patients with a BMS duration of 4 and 5 years represented 39.1% of the total (n = 9)"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2012</B>
<BR/>
</P>
</TD>
<TD>
<P>"The sample comprised 72 patients of both sexes with a diagnosis of BMS [...]. The study included patients [...] who reported symptoms of burning or pain in the oral mucosa of at least 6 months' duration and who presented with a clinically normal mucosa. [...] Patients who showed hyposalivation (salivary flow rate at rest of 0.1 mL/min), as well as alterations in their hemogram, serum levels of glucose, iron, folic acid, and vitamin B12, were also excluded"</P>
</TD>
<TD>
<P>"The time of development of BMS ranged from 6 months to 20 years, with a median of 24 months"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2015</B>
</P>
</TD>
<TD>
<P>"The study included patients [...] who reported having had symptoms of burning or pain in the oral mucosa for at least six months and who presented a clinically normal mucosa"</P>
</TD>
<TD>
<P>"The duration of the symptoms ranged from 6 months to 30 years; 33.3% [n = 26] of the patients had been presenting the disorder for one to three years"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Tammiala-Salonen 1999</B>
</P>
</TD>
<TD>
<P>"..patients who were referred [...] because of oral mucosal burning pain. [...] The patients underwent a thorough clinical examination,<BR/>including measurement of whole salivary flow, blood samples (blood count and levels of glucose, B<SUB>12</SUB> vitamins, and folate), and diagnosis of candidiasis. The investigators asked patients about pain intensity and duration, overall health, and medications. [...] Criteria for inclusion were daily, or almost daily, oral burning pain that had lasted 6 months or longer and had a moderate to severe intensity"</P>
</TD>
<TD>
<P>"The mean duration of pain in the trazodone group was 3.0 years (6 months to<BR/>17 years) and in the placebo group it was 2.8 years (6 months to 20 years)"</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>SD = standard deviation.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-11-09 13:07:59 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2">
<TITLE MODIFIED="2015-08-05 14:26:49 +0100" MODIFIED_BY="[Empty name]">Outcome measure scales</TITLE>
<TABLE COLS="6" ROWS="24">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Primary:</B>
<BR/>
<B>Symptom relief</B> (symptom intensity/pain), scales used</P>
</TH>
<TH>
<P>
<B>Primary:</B>
<BR/>
<B>Change in quality of life (QoL) (</B>anxiety, depression), scales used</P>
</TH>
<TH>
<P>
<B>Secondary:</B>
<BR/>
<B>Change in taste, scales used</B>
</P>
</TH>
<TH>
<P>
<B>Secondary:</B>
<BR/>C<B>hange in feeling of dryness; scales used</B>
</P>
</TH>
<TH>
<P>Additional assessment scales not relevant to this review</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Alvarenga da Silva 2014</B>
</P>
</TD>
<TD>
<P>EDOF-HC protocol (Orofacial Pain Clinic - Hospital das Clinicas)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Quantitative Sensory Testing (QST): gustative threshold</P>
</TD>
<TD>
<P>Xerostomia questionnaire<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Quantitative Sensory Testing (QST): olfactory threshold (1); thermal detection thresholds for cold (2) and warm (3) sensations; mechanical detection thresholds for touch (4), vibration (5), and electrical perception (6); mechanical pain sensitivity - superficial (7) and deep pain thresholds (8); electrical pain threshold at the teeth (9), corneal reflex (10), salivary flow (11)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bergdahl 1995a</B>
</P>
</TD>
<TD>
<P>VAS<SUP>2</SUP> (ranked 1-7)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bogetto 1999</B>
<BR/>
</P>
</TD>
<TD>
<P>Clinical Global Impression I (CGI I)</P>
</TD>
<TD>
<P>
<B>Anxiety: 
</B>Hamilton Anxiety Rating Scale (HARS)</P>
<P>
<B>Depression: </B>Montgomery&#8211;Åsberg Depression Rating Scale (MADRS)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cano-Carrillo 2014</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>
<B>General health assessment:</B> 36-Item Short Form Health Survey (SF-36)</P>
<P>
<B>Oral health impact on QoL:</B> Oral Health Impact Profile-14 (OHIP-14)</P>
<P>
<B>Anxiety/depression:</B> Hospital Anxiety and Depression (HAD) scale</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Carbone 2009</B>
</P>
</TD>
<TD>
<P>1. VAS (0-10)</P>
<P>2. McGill Pain Questionnaire (MPQ)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cavalcanti 2009</B>
</P>
</TD>
<TD>
<P>1. VAS (0-100 mm)</P>
<P>2. Global Perceived Effect (GPE)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2000</B>
</P>
</TD>
<TD>
<P>Bespoke burning mouth syndrome (BMS) symptomology change scale</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002a</B>
</P>
</TD>
<TD>
<P>Bespoke burning mouth syndrome (BMS) symptomology change scale</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002b</B>
</P>
</TD>
<TD>
<P>Bespoke burning mouth syndrome (BMS) symptomology change scale</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Grémeau-Richard 2004</B>
</P>
</TD>
<TD>
<P>Numerical Pain Scale (0-10)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Heckmann 2012</B>
</P>
</TD>
<TD>
<P>Numerical pain ratings scale (0-10)</P>
</TD>
<TD>
<P>
<B>Depression: 
</B>Beck Depression Inventory (BDI)</P>
</TD>
<TD>
<P>Taste test score (0-16)<SUP>3</SUP>
</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>1. Smell test score</P>
<P>2. Zerssen Mood Scale</P>
<P>3. Dementia: Mini-Mental State Examination</P>
<P>4. Salivary flow score (swab method: weight g/min)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Lopez-D'alessandro 2011</B>
</P>
</TD>
<TD>
<P>Bespoke geographical burning distribution numerical scale (0-4)</P>
</TD>
<TD>
<P>
<B>Anxiety: </B>Hamilton Anxiety Rating Scale (HARS) - baseline only</P>
<P>
<B>Anxiety/depression:</B> Hospital Anxiety and Depression (HAD) scale - baseline only</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2009b</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2011</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>
<B>General health assessment:</B> 36-Item Short Form Health Survey (SF-36)</P>
<P>
<B>Oral health impact on QoL:</B> Oral Health Impact Profile-49 (OHIP-49)</P>
<P>
<B>Anxiety/depression:</B> Hospital Anxiety and Depression (HAD) scale</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Marino 2010</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Palacios-Sánchez 2015</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>
<B>Depression: 
</B>Beck Depression Inventory (BDI) - baseline only, as covariate</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Rodríguez de Rivera-Campillo 2010</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 1999</B>
</P>
</TD>
<TD>
<P>VAS (0-8)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 2008</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>Assessed by posing simple questions. No standard QoL questionnaire used</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Silvestre 2012</B>
</P>
</TD>
<TD>
<P>VAS (0-10)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2012</B>
</P>
</TD>
<TD>
<P>1. Visual numeric scale (VNS) (0-10)</P>
<P>2. Faces scale (FS) (0-5)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2015</B>
</P>
</TD>
<TD>
<P>1. VAS (0-100 mm)</P>
<P>2. Visual numeric scale (VNS) (0-10)</P>
</TD>
<TD>
<P>Oral Health Impact Profile-14 (OHIP-14)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Tammiala-Salonen 1999</B>
</P>
</TD>
<TD>
<P>1. VAS (0-100 mm)</P>
<P>2. McGill Pain Questionnaire (MPQ)</P>
</TD>
<TD>
<P>
<B>Depression: </B>Beck Depression Inventory (BDI)</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>Outcome not assessed</P>
</TD>
<TD>
<P>n/a</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>No defined title. See original reference: <LINK REF="REF-Korn-2002" TYPE="REFERENCE">Korn 2002</LINK>.<BR/>
<SUP>2 </SUP>VAS: visual analogue scale.<BR/>
<SUP>3</SUP> No defined title. See original reference: <LINK REF="REF-Mueller-2003" TYPE="REFERENCE">Mueller 2003</LINK>.<BR/>
<SUP>4 </SUP>No defined title. See original reference: <LINK REF="REF-Navazesh-1982" TYPE="REFERENCE">Navazesh 1982</LINK>.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-11-09 12:37:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3">
<TITLE MODIFIED="2015-08-05 16:37:00 +0100" MODIFIED_BY="[Empty name]">Reported adverse effects</TITLE>
<TABLE COLS="3" ROWS="24">
<TR>
<TH>
<P>
<B>Study ID</B>
</P>
</TH>
<TH>
<P>
<B>Comparison</B>
</P>
</TH>
<TH>
<P>
<B>Adverse effects reported</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Alvarenga da Silva 2014</B>
</P>
</TD>
<TD>
<P>Topical treatments</P>
</TD>
<TD>
<P>Comment: no adverse event data reported, nor is there any indication that it was collected by investigators</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bergdahl 1995a</B>
</P>
</TD>
<TD>
<P>Psychological therapies</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bogetto 1999</B>
<BR/>
</P>
</TD>
<TD>
<P>Antidepressants and antipsychotics</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cano-Carrillo 2014</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "No patients experienced any adverse effects resulting from treatment at any of the evaluation times"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Carbone 2009</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "No adverse events were reported in any of the three groups" (refers to ALA; ALA + vitamins; placebo)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cavalcanti 2009</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "Seven patients had their data excluded from analysis, four of them did not complete the proposed treatment because of the symptoms that they judged as connected to treatment and these symptoms are presented with side-effects data"</P>
<P>Comment: adverse events fully reported in Table 3 in the paper. Of the 4 patients withdrawing due to severe adverse events, 2 were from each group (ALA and placebo)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2000</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "No adverse events were recorded in any of the groups"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002a</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "..symptomatic improvements in BMS treated with alpha-lipoic acid were seen without notable adverse effects"</P>
<P>Comment: Narrative report, indicating adverse events occurred, potentially missing data. No other adverse event data reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Femiano 2002b</B>
</P>
</TD>
<TD>
<P/>
<P>Cholinergics<BR/>
</P>
<P>Dietary supplements<BR/>
</P>
<P>Systemic treatments<BR/>
</P>
<P>Topical treatments</P>
</TD>
<TD>
<P>Quotes:<BR/>Bethanechol: "Four of the 20 patients complained of adverse effects (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain) but not severe enough to demand the suspension of treatment"<BR/>ALA: "Four patients reported heartburn but this was corrected by ranitidine 150 mg"</P>
<P>Comment: bethanechol data not usable in analysis as distribution of 5 adverse events between 4 complainants was unclear. Adverse events for lactoperoxidase not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Grémeau-Richard 2004</B>
</P>
</TD>
<TD>
<P>Benzodiazepines</P>
</TD>
<TD>
<P>Quotes: "Side effects (Table 2) were not significantly more frequent in the active treatment group: they were reported by nine out of 24 subjects in the clonazepam group and six out of 24 in the placebo group (P &gt; 0.05, X<SUP>2</SUP>-test). Two subjects in the active treatment group and one in the control group dropped out from the trial because of these side effects"</P>
<P>Comment: adverse events fully reported in 'Table 2' in the paper</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Heckmann 2012</B>
</P>
</TD>
<TD>
<P>Benzodiazepines</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Lopez-D'alessandro 2011</B>
</P>
</TD>
<TD>
<P>Anticonvulsants<BR/>
</P>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "the adverse effects that appeared were very mild"</P>
<P>Comment: narrative report, indicating adverse events occurred; data obtained from contact author</P>
<P>Gabapentin arm (n = 20): drowsiness (n = 5)</P>
<P>Gabapentin + ALA arm (n = 20): drowsiness (n = 2); mild headache (n = 1)</P>
<P>ALA arm (n = 20): mild headache (n = 2); intermittent facial skin rash (n = 1)</P>
<P>Placebo arm: no adverse effects reported<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2009b</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quotes: "All patients responded to a questionnaire on each of the visits (0, 1, and 2 months) in which they were asked about the possible adverse effects of the medication"; "adverse effects were minimal; only one patient [ALA group] abandoned treatment because of having gastrointestinal upset as the side effect of the medication"</P>
<P>Comment: narrative report, indicating adverse events occurred, potentially missing data. No other adverse event data reported, despite investigators repeatedly recording adverse events, and the statement relates only to the patient who withdrew from the trial due to severe side effects</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>López-Jornet 2011</B>
</P>
</TD>
<TD>
<P>Physical barriers</P>
</TD>
<TD>
<P>Quote: "No adverse effects were observed"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Marino 2010</B>
</P>
</TD>
<TD>
<P>Dietary supplements<BR/>
</P>
<P>Topical treatments</P>
</TD>
<TD>
<P>Quote: "All the patients successfully finished study I [the treatment phase, distinct from follow-up phase which 64% (36/56) completed] and no untoward effect occurred in any of the groups"</P>
<P>Re: Capsaicin: "We did not observe any adverse effects in our patients and the treatment was well tolerated by the patients despite the need for repeated applications because of its short duration of action"</P>
<P>Comment: no other adverse event data reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Palacios-Sánchez 2015</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quote: "All patients were assessed every 15 days [...] for the occurrence of side effects"</P>
<P>Comment: despite specifying assessing occurrence of adverse effects in the Methods section, there is no detail reporting their occurrence in the results</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Rodríguez de Rivera-Campillo 2010</B>
</P>
</TD>
<TD>
<P>Benzodiazepines</P>
</TD>
<TD>
<P>Quotes: "All the patients were scheduled for a visit after 1 week for the sole purpose of detecting undesirable side effects. They were again scheduled for visits after 1 months and 6 months , which allowed the clinicians to monitor their evolution"; "Some patients reported a sensation of effervescence and numbness of the tongue when the tablet was dissolved. [...] The only side effect registered was some degree of sleepiness in 5 patients in the clonazepam group, which did not require the clinicians to suspend the treatment"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 1999</B>
</P>
</TD>
<TD>
<P>Topical treatments</P>
</TD>
<TD>
<P>Quote: "No adverse effects were noted in the groups using the [Benzydamine] and placebo solutions"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sardella 2008</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quotes: "During the follow-up visits [1 month, 2 months and 3 months], the patients were explicitly asked about the occurrence of adverse events"; "One subject in the test group failed to finish the trial because a severe headache that developed during the fifth week was considered a side effect of the therapy"<BR/>Comment: despite recording adverse effects at 3 time points, no other adverse event data are reported except for explaining Group A dropout patient - not sufficient to use for estimation of risk ratio, as other data likely to be omitted from paper</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Silvestre 2012</B>
</P>
</TD>
<TD>
<P>Topical treatments</P>
</TD>
<TD>
<P>Quotes: "Patients were also questioned about possible adverse effects or discomfort caused by the treatments"; "Those subjects who developed adverse effects were removed from the study"; "The study initially involved 30 patients, of which 7 abandoned the trial in the first week of treatment [...] two complained of greatly increased burning sensation when using the [capsaicin] rinse"; "intense burning sensation was described by one-third of the subjects during and for a few minutes (maximum 20 minutes) after application of the capsaicin rinse"</P>
<P>Comment: reports patients developing adverse effects were removed from the study; however, numbers for analysis estimated from text to be 8 patients ("one-third" of group n = 23 to estimate whole patient integer) from intervention arm, in addition to the further 2 intervention arm patients who withdrew from the trial due to the increased burning sensation. Data combined for analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2012</B>
</P>
</TD>
<TD>
<P>Dietary supplements</P>
</TD>
<TD>
<P>Quotes: "12 withdrew from the study. Exacerbation of symptoms was reported by 6 individuals: 3 in the control group and 3 in the test group. 6 withdrew from the study for reasons unrelated to the treatment"; "One patient complained of somnolence and weight gain and another of insomnia. Two patients who took the test substance reported exacerbation of the symptoms in the first week of treatment, but this was also observed in 4 patients in the control group"</P>
<P>Comment: adverse effects experienced by dropout patients referred to separately under rationale for withdrawals. Data combined for analysis</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Spanemberg 2015</B>
</P>
</TD>
<TD>
<P>Electromagnetic radiation</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Tammiala-Salonen 1999</B>
</P>
</TD>
<TD>
<P>Antidepressants and antipsychotics</P>
</TD>
<TD>
<P>Quote: "Patients in the trazodone group reported significantly more dizziness (P &lt; 0.0001) and drowsiness (P &lt; 0.05) than patients in the placebo group (Table 1). Two patients in the trazodone group and 8 in the placebo group reported no side effects"</P>
<P>Comment: adverse events fully reported in Table 1 in the paper; however, effect P values estimated from reported data (tabulated in Additional <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>) are more conservative than the effect estimates narratively reported in the paper</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ALA = alpha lipoic acid.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-11-07 12:09:55 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-08-03 14:48:41 +0100" MODIFIED_BY="[Empty name]">Adverse event outcomes</TITLE>
<TABLE COLS="7" ROWS="43">
<TR>
<TH COLSPAN="7">
<P>
<B>Antidepressants/antipsychotics versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Intervention</B>
</P>
</TD>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>No of studies</B>
</P>
</TD>
<TD>
<P>
<B>No of patients</B>
</P>
</TD>
<TD>
<P>
<B>Risk ratio (M-H, Fixed, 95% CI)</B>
</P>
</TD>
<TD>
<P>
<B>Overall effect (P value)</B>
</P>
</TD>
<TD>
<P>
<B>Heterogeneity (P value; I<SUP>2</SUP>)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8">
<P>Antidepressants</P>
<P>(trazodone)</P>
</TD>
<TD>
<P>Dizziness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>11.61 (1.66 to 81.04)</P>
</TD>
<TD>
<P>P = 0.01</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>4.75 (1.18 to 19.07)</P>
</TD>
<TD>
<P>P = 0.03</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Abdominal pains</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>1.32 (0.42 to 4.15)</P>
</TD>
<TD>
<P>P = 0.64</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>1.58 (0.30 to 8.40)</P>
</TD>
<TD>
<P>P = 0.59</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Palpitations</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>1.06 (0.17 to 6.72)</P>
</TD>
<TD>
<P>P = 0.95</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Tremor</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>2.11 (0.21 to 21.32)</P>
</TD>
<TD>
<P>P = 0.53</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>3.17 (0.36 to 27.72)</P>
</TD>
<TD>
<P>P = 0.30</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Urinary incontinence</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>37</P>
</TD>
<TD>
<P>3.16 (0.14 to 72.84)</P>
</TD>
<TD>
<P>P = 0.47</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics</P>
</TD>
<TD COLSPAN="6">
<P>Adverse effect data were not available for analysis from the single included study comparing antipsychotics versus placebo (<LINK REF="STD-Bogetto-1999" TYPE="STUDY">Bogetto 1999</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Anticonvulsants versus placebo </B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Intervention</B>
</P>
</TD>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>No of studies</B>
</P>
</TD>
<TD>
<P>
<B>No of patients</B>
</P>
</TD>
<TD>
<P>
<B>Risk ratio (M-H, Fixed, 95% CI)</B>
</P>
</TD>
<TD>
<P>
<B>Overall effect (P value)</B>
</P>
</TD>
<TD>
<P>
<B>Heterogeneity (P value; I<SUP>2</SUP>)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Gabapentin</P>
</TD>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>31.95 (1.84 to 553.64)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Gabapentin + ALA</P>
</TD>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>14.52 (0.73 to 290.44)</P>
</TD>
<TD>
<P>P = 0.08</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Mild headache</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>8.71 (0.37 to 205.80)</P>
</TD>
<TD>
<P>P = 0.18</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Benzodiazepines versus placebo </B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Intervention</B>
</P>
</TD>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>No of studies</B>
</P>
</TD>
<TD>
<P>
<B>No of patients</B>
</P>
</TD>
<TD>
<P>
<B>Risk ratio (M-H, Fixed, 95% CI)</B>
</P>
</TD>
<TD>
<P>
<B>Overall effect (P value)</B>
</P>
</TD>
<TD>
<P>
<B>Heterogeneity (P value; I<SUP>2</SUP>)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Topical clonazepam</P>
</TD>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>114</P>
</TD>
<TD>
<P>2.71 (0.84 to 8.74)</P>
</TD>
<TD>
<P>P = 0.09</P>
</TD>
<TD>
<P>P = 0.16; I<SUP>2</SUP> = 48%</P>
</TD>
</TR>
<TR>
<TD>
<P>Dry mouth</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>3.00 (0.13 to 70.16)</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Spasmophilia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>3.00 (0.13 to 70.16)</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Euphoric behaviour</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>3.00 (0.13 to 70.16)</P>
</TD>
<TD>
<P>P = 0.49</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Cholinergics versus placebo </B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Bethanechol</P>
</TD>
<TD COLSPAN="6">
<P>Adverse effect data presented collectively and not usable for analysis from the single included study comparing cholinergics versus placebo (<LINK REF="STD-Femiano-2002b" TYPE="STUDY">Femiano 2002b</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Dietary supplements versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Intervention</B>
</P>
</TD>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>No of studies</B>
</P>
</TD>
<TD>
<P>
<B>No of patients</B>
</P>
</TD>
<TD>
<P>
<B>Risk ratio (M-H, Fixed, 95% CI)</B>
</P>
</TD>
<TD>
<P>
<B>Overall effect (P value)</B>
</P>
</TD>
<TD>
<P>
<B>Heterogeneity (P value; I<SUP>2</SUP>)</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5">
<P>ALA (+/- adjunctive ingredients)</P>
</TD>
<TD>
<P>Gastrointestinal complaints</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>138</P>
</TD>
<TD>
<P>4.00 (1.21 to 13.27)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>P = 0.78; I<SUP>2</SUP> = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Headache</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>118</P>
</TD>
<TD>
<P>10.87 (1.36 to 87.03)</P>
</TD>
<TD>
<P>P = 0.02</P>
</TD>
<TD>
<P>P = 0.82; I<SUP>2</SUP> = 0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>1.00 (0.07 to 14.85)</P>
</TD>
<TD>
<P>P = 1.00</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Increase in blood pressure</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>1.00 (0.07 to 14.85)</P>
</TD>
<TD>
<P>P = 1.00</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Intermittent facial skin rash</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>8.71 (0.37 to 205.80)</P>
</TD>
<TD>
<P>P = 0.18</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>'Catuama' herbal compound</P>
</TD>
<TD>
<P>Drowsiness</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>2.69 (0.11 to 63.96)</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Weight gain</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>2.69 (0.11 to 63.96)</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Insomnia</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>2.69 (0.11 to 63.96)</P>
</TD>
<TD>
<P>P = 0.54</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TD>
<P>Exacerbation of symptoms</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>72</P>
</TD>
<TD>
<P>1.12 (0.33 to 3.83)</P>
</TD>
<TD>
<P>P = 0.86</P>
</TD>
<TD>
<P>Not applicable</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Electromagnetic radiation versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Low-level laser therapy</P>
</TD>
<TD COLSPAN="6">
<P>Adverse effect data were not available for analysis from the single included study comparing electromagnetic radiation versus placebo (<LINK REF="STD-Spanemberg-2015" TYPE="STUDY">Spanemberg 2015</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Physical barriers</B> <B>versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Tongue protector</P>
</TD>
<TD COLSPAN="6">
<P>Adverse effect data were not available for analysis from the single included study comparing physical barriers versus placebo (<LINK REF="STD-L_x00f3_pez_x002d_Jornet-2011" TYPE="STUDY">López-Jornet 2011</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Psychological therapies versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Cognitive therapy</P>
</TD>
<TD COLSPAN="6">
<P>Adverse effect data were not available for analysis from the single included study comparing psychological therapies versus placebo (<LINK REF="STD-Bergdahl-1995a" TYPE="STUDY">Bergdahl 1995a</LINK>)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="7">
<P>
<B>Topical treatments versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Benzydamine hydrochloride oral rinse</P>
</TD>
<TD COLSPAN="6">
<P>Adverse data only presented for benzydamine hydrochloride oral rinse against placebo; narratively reported that no adverse effects occurred (<LINK REF="STD-Sardella-1999" TYPE="STUDY">Sardella 1999</LINK>)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>ALA = alpha lipoic acid; CI = confidence interval; M-H = Mantel-Haenszel.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-11-09 11:46:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<COMPARISON ID="CMP-001" MODIFIED="2016-11-09 11:32:58 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1">
<NAME>Antidepressants/antipsychotics versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-07-11 12:37:08 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.058745765915829" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="19" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Antidepressants/antipsychotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours antidepressants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.01" MODIFIED="2016-02-08 14:50:13 +0000" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Antidepressants - Trazodone</NAME>
<CONT_DATA CI_END="2.7556290256707383" CI_START="-0.2356290256707385" EFFECT_SIZE="1.2599999999999998" ESTIMABLE="YES" MEAN_1="5.92" MEAN_2="4.66" MODIFIED="2016-02-08 14:50:13 +0000" MODIFIED_BY="Jo C Weldon" ORDER="341" SD_1="2.32" SD_2="2.32" SE="0.7630900554643193" STUDY_ID="STD-Tammiala_x002d_Salonen-1999" TOTAL_1="18" TOTAL_2="19" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-11-09 11:33:11 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2">
<NAME>Anticonvulsants versus placebo</NAME>
<DICH_OUTCOME CHI2="0.02827529475681303" CI_END="7.670204370061061" CI_START="2.08599396157584" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8848069357361161" LOG_CI_START="0.31931304691980844" LOG_EFFECT_SIZE="0.6020599913279624" METHOD="MH" MODIFIED="2016-07-11 12:44:57 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.866463263156292" P_Q="0.8665411428274515" P_Z="3.000883310473692E-5" Q="0.028242011432637618" RANDOM="NO" SCALE="13.837300323007986" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="60" WEIGHT="100.0" Z="4.173399298815815">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Anticonvulsants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours anticonvulsants</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.31786531657046" CI_START="1.3629272692109742" DF="0" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.013589854546011" LOG_CI_START="0.1344726809094269" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2016-02-12 15:52:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.010480199512567435" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="30" WEIGHT="44.44444444444445" Z="2.5595691780019596">
<NAME>Gabapentin only</NAME>
<DICH_DATA CI_END="10.31786531657046" CI_START="1.3629272692109742" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="1.013589854546011" LOG_CI_START="0.1344726809094269" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2016-02-09 15:42:05 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.5163977794943222" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011" TOTAL_1="20" TOTAL_2="30" VAR="0.26666666666666666" WEIGHT="44.44444444444445"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.826864239814883" CI_START="1.7950792408965146" DF="0" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.9924149562243526" LOG_CI_START="0.25408362457144845" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2016-02-12 15:52:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="9.365069767584566E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="30" WEIGHT="55.55555555555556" Z="3.3089376278678357">
<NAME>Gabapentin + adjunctive ALA</NAME>
<DICH_DATA CI_END="9.826864239814883" CI_START="1.7950792408965144" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.9924149562243526" LOG_CI_START="0.2540836245714484" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2016-02-09 15:43:51 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.4336994790119515" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011" TOTAL_1="20" TOTAL_2="30" VAR="0.18809523809523815" WEIGHT="55.55555555555556"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-11-09 11:34:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3">
<NAME>Benzodiazepines versus placebo</NAME>
<CONT_OUTCOME CHI2="6.156814384823224" CI_END="-1.5415126185663095" CI_START="-2.139568120388998" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8405403694776536" ESTIMABLE="YES" I2="67.51566841238427" I2_Q="74.11955673784998" ID="CMP-003.01" MODIFIED="2016-07-11 12:47:24 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.04603255042653287" P_Q="0.04933494532052529" P_Z="1.641568674144473E-33" Q="3.863921455559045" RANDOM="NO" SCALE="4.465559853060928" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="12.063739319424457">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepines</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.2928929292641786" CI_END="-1.58643536324829" CI_START="-2.1923780414151075" DF="1" EFFECT_SIZE="-1.8894067023316987" ESTIMABLE="YES" I2="56.38697353735946" ID="CMP-003.01.01" MODIFIED="2015-08-13 12:22:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12996760328040335" P_Z="2.3474903014579128E-34" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="56" WEIGHT="97.41366785701885" Z="12.222836324789215">
<NAME>Topical clonazepam</NAME>
<CONT_DATA CI_END="-1.664913509017648" CI_START="-2.335086490982352" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.5" MODIFIED="2015-08-13 12:22:50 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="0.7" SD_2="0.4" SE="0.17096563693285768" STUDY_ID="STD-Gr_x00e9_meau_x002d_Richard-2004" TOTAL_1="22" TOTAL_2="23" WEIGHT="79.63594712059589"/>
<CONT_DATA CI_END="-0.6847922798675746" CI_START="-2.1032077201324255" EFFECT_SIZE="-1.3940000000000001" ESTIMABLE="YES" MEAN_1="2.848" MEAN_2="4.242" MODIFIED="2015-08-13 12:22:13 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="1.698" SD_2="1.199" SE="0.3618473225664173" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TOTAL_1="33" TOTAL_2="33" WEIGHT="17.77772073642296"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.859385096913685" CI_START="-1.859385096913685" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" MODIFIED="2015-08-13 12:22:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.5863321429811448" Z="0.0">
<NAME>Systemic clonazepam</NAME>
<CONT_DATA CI_END="1.859385096913685" CI_START="-1.859385096913685" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.5" MODIFIED="2015-08-13 12:22:39 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="2.4" SD_2="1.8" SE="0.9486832980505138" STUDY_ID="STD-Heckmann-2012" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.5863321429811448"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2016-11-09 11:34:52 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.1089406376032045" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="33" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - long-term (&gt;3 to &#8804;6 months)</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepines</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" MODIFIED="2015-08-13 12:22:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Topical clonazepam</NAME>
<CONT_DATA CI_END="-0.8250874136579788" CI_START="-1.9629125863420223" EFFECT_SIZE="-1.3940000000000006" ESTIMABLE="YES" MEAN_1="3.03" MEAN_2="4.424" MODIFIED="2015-08-13 12:22:13 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="1.357" SD_2="0.969" SE="0.29026685736550856" STUDY_ID="STD-Rodr_x00ed_guez-de-Rivera_x002d_Campillo-2010" TOTAL_1="33" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2016-08-08 12:46:19 +0100" MODIFIED_BY="Jo C Weldon" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.702466144102257" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in QoL - Depression - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepines</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" MODIFIED="2015-08-14 12:46:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Systemic clonazepam</NAME>
<CONT_DATA CI_END="0.5463320500961005" CI_START="-0.9463320500961007" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.8" MODIFIED="2015-08-13 12:25:49 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="0.8" SD_2="0.9" SE="0.38078865529319544" STUDY_ID="STD-Heckmann-2012" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2016-08-08 12:46:19 +0100" MODIFIED_BY="Jo C Weldon" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in taste - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Benzodiazepines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours benzodiazepines</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1054793941240604" CI_START="-3.1054793941240604" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="12.3" MODIFIED="2015-08-13 12:22:13 +0100" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="2.5" SD_2="2.3" SE="1.0742439201596627" STUDY_ID="STD-Heckmann-2012" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-11-09 11:35:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4">
<NAME>Cholinergics versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-11-09 11:35:37 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="46.44" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Cholinergics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cholinergics</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-05 11:24:43 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Bethanechol</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2016-02-09 15:37:02 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Femiano-2002b" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-11-09 11:38:39 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="5">
<NAME>Dietary supplements versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2016-11-09 11:37:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.35" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="156" TOTAL_2="148" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Dietary supplements</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dietary suppl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" MODIFIED="2016-05-24 15:22:00 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>ALA + adjunctive vitamins (Tiobec)</NAME>
<CONT_DATA CI_END="0.14441513574644183" CI_START="-3.3444151357464413" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="5.3" MODIFIED="2015-11-16 17:01:38 +0000" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="2.5" SD_2="2.2" SE="0.8900240767208814" STUDY_ID="STD-Marino-2010" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.8388143755559057" CI_START="-1.0588143755559043" EFFECT_SIZE="0.8900000000000006" ESTIMABLE="YES" MEAN_1="5.94" MEAN_2="5.05" MODIFIED="2015-11-16 17:00:57 +0000" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="2.73" SD_2="3.39" SE="0.9943113194568389" STUDY_ID="STD-Carbone-2009" TOTAL_1="18" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.02" MODIFIED="2016-05-24 15:22:00 +0100" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ALA + adjunctive lycopene + green tea extract (Thioderm)</NAME>
<CONT_DATA CI_END="2.848679859173683" CI_START="-0.4486798591736829" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="2.8" MODIFIED="2015-08-13 14:14:49 +0100" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="2.7" SD_2="2.5" SE="0.8411786503110564" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2009b" TOTAL_1="23" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.03" MODIFIED="2016-11-09 11:37:01 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>'Catuama' herbal compound</NAME>
<CONT_DATA CI_END="-1.0830655982010675" CI_START="-3.716934401798933" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="3.33" MEAN_2="5.73" MODIFIED="2015-08-13 14:14:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;VNS&lt;/p&gt;" NOTES_MODIFIED="2015-08-13 14:14:49 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="105" SD_1="2.49" SD_2="2.71" SE="0.6719176536848347" STUDY_ID="STD-Spanemberg-2012" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.04" MODIFIED="2016-11-09 11:37:06 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Hypericum perforatum (St John's Wort)</NAME>
<CONT_DATA CI_END="2.8705047570982583" CI_START="-0.5705047570982573" EFFECT_SIZE="1.1500000000000004" ESTIMABLE="YES" MEAN_1="6.15" MEAN_2="5.0" MODIFIED="2015-08-13 14:14:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;means and SDs calculated in excel from individual patient data presented in paper&lt;/p&gt;" NOTES_MODIFIED="2015-08-13 14:14:49 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="104" SD_1="2.44" SD_2="3.024" SE="0.877824679774414" STUDY_ID="STD-Sardella-2008" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.05" MODIFIED="2016-05-24 15:22:00 +0100" MODIFIED_BY="Jo C Weldon" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Lycopene</NAME>
<CONT_DATA CI_END="0.8605104559644727" CI_START="-1.0205104559644729" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="4.17" MODIFIED="2016-02-09 11:58:03 +0000" MODIFIED_BY="Jo C Weldon" NOTES="&lt;p&gt;VAS - Burning&lt;/p&gt;" NOTES_MODIFIED="2016-02-09 11:58:03 +0000" NOTES_MODIFIED_BY="Jo C Weldon" ORDER="103" SD_1="1.69" SD_2="1.7" SE="0.47986109101141616" STUDY_ID="STD-Cano_x002d_Carrillo-2014" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0">
<FOOTNOTE>VAS - burning relief</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="1.4990787796107867" CI_START="-0.7590787796107865" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" MEAN_1="6.12" MEAN_2="5.75" MODIFIED="2016-02-10 10:32:26 +0000" MODIFIED_BY="Jo C Weldon" NOTES="&lt;p&gt;VAS - Pain&lt;/p&gt;" NOTES_MODIFIED="2016-02-10 10:32:26 +0000" NOTES_MODIFIED_BY="Jo C Weldon" ORDER="103" SD_1="2.2" SD_2="1.87" SE="0.5760711872854889" STUDY_ID="STD-Cano_x002d_Carrillo-2014" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0">
<FOOTNOTE>VAS - pain relief</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.04405913825873285" CI_END="1.7579785517182043" CI_START="-2.539931316806457" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.39097638254412614" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.24501357214432126" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-11-09 11:37:34 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2" P_CHI2="0.8337437586670488" P_Q="1.0" P_Z="0.7213974454993137" Q="0.0" RANDOM="NO" SCALE="15.13" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="0.3565917629888729">
<NAME>Symptom relief - short term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Dietary supplements</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dietary suppl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.04405913825873285" CI_END="1.7579785517182043" CI_START="-2.539931316806457" DF="1" EFFECT_SIZE="-0.39097638254412614" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.24501357214432126" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-02-03 11:00:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8337437586670488" P_Z="0.7213974454993137" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="0.3565917629888729">
<NAME>ALA without adjunctive active ingredients</NAME>
<IV_DATA CI_END="1.861039554638481" CI_START="-2.541039554638481" EFFECT_SIZE="-0.34" ESTIMABLE="YES" ESTIMATE="-0.34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 10:51:25 +0000" MODIFIED_BY="[Empty name]" ORDER="43" SE="1.123" STUDY_ID="STD-Carbone-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="95.3232676565022"/>
<IV_DATA CI_END="8.507017401618077" CI_START="-11.367017401618076" EFFECT_SIZE="-1.43" ESTIMABLE="YES" ESTIMATE="-1.43" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-03 11:00:50 +0000" MODIFIED_BY="[Empty name]" ORDER="42" SE="5.07" STUDY_ID="STD-Cavalcanti-2009" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.676732343497813"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="7.836680890422669" CI_END="4.924474186455014" CI_START="2.5533147652911055" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="3.545945945945946" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="32" I2="48.95798290206683" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.6923598652677042" LOG_CI_START="0.4071043566775888" LOG_EFFECT_SIZE="0.5497321109726465" METHOD="MH" MODIFIED="2016-11-09 11:37:53 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3" P_CHI2="0.09774752609645943" P_Q="0.36874556783361945" P_Z="4.210664767402719E-14" Q="1.9952973732103219" RANDOM="NO" SCALE="909.41" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="116" TOTAL_2="160" WEIGHT="300.0" Z="7.554316086493269">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Dietary supplements</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dietary suppl</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.541054746619269" CI_START="1.7828334226683245" DF="0" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.8774320936947767" LOG_CI_START="0.25111076718234854" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2016-02-26 18:13:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.1308615510208814E-4" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="60" WEIGHT="100.0" Z="3.5315791889853063">
<NAME>ALA without adjunctive active ingredients (Ciagen)</NAME>
<DICH_DATA CI_END="7.541054746619269" CI_START="1.7828334226683247" EFFECT_SIZE="3.6666666666666665" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.8774320936947767" LOG_CI_START="0.2511107671823486" LOG_EFFECT_SIZE="0.5642714304385625" MODIFIED="2016-02-09 15:54:11 +0000" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.36790424753396817" STUDY_ID="STD-Lopez_x002d_D_x0027_alessandro-2011" TOTAL_1="20" TOTAL_2="60" VAR="0.13535353535353534" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.150437584193758" CI_END="6.382033211321228" CI_START="2.6298137657997946" DF="2" EFFECT_SIZE="4.096774193548387" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="15" I2="75.46144020685928" ID="CMP-005.03.02" LOG_CI_END="0.8049590598788042" LOG_CI_START="0.4199249943645641" LOG_EFFECT_SIZE="0.6124420271216842" MODIFIED="2016-02-09 15:54:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.016988565806678735" P_Z="4.5146913791873385E-10" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="99.99999999999997" Z="6.235107089415752">
<NAME>ALA + adjunctive vitamins (Tiobec)</NAME>
<DICH_DATA CI_END="15.62008191392984" CI_START="1.8210176234145075" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.1936833070492483" LOG_CI_START="0.26031414882327647" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2016-02-09 15:54:18 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.5482656637937835" STUDY_ID="STD-Femiano-2000" TOTAL_1="21" TOTAL_2="21" VAR="0.3005952380952381" WEIGHT="19.354838709677416"/>
<DICH_DATA CI_END="3.764666631906609" CI_START="1.5513399588371994" EFFECT_SIZE="2.4166666666666665" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="12" LOG_CI_END="0.5757265246712543" LOG_CI_START="0.1907069790314082" LOG_EFFECT_SIZE="0.38321675185133125" MODIFIED="2016-02-09 15:54:23 +0000" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.22616238698633406" STUDY_ID="STD-Femiano-2002a" TOTAL_1="30" TOTAL_2="30" VAR="0.051149425287356325" WEIGHT="77.41935483870967"/>
<DICH_DATA CI_END="574.8094256399673" CI_START="2.381658927175412" EFFECT_SIZE="37.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.7595238810172744" LOG_CI_START="0.3768795671167152" LOG_EFFECT_SIZE="1.568201724066995" MODIFIED="2016-02-09 15:54:32 +0000" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.399577064264758" STUDY_ID="STD-Femiano-2002b" TOTAL_1="20" TOTAL_2="20" VAR="1.9588159588159588" WEIGHT="3.225806451612903"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.483789698955847" CI_START="1.2004131240261815" DF="0" EFFECT_SIZE="2.32" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="0.6516452348942011" LOG_CI_START="0.07933073488759818" LOG_EFFECT_SIZE="0.3654879848908996" MODIFIED="2016-02-09 15:54:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.01230341003426255" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="2.5033204196644268">
<NAME>ALA + adjunctive lycopene + green tea extract (Thioderm)</NAME>
<DICH_DATA CI_END="4.483789698955847" CI_START="1.2004131240261815" EFFECT_SIZE="2.32" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.6516452348942011" LOG_CI_START="0.07933073488759818" LOG_EFFECT_SIZE="0.3654879848908996" MODIFIED="2016-02-09 15:54:41 +0000" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.3361803703063436" STUDY_ID="STD-Palacios_x002d_S_x00e1_nchez-2015" TOTAL_1="25" TOTAL_2="29" VAR="0.11301724137931034" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3641214965408738" CI_END="0.5889887946654434" CI_START="-2.366933274473774" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8889722399041652" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2016-11-09 11:38:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4" P_CHI2="0.833550745395863" P_Q="0.9919086266247081" P_Z="0.23844197692992664" Q="1.0284406873159822E-4" RANDOM="NO" SCALE="5.11" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.1788900605051802">
<NAME>Symptom relief - long-term (&gt;3 to &#8804;6 months)</NAME>
<GROUP_LABEL_1>Dietary supplements</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dietary suppl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6936139687510616" CI_START="-3.4936139687510623" DF="0" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2015-11-16 16:50:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49642876608704134" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="10" WEIGHT="32.47246785639979" Z="0.6801195580140543">
<NAME>ALA without adjunctive active ingredients</NAME>
<CONT_DATA CI_END="1.6936139687510616" CI_START="-3.4936139687510623" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="5.4" MODIFIED="2015-11-16 16:36:28 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;split control grp with ALA+ adjunctive (n=20)&lt;/p&gt;" NOTES_MODIFIED="2015-11-16 16:36:28 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="94" SD_1="3.39" SD_2="3.05" SE="1.3232967489245506" STUDY_ID="STD-Carbone-2009" TOTAL_1="14" TOTAL_2="10" WEIGHT="32.47246785639979"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3640186524721421" CI_END="0.9148808830356006" CI_START="-2.682219360406922" DF="1" EFFECT_SIZE="-0.8836692386856608" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" MODIFIED="2015-11-16 16:36:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5462830593344844" P_Z="0.3355597805175512" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="19" WEIGHT="67.52753214360021" Z="0.9629755997082202">
<NAME>ALA + adjunctive vitamins (Tiobec)</NAME>
<CONT_DATA CI_END="2.3470601426423916" CI_START="-2.9270601426423917" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="5.11" MEAN_2="5.4" MODIFIED="2015-11-16 16:36:53 +0000" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="3.98" SD_2="3.05" SE="1.3454635714957957" STUDY_ID="STD-Carbone-2009" TOTAL_1="18" TOTAL_2="10" WEIGHT="31.411299172417685"/>
<CONT_DATA CI_END="1.0593014249587163" CI_START="-3.859301424958717" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="5.5" MODIFIED="2015-11-16 12:46:28 +0000" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="2.9" SD_2="2.4" SE="1.2547686816479142" STUDY_ID="STD-Marino-2010" TOTAL_1="9" TOTAL_2="9" WEIGHT="36.11623297118253"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2016-11-09 11:38:39 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="24.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in QoL - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Dietary supplements</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dietary suppl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.01" MODIFIED="2016-02-24 14:39:48 +0000" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>OHIP-14</NAME>
<CONT_DATA CI_END="4.999824218500643" CI_START="-3.1398242185006433" EFFECT_SIZE="0.9299999999999997" ESTIMABLE="YES" MEAN_1="18.31" MEAN_2="17.38" MODIFIED="2015-11-11 15:33:23 +0000" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="7.78" SD_2="6.9" SE="2.076479083596891" STUDY_ID="STD-Cano_x002d_Carrillo-2014" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.02" MODIFIED="2016-02-24 14:54:48 +0000" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Surrogate measure - Anxiety</NAME>
<CONT_DATA CI_END="-0.4160028517273613" CI_START="-5.283997148272638" EFFECT_SIZE="-2.8499999999999996" ESTIMABLE="YES" MEAN_1="8.65" MEAN_2="11.5" MODIFIED="2016-02-24 14:54:48 +0000" MODIFIED_BY="Jo C Weldon" ORDER="142" SD_1="4.64" SD_2="4.14" SE="1.2418580991649322" STUDY_ID="STD-Cano_x002d_Carrillo-2014" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0">
<FOOTNOTE>Hospital anxiety scale - adjunctive surrogate marker for QoL in addition to OHIP-14</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.03" MODIFIED="2016-02-24 14:54:53 +0000" MODIFIED_BY="Jo C Weldon" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Surrogate measure - Depression</NAME>
<CONT_DATA CI_END="0.4917060325491178" CI_START="-4.231706032549118" EFFECT_SIZE="-1.87" ESTIMABLE="YES" MEAN_1="4.38" MEAN_2="6.25" MODIFIED="2016-02-24 14:54:53 +0000" MODIFIED_BY="Jo C Weldon" ORDER="142" SD_1="3.69" SD_2="4.72" SE="1.2049741991066947" STUDY_ID="STD-Cano_x002d_Carrillo-2014" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0">
<FOOTNOTE>Hospital depression scale - adjunctive surrogate marker for QoL in addition to OHIP-14</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2016-11-09 11:46:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="6">
<NAME>Electromagnetic radiation versus placebo</NAME>
<CONT_OUTCOME CHI2="1.1353514162600928" CI_END="-16.499530706971292" CI_START="-44.22166128320182" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-30.360595995086555" ESTIMABLE="YES" I2="11.921543790022962" I2_Q="11.921543790022962" ID="CMP-006.01" MODIFIED="2016-11-09 11:45:49 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1" P_CHI2="0.2866367849592444" P_Q="0.2866367849592444" P_Z="1.762680492981736E-5" Q="1.1353514162600928" RANDOM="NO" SCALE="64.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="4.2930087596197914">
<NAME>Symptom relief - VAS - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Electromagnetic radiation</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours electromagnetic r</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-18.539025543949897" CI_START="-55.34097445605011" DF="0" EFFECT_SIZE="-36.940000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" MODIFIED="2016-08-15 11:26:48 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="1.0" P_Z="8.33241396654572E-5" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="56.74290595060191" Z="3.934632362097795">
<NAME>Infrared laser</NAME>
<CONT_DATA CI_END="-18.539025543949897" CI_START="-55.34097445605011" EFFECT_SIZE="-36.940000000000005" ESTIMABLE="YES" MEAN_1="25.9" MEAN_2="62.84" MODIFIED="2016-08-15 11:25:48 +0100" MODIFIED_BY="Jo C Weldon" ORDER="43" SD_1="19.48" SD_2="26.3" SE="9.388424788003578" STUDY_ID="STD-Spanemberg-2015" TOTAL_1="20" TOTAL_2="10" WEIGHT="56.74290595060191"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6549827515137743" CI_START="-42.80501724848624" DF="0" EFFECT_SIZE="-21.730000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" MODIFIED="2016-09-16 13:26:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04329250058329746" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="9" WEIGHT="43.257094049398084" Z="2.0208769882318616">
<NAME>Red laser</NAME>
<CONT_DATA CI_END="-0.6549827515137743" CI_START="-42.80501724848624" EFFECT_SIZE="-21.730000000000004" ESTIMABLE="YES" MEAN_1="41.11" MEAN_2="62.84" MODIFIED="2016-09-16 13:26:04 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="27.14" SD_2="26.3" SE="10.752757405096867" STUDY_ID="STD-Spanemberg-2015" TOTAL_1="19" TOTAL_2="9" WEIGHT="43.257094049398084"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7064452862626784" CI_END="-3.093552758561162" CI_START="-7.38166071274006" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.237606735650611" ESTIMABLE="YES" I2="41.39864852097772" I2_Q="41.39864852097772" ID="CMP-006.02" MODIFIED="2016-11-09 11:46:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2" P_CHI2="0.19144731725008912" P_Q="0.19144731725008912" P_Z="1.685338120980496E-6" Q="1.7064452862626784" RANDOM="NO" SCALE="11.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="4.787902112891315">
<NAME>Change in QoL - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Electromagnetic radiation</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours electromagnetic r</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.639147380183283" CI_START="-9.360852619816718" DF="0" EFFECT_SIZE="-6.500000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" MODIFIED="2016-08-12 15:34:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="8.462509967895496E-6" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="56.16690054342396" Z="4.453136037579781">
<NAME>Infrared laser</NAME>
<CONT_DATA CI_END="-3.639147380183283" CI_START="-9.360852619816718" EFFECT_SIZE="-6.500000000000001" ESTIMABLE="YES" MEAN_1="6.89" MEAN_2="13.39" MODIFIED="2016-08-12 15:34:10 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="4.05" SD_2="3.62" SE="1.4596455049086403" STUDY_ID="STD-Spanemberg-2015" TOTAL_1="20" TOTAL_2="10" WEIGHT="56.16690054342396"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.38156917862749795" CI_START="-6.8584308213725045" DF="0" EFFECT_SIZE="-3.620000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" MODIFIED="2016-08-12 15:34:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.028459218891857242" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="9" WEIGHT="43.83309945657604" Z="2.190897386848605">
<NAME>Red laser</NAME>
<CONT_DATA CI_END="-0.38156917862749795" CI_START="-6.8584308213725045" EFFECT_SIZE="-3.620000000000001" ESTIMABLE="YES" MEAN_1="9.77" MEAN_2="13.39" MODIFIED="2016-08-12 15:34:23 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="4.92" SD_2="3.62" SE="1.6522909843838112" STUDY_ID="STD-Spanemberg-2015" TOTAL_1="19" TOTAL_2="9" WEIGHT="43.83309945657604"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2016-11-09 11:33:54 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="7">
<NAME>Physical barriers versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2016-02-03 10:35:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Physical barriers</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours physical barrier</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.01" MODIFIED="2015-08-13 11:57:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Tongue protector</NAME>
<CONT_DATA CI_END="-0.056238666385435065" CI_START="-2.143761333614564" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="5.6" MODIFIED="2015-08-13 11:57:21 +0100" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="2.2" SD_2="1.5" SE="0.532541078227774" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2016-02-24 14:54:38 +0000" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="75" TOTAL_2="75" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in QoL - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Physical barriers</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours physical barrier</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.01" MODIFIED="2016-02-24 14:39:30 +0000" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>OHIP-49</NAME>
<CONT_DATA CI_END="8.503320415600989" CI_START="-26.90332041560098" EFFECT_SIZE="-9.199999999999996" ESTIMABLE="YES" MEAN_1="44.52" MEAN_2="53.72" MODIFIED="2015-08-13 11:58:58 +0100" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="28.17" SD_2="35.3" SE="9.032472308288579" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.02" MODIFIED="2016-02-24 14:54:34 +0000" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Surrogate measure - Anxiety</NAME>
<CONT_DATA CI_END="3.5071915809721492" CI_START="-3.187191580972149" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="11.2" MEAN_2="11.04" MODIFIED="2016-02-24 14:54:34 +0000" MODIFIED_BY="Jo C Weldon" ORDER="163" SD_1="6.59" SD_2="5.43" SE="1.7077821875168977" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0">
<FOOTNOTE>Hospital anxiety scale - adjunctive surrogate marker for QoL in addition to OHIP-49</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.03" MODIFIED="2016-02-24 14:54:38 +0000" MODIFIED_BY="Jo C Weldon" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Surrogate measure - Depression</NAME>
<CONT_DATA CI_END="2.7032596623245873" CI_START="-3.9832596623245884" EFFECT_SIZE="-0.6400000000000006" ESTIMABLE="YES" MEAN_1="8.28" MEAN_2="8.92" MODIFIED="2016-02-24 14:54:38 +0000" MODIFIED_BY="Jo C Weldon" ORDER="163" SD_1="5.93" SD_2="6.13" SE="1.705776069711379" STUDY_ID="STD-L_x00f3_pez_x002d_Jornet-2011" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0">
<FOOTNOTE>Hospital depression scale - adjunctive surrogate marker for QoL in addition to OHIP-49</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2016-11-09 11:42:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="8">
<NAME>Psychological therapies versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2016-11-09 11:42:08 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.21" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - long-term (&gt;3 to &#8804;6 months)</NAME>
<GROUP_LABEL_1>Psychological therapies</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours psychological</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.175305536111831" CI_START="-4.224694463888168" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="4.6" MODIFIED="2015-08-13 12:02:22 +0100" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="1.1" SD_2="1.7" SE="0.5228129047119374" STUDY_ID="STD-Bergdahl-1995a" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2016-11-09 11:42:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="9">
<NAME>Topical treatments versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2016-05-24 15:22:12 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Topical treatments</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.01" MODIFIED="2016-05-24 15:22:12 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Capsaicin oral rinse</NAME>
<CONT_DATA CI_END="-0.6159251633239011" CI_START="-4.184074836676099" EFFECT_SIZE="-2.4" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="5.3" MODIFIED="2016-02-02 11:36:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;same control group for lactoperoxidase and capsaicin - split?&lt;/p&gt;" NOTES_MODIFIED="2016-02-02 11:36:01 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="131" SD_1="2.6" SD_2="2.2" SE="0.9102589898327996" STUDY_ID="STD-Marino-2010" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.01.02" MODIFIED="2016-05-24 15:22:12 +0100" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Lactoperoxidase oral rinse (Biotene)</NAME>
<CONT_DATA CI_END="0.005442202801660967" CI_START="-3.4054422028016607" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.3" MODIFIED="2016-02-02 11:36:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;same control group for lactoperoxidase and capsaicin - split?&lt;/p&gt;" NOTES_MODIFIED="2016-02-02 11:36:03 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="124" SD_1="2.4" SD_2="2.2" SE="0.870139561876632" STUDY_ID="STD-Marino-2010" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-11 13:07:24 +0100" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.103740201173807" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - short-term (&#8804;3 months)</NAME>
<GROUP_LABEL_1>Topical treatments</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours topical treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-09 15:56:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Benzydamine hydrochloride oral rinse</NAME>
<DICH_DATA CI_END="4.671852101612958" CI_START="0.05351196796527171" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6694890857160593" LOG_CI_START="-1.2715490770440216" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2016-02-09 15:56:23 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Sardella-1999" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-09 16:02:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Lactoperoxidase oral rinse (Biotene)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-09 16:02:12 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.0" STUDY_ID="STD-Femiano-2002b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-02-09 16:03:19 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Topical urea (10%)</NAME>
<DICH_DATA CI_END="1.8029595206536169" CI_START="0.4983728123960872" EFFECT_SIZE="0.9479166666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.25598597622095276" LOG_CI_START="-0.30244565765790243" LOG_EFFECT_SIZE="-0.02322984071847483" MODIFIED="2016-02-09 16:03:19 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.32802550602160896" STUDY_ID="STD-Alvarenga-da-Silva-2014" TOTAL_1="12" TOTAL_2="13" VAR="0.10760073260073261" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2016-11-09 11:42:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.67" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Symptom relief - long-term (&gt;3 to &#8804;6 months)</NAME>
<GROUP_LABEL_1>Topical treatments</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours topical treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.03.01" MODIFIED="2016-05-24 15:22:21 +0100" MODIFIED_BY="Jo C Weldon" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Capsaicin</NAME>
<CONT_DATA CI_END="-0.09002142121922363" CI_START="-5.109978578780776" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="5.5" MODIFIED="2016-02-02 11:34:54 +0000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="3.0" SD_2="2.4" SE="1.2806248474865698" STUDY_ID="STD-Marino-2010" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.03.02" MODIFIED="2016-05-24 15:22:21 +0100" MODIFIED_BY="Jo C Weldon" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Lactoperoxidase (Biotene)</NAME>
<CONT_DATA CI_END="0.9093300120213255" CI_START="-3.9093300120213255" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.5" MODIFIED="2016-02-02 11:34:56 +0000" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="2.8" SD_2="2.4" SE="1.2292725943057183" STUDY_ID="STD-Marino-2010" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-11-09 22:10:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-11-01 16:07:57 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtEAAAIRCAYAAACMIeGzAABDN0lEQVR42u3df6RVWR8/8CFJkkQy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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-11-09 22:10:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAa8AAAR+CAIAAADoUy17AABReElEQVR42u3dsW4bSb62cQIGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-11-09 22:10:57 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtUAAAEACAMAAABLdnpYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-11-09 22:56:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<APPENDIX ID="APP-01" MODIFIED="2016-11-09 22:56:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="1">
<TITLE MODIFIED="2016-11-03 15:29:02 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">Cochrane Oral Health's Trials Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-09 22:56:31 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>From February 2014, searches of Cochrane Oral Health's Trials Register for this review were undertaken using the Cochrane Register of Studies and the search strategy below:</P>
<P>1 ("burning mouth":ti,ab) AND (INREGISTER)<BR/>2 ("burning tongue":totalling,ab) AND (INREGISTER)<BR/>3 (glossodynia:ti,ab) AND (INREGISTER)<BR/>4 (glossopyrosis:ti,ab) AND (INREGISTER)<BR/>5 ((stomatodynia or stomatopyrosis):ti,ab) AND (INREGISTER)<BR/>6 (("oral dysaesthesia" or "oral dysesthesia"):ti,ab) AND (INREGISTER)<BR/>7 (BMS:ti,ab) AND (INREGISTER)<BR/>8 (#1 or #2 or #3 or #4 or #5 or #6 or #7) AND (INREGISTER)</P>
<P>Previous searches of Cochrane Oral Health's Trials Register were undertaken using the Procite software and the search strategy below:</P>
<P>("Burning mouth syndrome" OR "Burning mouth" OR "Burning tongue" OR Glossodynia OR Glossopyrosis OR Stomatodynia OR Stomatopyrosis OR "oral dysaesthesia" OR "oral dysesthesia" OR ( #4 CONTAINS BMS) OR (#43 CONTAINS BMS))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-11-03 15:30:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="2">
<TITLE MODIFIED="2016-11-03 15:29:35 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">Cochrane Central Register of Controlled Trials (CENTRAL) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 15:30:21 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>#1 MeSH descriptor Burning Mouth Syndrome this term only<BR/>#2 (burning in All Text near/3 mouth in All Text)<BR/>#3 (burning in All Text near/3 tongue in All Text)<BR/>#4 MeSH descriptor Glossalgia this term only<BR/>#5 Glossalgia* in All Text<BR/>#6 Glossodynia* in All Text<BR/>#7 Glossopyros* in All Text<BR/>#8 Stomatodynia* in All Text<BR/>#9 Stomatopyros* in All Text<BR/>#10 "oral dysaesthesia" in All Text<BR/>#11 "oral dysesthesia" in All Text<BR/>#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-11-03 15:31:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="3">
<TITLE MODIFIED="2016-10-13 10:32:13 +0100" MODIFIED_BY="[Empty name]">MEDLINE Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 15:31:26 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>1. Burning Mouth Syndrome/<BR/>2. (burning adj3 mouth).mp.<BR/>3. (burning adj3 tongue).mp.<BR/>4. Glossalgia/<BR/>5. Glossalgia$.mp.<BR/>6. Glossodynia$.mp.<BR/>7. Glossopyros$.mp.<BR/>8. Stomatodynia$.mp.<BR/>9. Stomatopyros$.mp.<BR/>10. (oral adj dysaesthesia).mp.<BR/>11. (oral adj dysesthesia).mp.<BR/>12. or/1-11<BR/>
</P>
<P>This subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials (RCTs) in MEDLINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the<I> Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.1.0 (updated March 2011) (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. or/1-8<BR/>10. exp animals/ not humans.sh.<BR/>11. 9 not 10<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-11-03 15:31:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="4">
<TITLE MODIFIED="2016-10-13 10:32:44 +0100" MODIFIED_BY="[Empty name]">Embase Ovid search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 15:31:17 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>1. Burning Mouth Syndrome/<BR/>2. (burning adj3 mouth).mp.<BR/>3. (burning adj3 tongue).mp.<BR/>4. Glossalgia/<BR/>5. Glossalgia$.mp.<BR/>6. Glossodynia$.mp.<BR/>7. Glossopyros$.mp.<BR/>8. Stomatodynia$.mp.<BR/>9. Stomatopyros$.mp.<BR/>10. (oral adj dysaesthesia).mp.<BR/>11. (oral adj dysesthesia).mp.<BR/>12. or/1-11</P>
<P>This subject search was linked to Cochrane Oral Health's filter for identifying RCTs in Embase Ovid:<BR/>
</P>
<P>1. random$.ti,ab.<BR/>2. factorial$.ti,ab.<BR/>3. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>4. placebo$.ti,ab.<BR/>5. (doubl$ adj blind$).ti,ab.<BR/>6. (singl$ adj blind$).ti,ab.<BR/>7. assign$.ti,ab.<BR/>8. allocat$.ti,ab.<BR/>9. volunteer$.ti,ab.<BR/>10. CROSSOVER PROCEDURE.sh.<BR/>11. DOUBLE-BLIND PROCEDURE.sh.<BR/>12. RANDOMIZED CONTROLLED TRIAL.sh.<BR/>13. SINGLE BLIND PROCEDURE.sh.<BR/>14. or/1-13<BR/>15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)<BR/>16. 14 NOT 15</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-11-03 15:32:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="5">
<TITLE MODIFIED="2016-10-13 10:33:18 +0100" MODIFIED_BY="[Empty name]">US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 15:32:18 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"burning mouth" or "burning tongue"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-11-03 15:32:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch" NO="6">
<TITLE MODIFIED="2016-10-13 10:33:26 +0100" MODIFIED_BY="[Empty name]">World Health Organization International Clinical Trials Registry Platform search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-03 15:32:27 +0000" MODIFIED_BY="Luisa M Fernandez Mauleffinch">
<P>"burning mouth"</P>
<P>"burning tongue"</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;21 &lt;/span&gt;studies included in quantitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;23 studies (25 articles) included in qualitative synthesis&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;64 articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;377 records screened&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;377 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;560 records identified through database searching&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;313 records discarded&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;37 articles excluded, with reasons&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 articles awaiting classification&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>